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Abstract
The HPV vaccine was first made available to girls and women in 2006. Despite
support for the vaccine from health care professionals and governments, vaccination rates
remain lower than anticipated. This study had two goals: (1) To investigate factors that
predict actual and intended vaccinations, and (2) to test a model of HPV vaccination
intentions. An adapted Health Belief Model was used as the theoretical framework to
guide this study. The model components assessed in this study were: Perceived severity,
perceived susceptibility, perceived barriers, perceived benefits, cues to action, selfefficacy, knowledge, and subjective norms. Each model component was assessed by at
least one variable, with some model components being assessed with multiple variables.
Participants were 374 women, aged 18 to 30, residing in Canada. Data were collected
using an online questionnaire.
Logistic regression analyses revealed that actual vaccination decisions were
directly influenced by the following model components and variables: Perceived severity
(severity of treatment), perceived barriers (vaccine safety concerns, fear of doctor stigma,
insurance coverage), and cues to action. Multiple regression analyses revealed that
vaccination intentions were influenced by: Perceived benefits (vaccine positive beliefs,
vaccine effectiveness), barriers (vaccine safety concerns), cues to action, self-efficacy,
and subjective norms. A structural equation model to assess HPV vaccination intentions
was tested. With a few modifications, support for the model was found. This model
revealed that all of the theoretical components measured in this study contributed directly
or indirectly to vaccination intentions.
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This study revealed that actual and intended HPV vaccinations are predicted by
different variables. In addition, it also found support for a complex model of vaccination
intentions. A unique contribution was the finding that women’s fear of experiencing
stigma from doctors by asking for the vaccine impacted actual vaccination decisions.
Vaccine safety concerns were also found to impact actual uptake. Finally, healthcare
professionals may also benefit from understanding that cues to action were found to be
predictive of behaviours, suggesting that women who are exposed to more cues are more
likely to get vaccinated.
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Chapter I
Introduction
In 2006 the first vaccine for Human Papillomavirus (HPV), the common sexually
transmitted infection (STI) that can cause genital warts and cervical cancer, was made
available to girls and women in Canada and the USA (Gillison, 2008; Krishnan, 2008;
McKaig, Barie, & Olshan, 1998; National Advisory Committee on Immunization , 2007).
The announcement of the release, and subsequently, of government plans to begin mass
school-based vaccination programs for girls, was not met with unanimous public support.
Instead, many news stories and internet communications about the vaccine were negative
in tone, describing possible risky side-effects and fears about the influence of the vaccine
on teen sexual behaviour. Media titles about the HPV vaccine included: Our girls are not
guinea pigs: Is an upcoming mass inoculation of a generation unnecessary and
potentially dangerous? (Gulli, 2007), Experts raise worries about HPV vaccine (ctv.com,
July 2007), Schoolgirl dies after cervical cancer vaccination (Adetunji, 2009), and
Defusing the War Over The “Promiscuity” Vaccine (Gibbs, 2006). It should be noted that
an inquiry into the death of the school-aged girl from the United Kingdom revealed that
she did not die as a result of the HPV vaccine.
Although many initial media stories about the HPV vaccine were negative, the
benefit of vaccination is widely recognized by health professionals. School-based
vaccination programs are offered in every province in Canada, and public health
departments continue to support the vaccine. For instance, the Public Health Agency of
Canada and the US Department of Health and Human Services both endorse the HPV
vaccine on their websites. To combat negative media stories about the vaccine, Canada’s
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Chief Public Health Officer issued a public statement refuting a negative story published
by MacLean’s magazine (Public Health Agency of Canada, 2007). Although the negative
public discourse about the HPV vaccine eventually ceased, HPV vaccination rates have
not reached anticipated goals in some school based programs in Canada, and very few
women outside of school based programs have been vaccinated. Why?
Although health professionals may recognize the benefits of HPV vaccination, the
general public may not. While HPV is a common STI that infects approximately 50-80%
of individuals at some point in their lifetime (Henderson, Yasgur, & Warshowsky, 2002;
National Advisory Committee on Immunization , 2007), individuals may not recognize
the benefits of vaccination. This may be a result of the way in which the vaccine is
promoted in popular advertisements, namely, as a defence against cervical cancer. A
description of other benefits, such as protection from genital warts, is often lacking.
Cervical cancer, however, is not a common illness within Canada. Approximately 1400
women are diagnosed with it a year, with 400 women dying from it (Health Canada,
1999). Because of these statistics (low in comparison to other cancers), girls and women
in Canada may not feel susceptible, and thus may not feel that the HPV vaccine is
necessary or beneficial.
For women who do recognize that they are at risk of HPV infection, and wish to
avoid possible negative health effects, social and psychological factors may influence
their actual vaccination behaviour. Women may want the vaccine but may have concerns
about its safety, especially after the attention paid to this subject in the popular media.
Related to the fear of negative side-effects, a general distrust of doctors or pharmaceutical
companies may also influence perceptions of the HPV vaccine. If women distrust the
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advice of those in the medical field, they may not be willing to act on their prompts to be
vaccinated. In addition to these possible barriers, HPV’s sexually transmitted infection
(STI) status may also impede women from obtaining the vaccine. Because STIs are
viewed negatively by society, women may be uncomfortable asking for a STI vaccine.
While it is possible that these variables influence HPV vaccination decisions, research
into some of these factors has not yet been conducted. Because of this, investigating how
physician and pharmaceutical distrust, as well as comfort with sexuality and the STI
status of HPV, influences vaccination decisions, was one of the main objectives of the
current study.
Of course, in addition to these possible predictors of HPV vaccination decisions,
past research has also investigated the relationship between HPV vaccinations and
various other factors. These include: feelings of susceptibility to HPV infection (Kuitto,
Pickel, Neumann, Jahn & Metelmann, 2010), a fear of needles (Gottvall, Larsson,
Hoglund & Tyden, 2009), HPV knowledge (Woodhall et al., 2007), a fear of side-effects
(Burke, Vail-Smith, White, Baker & Mitchell, 2010), perceived benefits of vaccination
(Dempsey, Zimet, Davis & Koutsky, 2006), cost (Kahn, Rosenthal, Jin, Huang,
Namakydoust & Zimit, 2008), feelings of self-efficacy (Buchanan, 2008; Kahn et al.,
2008), and health care provider cues to action (Caskey, Lindau & Alexander, 2009).
While direct relationships between a host of predictor variables and HPV
vaccination decisions have been examined in previous research, a comprehensive
understanding of how the types of variables interact with each other to predict decisions
is still lacking. Thus, another main objective of the current study was to develop a
comprehensive understanding of these relationships. This was done by testing a
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theoretically based model of vaccination intentions that included many of the variables
that had been used in previous research. To date, one of the most comprehensive
theoretically guided studies of HPV vaccination intentions was conducted by Buchanan
(2008) for her dissertation. She compared two theoretical models, the Health Belief
Model and the Theory of Planned Behaviour, to see which would better explain HPV
vaccination intentions. Her sample was comprised of American university students, and
the study was conducted soon after the release of the vaccine. Buchanan found that an
integrated model that used variables from each theory was actually more predictive of
intentions than either theory alone. While Buchanan’s research was a good first step to
developing a model of HPV vaccination decisions, in her study the components of each
model were simply tested to see if they had direct relationships with the outcome
variable. How the various model components may influence each other was not
investigated. In order to build upon this, the current study took the testing of a theoretical
model one step further, by developing and testing a more complex model of the decision
process.
In summary then, the objectives of this study were to investigate factors related to
actual and anticipated vaccinations in a sample of young women residing in Canada.
Direct relationships between possible predictor variables and vaccination outcomes were
investigated. In addition, a proposed model of HPV vaccination intentions was tested.
While these were the main objectives of this study, this study also makes an important
contribution to the area of HPV research because it is one of the first studies to be
conducted in Canada with young adult women. Because many studies have been
conducted in the US, where the health-care system is different from Canada, and where
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the cultural values of some segments of society may be quite different, it will be
advantageous to investigate possible predictors of HPV vaccinations in Canada. Finally,
this study was also important because of the timing of this research. Many earlier studies
about the HPV vaccine had to investigate intentions to vaccinate because they were
conducted prior to the release of the vaccine. Because the vaccine had been available for
five years at the time this study was conducted, actual vaccination behaviours, as well as
intentions, were able to be investigated.
Background: What is Human Papillomavirus (HPV)?
Human Papillomaviruses are a family of over 100 viruses, at least 40 of which
have been found to infect the genital region (National Advisory Committee on
Immunization, 2007). Genital HPV infection can lead to the development of genital warts
when individuals are infected with low risk strains such as types 6 or 11, or abnormal
changes in squamous epithelial cells, such as the skin or mucosae, that can lead to certain
genital and head and neck cancers when people are infected with high risk strains such as
types 16 and 18 (Henderson, et al., 2002; National Advisory Committee on
Immunization, 2007).
Prevalence. HPV is often cited as the most common STI in the world, with 50 to
80% of people being infected with it at some time in their lives (Henderson, et al., 2002;
Krishnan, 2008; National Advisory Committee on Immunization, 2007). Canadian
studies have found that the proportion of women infected with HPV at any one time is
estimated to be between 10 - 29%, although studies have found that rates vary by region,
age and ethnicity (National Advisory Committee on Immunization , 2007). Sellors et al.
(2000), in a study investigating HPV infection rates in Ontario, found that 24% of women
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aged 20 to 24 had HPV, with the rate declining as women aged. For example, 16.4 % of
women aged 25 to 29 had HPV, 12.3% of those aged 30 to 34 had it, and 9.6% of women
aged 35 to 39 were positive for HPV. Data were presented for women up to the age of 50.
Another study, conducted in Montreal, examined rates of infection for both high risk and
low risk strains of HPV. The study found that 21.8% of young women had high risk HPV
infections, and 14.8% had low risk infections (Richardson et al., 2003). The women in
this sample had a mean age of 23 years. Although the HPV virus can be found in many
women, the majority will never notice that they are infected. In most cases the virus
spontaneously clears the body without causing any adverse physical effects (Krishnan,
2008; The Society of Obstetricians and Gynaecologists of Canada, 2007). However, a
proportion of women and men will go on to experience physical symptoms of HPV
infection.
Within Canada, studies investigating the prevalence of genital warts are lacking,
although a study in Ontario found that 1.1% of women who attended health clinics had
genital warts (National Advisory Committee on Immunization, 2007; Sellors et al.,
2000). Rates from the United Kingdom and the United States of America estimate that
approximately 1.5 people per 1000 have them. Younger individuals are more likely to
have genital warts. For instance, six in 1000 women aged 20-24, and five in 1000 men
aged 25-29 were found to have genital warts (National Advisory Committee on
Immunization, 2007). For most individuals, the condition resolves within one to two
years, although the virus can remain in the body indefinitely, making future outbreaks
possible (National Advisory Committee on Immunization, 2007).
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When looking at cervical dysplasia and cervical cancer in particular, Henderson,
et al. (2002) reported that 10% of women infected with high risk HPV strains will go on
to develop abnormal cervical cell changes. The Canadian Women’s Health Network
(2007) states that 8% of the 4 million Pap tests done in Canada each year (approximately
325,000) require follow-up due to abnormal results. From the time risky (high grade) cell
changes begin, it can take up to 10 years for cervical cancer to develop. However, in a
small minority of cases, cervical cancer can develop very quickly, in less than a year
(National Advisory Committee on Immunization, 2007). Cervical cancer normally peaks
in women in their 40s, and then again over the age of 70 (National Advisory Committee
on Immunization, 2007), although the Public Health Agency of Canada (2009) notes that
67% of cervical cancer occurs in women aged 30-59. In Canada in 2001, approximately
1450 cases of cervical cancer were diagnosed, and 420 women died (Shah, 2003).
Fortunately, the treatment for cervical cancer, if caught early, is quite effective. For those
women diagnosed with cervical cancer, 74% will still be alive five years post-diagnosis
(Public Health Agency of Canada, 2009). This is a result of the various types of treatment
that are available to women who are diagnosed, such as chemotherapy, radiation, and
hysterectomy.
Pap testing has also been a powerful tool to prevent deaths from cervical cancer.
Since Pap testing began in the 1960s, rates of cervical cancer have declined greatly.
Regular Pap smear testing allows cervical cell changes to be detected early on, in most
cases before the development of cancer. Unfortunately, not all women obtain regular Pap
testing, so some women remain at risk for developing cervical cancer. There is also a
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small minority of women who develop cervical cancer very quickly, before pre-cancerous
cell changes can be caught through tests.
Reactions to HPV infection. While regular testing can allow the majority of
women to avoid the most severe outcome of an HPV infection, it does not protect women
from other negative effects such as psychological distress and potentially painful
treatments. Research into women’s reactions to being told they have HPV or an abnormal
Pap smear test has shown that the majority of these women experience adverse
psychological reactions such as anxiety and distress (Biro, Rosenthal, Wildey & Hillard,
1991; Doherty, Richardson, Wolfe & Raju, 1991; Juraskova, Butow, Sharpe & Campion,
2007; Karasz, McKee & Roybal, 2003; McCaffery, Waller, Forrest, Cadman, Szarewki &
Wardle, 2004; Perrin et al., 2006). For example, in a study of English women attending a
colposcopy clinic after an abnormal Pap test (N=102), 90% of participants reported
feelings of fear and worry as an initial response, while 67% reported feelings of
depression (Gath, Hallam, Mynors-Wallis, Day & Bond, 1995). A recent study
conducted in Canada also found that women had negative reactions to abnormal Pap
smears (Drolet et al., 2012). This study found that 46% of women with an abnormal test
felt anxiety/depression, with 35% of women still having clinically significant anxiety 12
weeks after diagnosis (Drolet et al., 2012).
Women’s sexuality has been found to be greatly impacted by HPV infection in a
negative fashion, with some women reporting a decreased desire to have sex (Biro,
Rosenthal, Wildey & Hillard, 1991; Campion, Brown, McCance, Atia, Edwards, Cuzick
& Singer, 1988; Gath, Hallam, Mynors-Wallis, Day & Bond, 1995), decreased sexual
enjoyment (Filiberti, Tamburini, Stefanon, Merola, Bandieramonte, Ventafridda & De
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Palo, 1993; Gath, Hallam, Mynors-Wallis, Day & Bond, 1995), and less arousal and
orgasm (Campion, Brown, McCance, Atia, Edwards, Cuzick & Singer, 1988). In
addition, some women who have received medical treatment of the cervix report
discomfort during sex and increased negative feelings toward sex, even five months after
diagnosis and treatment (Campion, Brown, McCance, Atia, Edwards, Cuzick & Singer,
1988).
Perceptions of past and future sexual or romantic partners are also influenced by
diagnosis. For example, women who had abnormal Pap tests reported feeling worse about
past sexual relationships after they were diagnosed with HPV (McCaffery, Waller,
Forrest, Cadman, Szarewki & Wardle, 2004). In another study, a worsening of the
emotional relationship between romantic partners was reported (Filiberti et al., 1993).
Not only are perceptions of past relationships tainted by diagnosis, but fear for future
relationships is also reported as a concern of patients by college health care providers
(Linnehan & Groce, 1999).
Fear of developing cancer is also a common reaction after an abnormal Pap test or
HPV diagnosis (Gath, Hallam, Mynors-Wallis, Day & Bond, 1995; Juraskova, Butow,
Sharpe & Campion, 2007; Karasz, McKee & Roybal, 2003; Maissi, Marteau, Hankins,
Moss, Legood & Gray, 2004). Interviews with women who had cervical abnormalities
found that before treatment, 16 of the 21 women interviewed had fears about the
possibility of developing cancer (Juraskova, Butow, Sharpe & Campion, 2007). These
fears remained post-treatment for nine of the women, indicating that treating the
immediate threat does not ease some women’s worries. Health care providers also
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recognize that their patients experience a fear of cancer, with providers reporting that
patients communicate these fears to them (Linnehan & Groce, 1999).
In addition to negative psychological reactions, women also experience concerns
related to their physical bodies. For example, women experience fears of HPV treatment
(Doherty, Richardson, Wolfe and Raju, 1991), and concerns that the virus will negatively
affect their fertility (Juraskova, Butow, Sharpe & Campion, 2007). These concerns are
justified, as medical treatments can be uncomfortable and painful. In addition, knowledge
that the health of the cervix may be compromised, now or in the future, would not
surprisingly cause women to ponder about future childbearing.
As the above research highlights, women have multiple negative reactions to
being diagnosed with HPV or having an abnormal Pap test. Thus, while Pap testing is an
important and vital component of ensuring women’s health, a vaccine that would enable
women to avoid HPV infections altogether would ensure that women do not have to
experience these varied negative reactions to symptomatic infections and treatment. It is
important to recognize that many of the negative reactions that women have to diagnosis
are likely related to HPV’s STI status. While previous research has not investigated this
link, the current study examined whether a relationship does exist. Findings from HPV
research that has found that women feel anxious and depressed after diagnosis, and that
they have concerns about past and future relationships, may indirectly demonstrate how
the stigma of STIs negatively influence women.
Risk factors. There are various risk factors that are associated with HPV
infection. Demographically, groups of women in Canada who tend to have the highest
rates of infection are younger women (with highest rates for men and women under the
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age of 25) and Aboriginal women (Krishnan, 2008; National Advisory Committee on
Immunization, 2007). For all women, factors that are related to an increased risk of
contracting HPV are: number of lifetime sexual partners, having unprotected sex,
engaging in activities that lead to sexual risk taking (e.g., substance abuse), younger age
at first intercourse (through its link to number of partners, cervical development, and
risky behaviours), and having a sexual partner who has had multiple partners (Henderson,
et al., 2002; Krishnan, 2008).
Unfortunately, knowledge of these risk factors does little to decrease the stigma of
individuals infected with an STI. A girl or woman reading these risk factors may notice
that they describe behaviours typically labelled as amoral by society. In order to avoid
association with a group often deemed undesirable, girls or women may tell themselves
they are not at risk of HPV infection, thus having an impact on their desire to obtain the
vaccine. In addition, if women do recognize that they are at risk of HPV infection, be it
regular risk or high risk, they may be reluctant to ask for a vaccine for a virus known to
infect those who engage in risky sexual behaviours more frequently. To do so may be to
open oneself up to experiencing stigma.
Disadvantaged women. Individuals who are socially disadvantaged experience
an increased incidence of various diseases, cervical cancer included (Raphael, 2009). The
over-representation of poor, rural, isolated, under-educated, immigrant, and/or minority
women (McGibbon, 2009; Rimer, McBride and Crump, 2001; Shah, 2003; Tiersma et al.,
2004) in those who are diagnosed with cervical cancer, or more severe forms of cervical
dysplasia, highlights how social determinants of health impact these women. Women
who belong to one or more of these groups may have limited access to appropriate or
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reliable health care, and they may have a limited ability to engage in health promotion
and protection activities. For example, African American women were found to be
diagnosed with cervical cancer at a later stage, to be less likely to receive treatment in
comparison to Caucasian women, and to be more likely to die as a result of cervical
cancer (McGibbon, 2009). Sadly, the factors that contribute to disadvantaged women’s
lack of Pap testing are also likely to have an impact on their ability to obtain the HPV
vaccine. This argument is often made to demonstrate how the HPV vaccine will not
necessarily save the lives of women living in Canada or the USA. While this is an
important point that must be addressed, be it with more funding for Pap testing for
disadvantaged women or free HPV vaccinations for those in need, the importance of the
HPV vaccine in protecting women’s health should not be dismissed.
Background: The HPV Vaccine
So far, this paper has discussed the HPV vaccine without providing detail about
when it was developed and vaccination goals. The first HPV vaccine was released for
females in 2006. In 2010 it was also approved for males. The vaccine protects against 4
strains of HPV that cause 70% of cervical cancers and 90% of genital warts (Krishnan,
2008). In Canada, the vaccine was first approved for girls and women aged nine to 26,
and the National Advisory Committee on Immunization recommends that women up to
the age of 26 be vaccinated (2007). The Public Health Agency of Canada (2011)
“recommend[s] the vaccine for females 14 to 26 years of age as there still is the potential
for benefit regardless of previous sexual activity, Pap abnormalities, cervical cancer,
anogenital warts or a known HPV infection.” Currently, grade eight girls in Canada may
receive the HPV vaccine for free. Outside of grade eight, other girls and women are
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responsible for payment of the three-dose vaccine, either personally or through their
insurance providers if they are eligible.
The vaccine has been widely touted by professionals as a promising tool to
combat HPV infection. Initial models created to assess clinical population effects of
widespread vaccination defined the best-case scenario as vaccination uptake levels of 70100% of the targeted population (Dempsey & Mendez, 2010). It was assumed in initial
modelling that these targets would be reached within a few years of vaccine introduction,
although these goals may have been too idealistic given the nature of the vaccine and the
target population (Dempsey & Mendez, 2010).
For an HPV vaccination program to be successful, the majority of girls and
women (and now boys and men) must be vaccinated. Unfortunately, although many
preliminary studies found that a majority of parents would approve the vaccine for their
daughters, or that young women and girls believed that they would accept the HPV
vaccine when it became available, actual vaccination rates are lower than expected.
Anticipated rates of vaccine acceptance. Prior to 2006, even though the
introduction of an HPV vaccine was considered controversial in some circles, the
majority of individuals for whom permission to vaccinate was required, namely mothers
of daughters and young women, appeared to accept the idea of the vaccine, or to be open
to learning more about it. For example, despite a general lack of public awareness of the
impending availability of an HPV vaccine in 2003, a study conducted by Kahn,
Rosenthal, Hamann and Bernstein (2003) found that the majority of study participants (52
young women with a mean age of 25) had positive attitudes toward an HPV vaccine, with
89% of them believing that it would be a good idea to get vaccinated. Jones and Cook
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(2008) found similar high rates of acceptance. They examined the vaccination intentions
of male and female college students, and found that 88.6% of women and 77.5% of men
would get the vaccine (Jones and Cook, 2008). Kahn et al. (2008) found slightly lower
levels of acceptance with a younger sample. Their results indicated that 66% of their
sample of 409 sexually experienced girls and women aged 13-26 intended to get the HPV
vaccine. This lower rate is likely influenced by the responses of the younger girls in the
sample who may not be sexually experienced, and thus may not feel at risk for acquiring
an STI. The one Canadian study that examined HPV vaccine acceptance found similar
rates to those above, where 89% of their adult male and female sample would recommend
the HPV vaccine to daughters or nieces (Sauvageau, Duval, Cilca, Lavoie & Ouakki,
2007). A number of other studies have also found similar results (Brewer & Fazekas,
2007; Christian, Christian & Hopenhayn, 2009; Constantine & Jerman, 2007; Lenselink
et al., 2008; Marshall, Ryan, Roberton & Baghurst, 2007; Woodhall et al., 2007). As
previous research has demonstrated then, a majority of individuals reported that they
would accept or support an HPV vaccine. Unfortunately, perceptions do not appear to
predict real-world behaviours in this situation.
Actual rates of vaccine acceptance. Although initial interest in the HPV vaccine
appeared positive, actual vaccine uptake rates after the 2006 release were surprisingly
low, ranging from 50-85% for school based programs and 10-30% for non-school-based
programs. Initial cost-benefit studies predicted vaccination uptake rates of 70-100%
within five years (Dempsey & Mendez, 2010; Kim & Goldie, 2008). Dempsey and
Mendez (2010) have described how various policy decisions impact uptake rates. They
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predicted that with a mandated school-based program 70% coverage could be obtained in
8 years, but with no mandated program this rate would not be reached for 23 years.
Research has consistently found that acceptance rates do differ depending upon
the setting/target group (i.e., school based programs versus non-school based programs).
For Canadian school-based vaccination programs, rates of receipt range from 50% to
85% depending upon the province, with east coast provinces having the highest uptake
rates and Ontario, Alberta and Manitoba the lowest (Canadian Women’s Health Network,
2008; Graveland, 2009). In Canada, school-based vaccination programs for girls began in
some provinces in 2007 and expanded into others in 2008. After the first year schoolbased vaccination programs were available in Nova Scotia, Prince Edward Island, and
Newfoundland, uptake of the HPV vaccine was at 80% and above (Canadian Women’s
Health Network, 2008). Graveland (2009) reported that in Nova Scotia and Prince
Edward Island rates were 80% for school-based programs, in Newfoundland they were
83%, and in Quebec rates ranged from 84-87%. Rates in Ontario were lower, where
approximately 50% of girls received the vaccine through school-based programs
(Graveland, 2009; The Canadian Women’s Health Network, 2008). In the West, 66% of
girls were vaccinated in British Columbia, while in Alberta and Manitoba 50-55% had
received vaccines through school programs (Graveland, 2009).
Uptake among girls and women not eligible for school-based program is even
lower than the lowest school-based rates, with only 10% to 30% of females obtaining the
vaccine (Caskey, Lindau and Alexander, 2009; Gottlieb et al., 2009). For example,
Caskey et al. (2009) conducted a large nationally representative study of American girls
and women (n = 1011) and found that 30% of 13 to 17 year olds, and 9% of 18 to 26 year
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olds reported that they had received at least one of the three required HPV vaccine shots.
A smaller study of university women found that of 64 participants, only 4 had received
the HPV vaccine and of those who had not been vaccinated, only 65% were interested in
getting it (Gerend & Magloire, 2008). Not surprisingly perhaps, age influences HPV
vaccine usage. Gottlieb et al. (2009) found that only 10% of their study sample had
actually gotten the HPV vaccine, even though the sample was located in an area with
elevated cervical cancer rates. Age was a factor, with 17.5% of 16-18 year olds getting
the vaccine, compared to 6.4% of 10 to 12 year olds. As these results indicate, it is clear
that non-school-based HPV vaccination efforts as they currently exist are largely
ineffective at encouraging girls and women to obtain the vaccine (Rouzier & Giordanella,
2010).
Age, vaccine acceptance, and the current study. While the success of schoolbased HPV vaccination programs depends largely on the views and support of school
boards and parents, grade-eight girls themselves are likely to have little decision-making
power, or interest, in whether they receive the HPV vaccine or not. The group of women
who have the most control over their own inoculation are those over the age of 18. While
vaccination at younger ages (before girls are sexually active) is the most effective way to
prevent HPV infection, promoting and vaccinating older girls and women can also be
important. The Public Health Agency of Canada (2011) reports that while there is no
official recommendation to vaccinate women over the age of 26, that the use of the
vaccine for women over this age can still be considered.
In addition to the official age recommendations provided by governing health
bodies, it is also important to understand the HPV vaccination beliefs and behaviours of
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women in their twenties (and beyond), because of current societal dating and marriage
trends. Canadians are marrying later (Clark & Crompton, 2008), and thus dating longer,
suggesting that many women may still be exposed to new sexual partners well past their
26th birthdays. In addition, divorce is fairly common; consequently, women can find
themselves dating again at the end of a marriage or long-term relationship. The average
age of a second marriage is 39 years (Clark & Crompton, 2008). Although statistics on
cohabitation are not available, the divorce and dating pattern for individuals in commonlaw relationships is most likely similar to that of individuals who marry, with some
statistics indicating that common-law relationships are even more unstable (Clark &
Crompton, 2008). As these statistics demonstrate, then, many women, including those
over the age of 26 or who may be deemed at low-risk due to their current relationship
status, can still benefit from the HPV vaccine.
In light of the need for women over the age of 18 to be vaccinated against HPV
infection, the current study examined the vaccination beliefs of women aged 18 to 30.
These are women who currently fall within the recommended vaccination age range of 14
to 26, or who did fall within this age range when the vaccine was first approved in 2006.
Vaccination in Canada: Conclusions. As the research described in the sections
above indicates, although intentions to become vaccinated against HPV appeared high
before the release of the vaccine, once it became available, actual rates of receipt were
lower than anticipated. While some school-based programs in Canada are effective
(obtaining over 80% vaccination rates), other school-based programs, and all non-school
based efforts, have been much less effective at encouraging the majority of girls and
women to obtain the HPV vaccine. The reasons for this lack of uptake need to be
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investigated fully if the HPV vaccine is to be successful in protecting all women from
HPV infections and their resulting negative physical and psychological effects. Gaining
an understanding of the complex factors that influence the receipt of a vaccine for an STI
is also important because other STI vaccines are also needed and in development.
It is evident that there are notable differences in HPV vaccination rates. Cost and
ease of access appear to impact uptake rates as free, school-based programs are the most
effective means of vaccine delivery. However, the variance observed between uptake
rates by province, and even between women who are not eligible for school-based
programs, indicates that factors more complex than cost and accessibility are at play.
There are various psychological, social, and practical reasons for why some girls and
young women do not obtain the HPV vaccine. These reasons are discussed in the
following sections.
Distrust of the Medical Establishment and How it Can Impact Vaccinations
In the 1970s and 1980s, research on the growing distrust of the medical
establishment began to appear (Betz & O’Connell, 1983; Shontz, 1974 ). Betz and
O’Connell (1983) published an article discussing the growing distrust of professionals in
North American society, stating that a Harris poll conducted in 1976 found that
confidence in the medical institution declined from 72% to 43% between 1966 and 1975.
Unfortunately, this distrust may still be present. Armstrong et al. (2006) found that
distrust in the health care system is relatively high in the United States. Their sample was
composed of 961 primarily Caucasian individuals, 80% of whom had health insurance.
Eighty-two percent of their participants believed that people die every day because of
mistakes made by the health care system, 58% believed that if a mistake was made in
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their health care that the health care system would try to hide it, and 71% believed that
there are ingredients in medicines that people are not informed about. While distrust in
institutions or organizations appears to be high, Hall, Dugan, Zhang, Michra (2001) in
their review of physician trust, have stated that individuals may have different
perceptions of trust of individual doctors in comparison to health care systems or
organizations. They report that “90% or more of patients express some level of trust in
their physician, and two-thirds express strong trust” (p. 626). These researchers also note
that in comparison to physicians, trust in health care establishments such as hospitals and
insurance companies is lower. In light of these varying perceptions of trust, the current
study examined participant perceptions of trust in physicians, as well as their trust in a
larger health entity and key player in the vaccine industry, pharmaceutical companies.
This was done in order to determine current levels of trusts in Canada, and whether
perceptions of trust are related to HPV vaccination behaviours or intentions.
Medical distrust has been linked to various health related behaviours. A study that
looked at the construct of trust in the healthcare system and the use of preventative
medical services in a sample of 1681 older adults found that having trust in one’s
personal physician was related to use of preventative health services, with higher levels
of distrust being associated with lower rates of health service usage (Musa, Schulz,
Harris, Silverman & Thomas, 2004). Not only are levels of trust related to healthcare
usage, but also to perceptions of actual health. One study found that distrust in the health
care system was significantly related to worse self-reported health (Armstrong et al.,
2006). As this research reveals, then, the concept of trust in the healthcare field is
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important, as a lack of trust can be expected to lead to negative health outcomes, such as
lack of vaccination behaviours.
How has medical distrust arisen? Betz and O’Connell (1983) proposed that
distrust in doctors rose in the 1970s because the doctor-patient relationship had become
more impersonal, short-lived, and specialized as individuals saw various doctors rather
than relying on one family physician. The bureaucracy associated with medicine, as well
as increased feelings of social distance and increased population mobility (and the result
that many individuals do not know or have community connections to their doctors) were
also discussed as contributing to increased physician distrust.
More recently, high-profile medical mistakes or adverse research findings may
have had a negative impact on public perceptions of the medical establishment as well.
For instance, stories about dangerous drugs or supplements such as the diet drug Fen
Phen, which can cause heart damage; the diabetes medication Avandia, which also has
been found to damage the heart; and Accutane, the acne medication which has now been
linked to Crohn’s disease and Colitis, may all impact the public’s trust. One of the most
high-profile and emotionally-charged health-related controversies however, is that of a
proposed link between childhood vaccinations and autism. This controversy, along with
its impact on vaccination rates and the anti-vaccine movement in general, will be
discussed in the next section.
Anti-vaccine sentiment. The first vaccines were created over a century ago, and
since that time immunizations have played an important role in maintaining population
health, so much so that vaccines are touted as one of the most important medical
advances in history to date (Link, 2005). Although the majority of individuals believe in

Factors that influence HPV vaccinations 21

the benefit of vaccines (Heller, 2008), an anti-vaccine sentiment has gained popularity.
Allen (2007), a writer and journalist, reports in his well-received book on vaccines that
the latest controversy surrounding vaccines developed over the last decade. He reports
that this was due to a number of factors: (1) the removal of a number of pharmaceuticals
from shelves due to safety concerns, and a resulting suspicion of the safety of all
pharmaceuticals, (2) distrust in those who regulate medicines, and (3) the popularity of
the theory that the Measles Mumps Rubella (MMR) vaccine causes autism.
The idea that vaccines cause autism began in the late 1990s and gained popularity
in the early 2000s (Allen, 2007). The idea came from a study that was published in the
esteemed medical journal, the Lancet, in 1998. The study, led by Andrew Wakefield,
stated that a possible link between the Measles Mumps Rubella (MMR) vaccine and
autism may exist. In 2004, 10 of the original 12 authors of the article issued a statement
in the Lancet that they wanted to retract the interpretation that there may be a link
between the vaccine and autism from the original article (Murch et al., 2004). The
journal article itself has since been retracted (The Editors of The Lancet, 2010), and in
2011, the British Medical Journal reported that the study was a deliberate fraud. Before
the official retraction, various studies were conducted in order to investigate the possible
relationship between vaccines and autism. One of these studies was conducted in Quebec,
and like the others, found that no link exists (Fombonne, Zakarian, Bennett, Meng &
McLean-Heywood, 2006).
While the Lancet article was eventually retracted, damage to the public’s trust in
vaccines had already been done. Some individuals now feared vaccinations and the
potential side effects the public feared they could produce. Popular media both
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propagated this fear and tried to calm it. Articles from popular media included titles such
as: An Epidemic of Fear: How Panicked Parents Skipping Shots Endangers Us All
(Wallace, 2009), H1N1 Flu Shot: 3 Major Fears Debunked (Biba, 2009), The Autism
Debate: Who’s Afraid of Jenny McCarthy? (Greenfeld, 2010), The Vaccine-Autism link
an Elaborate Fraud (MacLeans, 2011), Autism, Vaccines and Fear (Wente, 2010), and
Swine Flu Fiasco: Everyone Needs the Vaccine. Few Plan to Get it. What you Need to
Know. What You Need to Do (Gulli, 2009). A Canadian study that was conducted to
investigate attitudes toward vaccines found that while the majority of respondents had
positive views of the effectiveness of vaccines, 62% of participants were reluctant to
dismiss anti-vaccine positions (Ritvo et al., 2003). Surprisingly, 45% of participants
reported that they did not have enough knowledge about the safety of vaccines to
comment on the topic. The authors noted that participants’ lack of knowledge about
vaccines may cause them to be susceptible to anti-vaccine messages, a concern they
believed public health should take seriously in the event of an emergency that would
require vaccinations.
Not only have some people internalized fears about vaccines, but actual
behaviours have also changed. Some countries experienced actual drops in vaccination
rates. For instance, in the USA in the early 2000s only 2% of parents refused to vaccinate
their children, but throughout the 2000s vaccination rates decreased in some areas, with
vaccine exemption rates in some communities doubling and tripling (Allen, 2007). For
example, by 2004, vaccination rates in one Colorado community had fallen so much that
1200 cases of Whooping Cough were reported, the highest rate of the illness since 1964
(Allen, 2007). The United Kingdom also experienced drops in immunization rates. In the
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mid-nineties the vaccination rate for the MMR vaccine was above 90%. This fell to a low
of 80% in 2003-2004, although it is currently increasing again (rates were 88% for 20092010). Rates have yet to reach their mid-1990s levels however, or the World Health
Organization goal of 95% uptake (National Health Service, 2010). In Canada, while
drops in childhood immunization rates haven’t been as large as those of the USA.,
England, or Ireland for example, immunization rates for many viruses and illnesses are
still lower than target levels. The Influenza vaccine, for instance, while becoming more
popular over the last decade, was still only obtained by 34% of the population in 2005
(Statistics Canada, 2008). During the H1N1 vaccine program of 2009, when all
Canadian’s were urged to obtain the vaccine for this particularly severe flu strain, only
41% of Canadians were vaccinated (Gilmour & Hofmann, 2010).
Research has been conducted to investigate how fears of vaccine safety and
distrust in the medical establishment influences immunization decisions. Prislin, Dyer,
Blakely and Johnson (1998) conducted in-person interviews with 4832 parents. They
found that while external barriers (e.g., cost, logistical considerations) play a part in
influencing whether parents have children vaccinated, factors such as beliefs about
natural immunity, distrust of health professionals, and vaccine safety concerns also play a
role. Research has also revealed a potential paradox, where individuals believe in medical
science, but distrust health professionals. Gullion, Henry and Gullion (2008) conducted
interviews with 25 parents who consciously chose to forgo or delay childhood
vaccinations. Themes that arose from these interviews showed that parents place a high
value on scientific knowledge, while at the same time voicing their distrust of the medical
community. Some participants reported that they were suspicious of the reasons
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physicians supported vaccines, stating that they believed doctors had specific agendas
such as being rewarded financially. Some participants also mentioned that they do believe
that physicians have good intentions, but that they are too busy to stay current with new
medical developments. Thus, these parents believed that by doing their own research they
could gain more knowledge about vaccinations than their physicians. To explain this
distrust, the authors of the study discussed the current nature of physician visits. They are
often short, and physicians do not have time to devote to explaining medical procedures
or decisions. This means that individuals often do not have their medical information
needs met, resulting in fears or concerns that are not addressed by doctors (Gullion,
Henry and Gullion, 2008). Because of this, individuals begin seeking out their own
medical information.
Fear of the HPV vaccine. Given the anti-vaccine sentiment that grew in the
2000s, it may not be surprising that when the HPV vaccine was released in 2006 that it
was met with controversy and fear by some. As the media articles mentioned earlier in
this document highlight, some individuals feared potential side effects from the HPV
vaccine, and others feared its impact on girls’ sexuality. When beliefs about the safety of
the HPV vaccine were actually investigated, it was found that while a majority of
individuals believe the vaccine is safe, a portion of people are uncertain. For example, a
study by Rosenthal et al. (2008) found that 57% of parents agreed that the HPV vaccine
was safe, 33% were unsure, and 10% did not think that it would be safe to give to their
children. In another study of 52 women aged 18 to 30 that investigated factors associated
with HPV vaccination, 75% of the sample reported that they believed the HPV vaccine
was very or extremely safe (Kahn, Rosenthal, Hamann and Bernstein , 2003). This
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suggests that 25% of the sample were either uncertain, or did not believe this. Concerns
about HPV vaccine safety, if administered to the self or a daughter, were also found in
others studies where the rates of participants who had safety concerns were 24% (Caskey,
Lindau & Alexander, 2009), 7% (Constantine & Jerman, 2007), and 5% (Marshall, Ryan,
Roberton and Baghurst, 2007), and the rates of concern about side-effects were 66%
(Marshall et al., 2007). A Canadian study conducted in British Columbia that investigated
predictors of school-based HPV vaccine acceptance found that fear of the safety of the
vaccine was a predictor of parent’s decisions to have their daughters’ vaccinated, with
29.2% of the sample reporting this as a reason for not having their daughter vaccinated in
the school-based program (Ogilvie et al., 2010).
While concerns about the safety of the HPV vaccine may be related to fears of
vaccines in general, concerns about sexuality, or other factors, the newness of the HPV
vaccine and thus a lack of data on side effects may have contributed to the relatively high
rates of concern reported for this specific vaccine. In fact, in a study of parental attitudes
towards HPV vaccination, Gerend, Weibley and Bland (2009) found that 50% of the
parents in their sample of 82 individuals felt reluctant to give the new HPV vaccine to
their daughters. They reported that they would feel more secure if the vaccine had been
safely on the market for three years or longer. The current study was able to investigate if
concerns about vaccine safety impact HPV vaccinations, along with an examination of
the many other factors that may influence vaccine uptake.
While it is obvious that concerns about the vaccine do exist, do such concerns
actually influence uptake? Research has examined how a fear of side effects influences
HPV vaccination behaviours, and some studies have found that concerns do influence
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acceptance (Kahn et al., 2008; Woodhall et al., 2007). For instance, a study by Woodhall
et al. (2007) found that of 727 parents surveyed, of those who were resistant to having
their child vaccinated, 13% rated their concern about the safety of the HPV vaccine as
high, and 57% rated their concern as medium. Kahn et al. (2008) also conducted a study
investigating HPV vaccination rates and factors that influence intentions to receive it.
Their sample was comprised of 409 sexually experienced women aged 13 to 26.
Questionnaires assessed HPV vaccination history, demographics, behaviours, knowledge,
beliefs, and gynaecologic history. The results of the study indicated that only 5% of the
sample had received one of the HPV vaccine shots and that various factors were related
to future HPV vaccination intentions. Concerns about the safety of the vaccine was one
factor. Others included practical barriers like cost, knowledge, norms, and perceived
severity and benefits. While it is obvious that concerns about side effects influence
acceptance of the vaccine, it is important that other possible concerns also be
investigated. Concerns that were investigated in the present study include: trust in
physicians, trust in pharmaceutical companies, concerns about the STI status of the
vaccine and associated stigma, along with many other variables.
It is important to note here, that the safety of the HPV vaccine has been widely
demonstrated through research (Harper et al., 2006; Munoz, 2009). In a study conducted
by Medina et al. (2010), 1035 girls from 12 countries were administered the HPV
vaccine, while 1032 girls were administered the hepatitis A vaccine. The hepatitis group
was used as a control group. The HPV vaccine was not found to lead to more serious
adverse event reports than the hepatitis vaccine. Only one reported adverse event from
the HPV group was deemed to be related to vaccination. This reaction was a urinary tract
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infection in conjunction with elevated liver enzymes (the participant recovered). Other
serious medical events that were reported by the HPV group were not related to
vaccination, as any adverse medical event that occurred in the months after vaccination
was recorded. These serious adverse events included things such as: pneumonia,
enterobiasis, gastroenteritis, upper respiratory tract infection, gunshot wound,
dehydration, abdominal pain, bronchitis, and injury. Individuals in the HPV group did
report more headache, fatigue, muscle pain, and rash than those in the control group,
however.
Distrust and safety concerns and the current study. In summary, the goals of
the current research as they pertain to the concept of medical distrust, included an
examination of: (1) perceptions of the safety of the HPV vaccine, (2) beliefs in the
trustworthiness of physicians, and (3) beliefs in the trustworthiness of pharmaceutical
companies, and how these variables were related to HPV vaccination decisions.
The STI Status of HPV And How It Can Impact Vaccination
When investigating factors that impact HPV vaccination behaviours, it is
important to recognize that the HPV vaccine is not just a regular vaccine. The sexually
transmitted nature of the human papillomavirus means that there are unique social and
psychological factors tied up in perceptions of the vaccine. As Casper and Carpenter
(2008) state in their examination of the HPV vaccine and notions of sexuality, the HPV
vaccine “provokes longstanding controversies swirling around sex, gender and women’s
bodies” (p.896). While little research has examined how the sexually transmitted nature
of the human papillomavirus influences actual vaccine acceptance, it is likely that factors
such as STI stigma and shame, embarrassment, and sexual comfort or discomfort may
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influence actual or anticipated HPV vaccine receipt. It is important to note that Zimet,
Liddon, Rosenthal, Lazcano-Ponce and Allen (2006), reported in their review of factors
that influence vaccinations that the STI status of the HPV vaccine should not impact
uptake. They based this belief on research that investigated young adults’ interest in the
vaccine and the finding that a large majority of youth were interested in obtaining it, even
when it was described as an STI vaccine. We now know, however, that HPV vaccine
uptake has not reached anticipated levels. It is the belief of this author that the STI status
of HPV does have an impact on participants’ vaccination decisions.
Heller (2008) outlined the unique challenges that face vaccines for sexually
transmitted infections in a discussion about the potential development of an HIV vaccine.
He outlined how negative social perceptions about HIV and the “type” of people who
acquire it, hampers public support for HIV preventative measures such as a vaccine.
Because of the manner in which HIV is spread, either through unprotected sexual contact,
intravenous drug use, or blood transfusions, individuals infected with it are blamed for
their infections, Heller notes (2008). While part of the negative reaction to the HIV
vaccine is likely related to homophobia, as HIV was first described as a disease of gay
men, stigma is associated with all STIs, due to the sexually transmitted nature of the
viruses, and the perceptions of the people who get them. Because of this, vaccines for any
STI may face backlash. For example, Allen (2007) described how protests of schoolbased Hepatitis vaccination programs arose in the 1990s. Religious organizations and
their supporters protested the use of the vaccine, in part due to its status as a virus that
could be spread by sex or intravenous drug use (Allen, 2007).
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Due to the negative perceptions that people have of STIs, there are likely various
barriers that impede individuals from wanting to obtain a vaccine for an STI. First, people
may not believe they are at risk of STI infection because they think that they are not the
“type” of person who would get an STI (e.g., promiscuous, risky, likely to have infected
partners). Second, individuals may blame those who do acquire STIs for their own
infections, and thus may not support preventative measures. Third, even if individuals do
believe in STI vaccination and that they are at risk for acquiring an STI, they may fear
stigma from health professionals, friends or romantic partners if they obtain the vaccine.
And finally, individuals may simply be too embarrassed to discuss sexually related topics
with healthcare providers. As this list demonstrates, there are many STI-related reasons
why an individual may not want the HPV vaccine, or may not feel comfortable asking for
it. While all individuals in North American society do not hold prejudicial attitudes
towards sex, STIs, or those who are infected with them, prejudices are held by some
individuals, and thus fears of STIs and associated stigma abound. Research findings
concerning STI associated stigma will be discussed next.
STIs, stigma and shame. Research has consistently found that STIs are viewed
negatively. For example, Smith, Mysak and Michael (2008) conducted a study using
vignettes that described the diagnosis of a target with either a sexually transmitted
infection or another illness, in which symptoms and prognosis were held constant.
Results indicated that targets who were described as having a STI were rejected more by
study participants. Interestingly, although gender was hypothesized to influence target
perceptions, with women being perceived more negatively, no differences were found.
The authors note that this is in line with more recent research, and may indicate that
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sexual double standards are decreasing. Thus, STI stigma is a concern for both men and
women. Another study, conducted by East, Jackson, Peters and O’Brien (2010) using
online interviews, also found that participants admitted to viewing those who had STIs
negatively, even though the participants had recently been diagnosed with an STI
themselves. The study authors proposed that these individuals were experiencing selfblame and shame, and were attempting to deal with their diagnosis by denying and
minimizing their infections to themselves and to others (and thus not identifying with
others who have STIs). Some participants did indicate that they felt shame because of
their infection, and that it lead to their denial.
Feelings of stigma and shame by those infected with STIs were also found in
other studies. In an interview study of 60 individuals with either HPV or Genital Herpes
that was conducted to investigate the impact of STI infection on individuals and their
relationships, the majority of participants stated that “the stigma associated with having
an STI made them feel depressed, sad or upset” (Newton & McCabe, 2008, p. 866).
Consistent with the Newton and McCabe study that had a sample in which half of its
members had HPV (30 individuals had HPV, and 30 had herpes), other studies
investigating perceptions of HPV infection have also found that individuals do perceive
an HPV infection as stigmatizing (Kahn et al., 2007; Perrin et al., 2006).
The negative associations that individuals hold of STIs and the people who get
them are not only detrimental because of the psychological and social effects they have
on individuals, but also because these STI fears can act as a barrier to seeking STI testing
or treatment, and thus may lead to negative physical outcomes as well. For example, a
study of 594 youth revealed that youth who view STIs as stigmatizing have a decreased
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likelihood of being tested for STIs (Cunningham, Kerrigan, Jennings & Ellen, 2009).
This finding was true for both males and females. Interestingly, this relationship was not
found when perceptions of STIs as shameful were assessed in this study. However,
Cunningham et al. noted that shame was found to influence STI testing in another study.
Similar results were also found in a large study (N = 1973) by Fortenberry et al. (2002),
who found that feelings of STI stigma and shame acted as barriers to STI testing,
although STI stigma appeared to have the largest influence. A relationship between
stigma and STI testing was also found by Barth et al. (2002). They investigated factors
that influenced whether youth would seek STI testing and found that a fear of stigma was
one of the reasons individuals did not get tested. More specifically, participants reported
that they feared being perceived negatively by others (e.g, as dirty, stupid, or loose),
being embarrassed or gossiped about, and feeling shame, guilt or other negative
emotions. Finally, Balfe et al. (2010) conducted interviews with 35 Irish women, asking
about perceptions of individuals with an STI. Participants viewed women with
Chlamydia, or who needed testing for Chlamydia, as irresponsible and sexual risk-takers,
quite different from how the participants viewed themselves, indicating that people who
acquire STIs are others. Participants viewed being tested for Chlamydia negatively, and
reported that doing so would open them up to stigma and social ostracism. To
participants, not getting tested for the STI was a positive thing which enabled the women
to maintain their sense of being a “good” person. As the research outlined above exhibits,
negative perceptions of STIs do influence whether individuals will undertake
preventative health measures (e.g., STI testing, STI vaccinations).
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Even when the time for prevention has passed and treatment is needed, fear and
stigma may still lead to a lack of treatment seeking. For example, Lichtenstein (2003)
conducted focus groups with 42 participants to investigate how STI related stigma
impacts individuals’ willingness to seek treatment in the southern USA. Findings from
the focus groups confirmed that STI related stigma did impact participant willingness to
seek treatment for STIs. Four types of stigma concerns were revealed in the focus groups.
Individuals feared stigma because of: religious reasons, concerns about their privacy,
fears of being the target of gossip, and concerns having to do with race. As this study
demonstrates, STIs and how they are perceived by society has a very large impact on
individual behaviour.
Sexual comfort, sexual activity, and the HPV vaccine. While the stigma and
shame associated with STIs is widely shown to influence STI-related health behaviours, it
is likely that other sexually related factors such as comfort with sexual communication
and conservatism also influence sexual health behaviours, and thus HPV vaccine
acceptance. Comfort communicating with a health professional about the HPV vaccine
may be important for women who want to obtain the vaccine. When speaking with health
care providers, the topic of the vaccine may also come up in conjunction with
conversations about other sexual behaviours, and thus comfort engaging in these
conversations may prove to be important to HPV vaccine acceptance. Research that has
investigated comfort discussing sexuality and STI vaccine behaviours is limited.
However, Gamble, Klosky, Parra and Randolph (2010), wrote a review article about
factors associated with family HPV vaccine decision-making. In it they recognized that
sexual communication may be an important factor related to HPV vaccine acceptance. In
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their article, their discussion focused on parent-child sexual communication, and how
comfort in engaging in this type of talk is important for adolescent sexual health. They
recommended that more research be conducted in this area.
Conservatism may influence how individuals feel about sex and STIs in general.
For instance, sexual and social conservatism were found to be associated with higher
scores on STI stigma and shame measures in a Canadian study of 218 male and female
university students (Foster & Byers, 2008). Sexual conservatism has definitely been
found to influence some parents’ perceptions of the HPV vaccine. When the HPV
vaccine was released in the USA in 2006 conservative parents protested, often stating that
mandatory vaccination of young girls was immoral and compromised family values
(Krishnan, 2008). Opponents to mandatory HPV vaccine programs stated that because the
virus is spread sexually, and not through uncontrollable transmission methods like
surface germs or sneezing, that parents should have the choice to vaccinate their children.
For parents with sexual concerns, one of the most publicized criticisms of the HPV
vaccine was the belief it would encourage teen girls to have sex or to be promiscuous,
either because having parents approve an STI vaccine would be seen as synonymous with
giving consent for sex, or because teens would believe that they were now protected
against other STIs as well.
In light of the controversy surrounding the HPV vaccine launch, researchers
investigated whether parents and youth really did believe that the HPV vaccine would
increase sexual activity, and whether these beliefs would influence decisions to vaccinate.
A Canadian study comprised of 471 adults aged 19 to 69 investigated various
demographic factors associated with Pap testing and HPV vaccine beliefs and practises.
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When results were examined, it was found that 12% of individuals believed the HPV
vaccine would encourage early sexual activity, and that 19% of individuals somewhat
believed that it would (Sauvageau et al., 2007). Luckily, in spite of these beliefs, 89% of
the sample would recommend the vaccine to their daughters or nieces. Interestingly, this
study found that opinions about the influence of vaccine receipt on sexual activity varied
with age (Sauvageau et al., 2007). Older individuals were more likely to believe that the
vaccine would encourage an earlier onset of sexual activity than did younger individuals,
with 19% of male and female participants under the age of 30 believing that the vaccine
would encourage earlier sex, and 47% of participants aged 60-69 believing it would do
so. Other studies have also found that some individuals believe that HPV vaccinations
would encourage early sexual activity, although these individuals are usually the
minority. A study that looked at factors associated with HPV vaccine acceptance in a
sample of California mothers found that 18% of their sample would not vaccinate their
daughters, and that of these mothers, 11% would not vaccinate their daughters because
they had either moral or pragmatic concerns about the effect vaccination would have on
their daughters’ sexual behaviour (Constantine & Jerman, 2007). The majority of study
participants (75%) did support immunization by age 13 however, and stated they did so
for health and safety reasons. A study by Bernat et al. (2009) found a similar proportion
of parents who believed that the HPV vaccine would impact sexuality. They found that
12.8 % of parents believed that the HPV vaccine would cause increased sexual activity.
Marshall, Ryan, Roberton and Baghurst (2007) also found similar results, with 5% of
their Australian parent sample (N = 2002) reporting concerns about the HPV vaccine
leading to promiscuity.

Factors that influence HPV vaccinations 35

Although research does show that a small proportion of individuals believe that
the HPV vaccine will impact sexual behaviour, it does not show that it increases sexual
activity in youth or that vaccination leads to risky sexual practices (e.g., not using
condoms, not getting Pap tests). Kahn, Rosenthal, Hamann and Bernstein (2003) studied
52 young women between the ages of 18 and 30, and found that most of their study
participants reported that they would not engage in more risky sexual behaviours if they
got the HPV vaccine. Related to this, after the release of the HPV vaccine, Caskey,
Lindau and Alexander (2009) conducted a study of 1011 women. In order to investigate
perceptions of the HPV vaccine, participants were asked a variety of questions about it.
When asked about the need to use condoms after vaccination, women who had received
the vaccine correctly responded in 98% of cases that condoms were still necessary.
Meanwhile, 18% of non-vaccinated women did not know if women would need to use
condoms after vaccination or not. When asked about the need to get Pap tests after
vaccination, 19% of women who had been vaccinated were not sure if they still had to get
them, while 24% of women who had not been vaccinated did not know if women would
still need to get them if they were vaccinated. These study results highlight that receiving
the HPV vaccine does not lead to increases in sexual risk taking, and thus researchers in
this area can feel confident that recommending the HPV vaccine is not detrimental to
women’s health. However, the research does reveal that all women require more
education about the HPV vaccine and health protective behaviours that must continue
after vaccination.
The STI status of HPV and the current study. As previously demonstrated, the
HPV vaccine is likely perceived as more than just a regular vaccine. The sexually
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transmitted nature of the HPV virus is likely to have an impact on vaccine acceptance and
uptake. This study examined these factors. Specifically, this study investigated
participants’ perceptions of STIs (i.e., as shameful and stigmatizing), their level of
comfort with sexuality (i.e., sexual permissiveness), and their comfort asking a doctor for
the HPV vaccine.
While this study was among the first to examine how the STI status of HPV and
distrust in the medical establishment influences HPV vaccinations, there are various other
psychological, social, and practical factors that have been found to influence actual or
intended vaccinations. In order to develop a clear understanding of the various factors
that influence vaccinations, these additional factors were also organized and assessed in
this study. The theoretical framework that was used to organize this study is described
next.
Theoretical Framework
Research in the area of HPV vaccination decisions has often utilized variables
drawn from various health behaviour change theories. Concepts from theories such as the
Theory of Planned Behaviour (TPB), Social Cognitive Theory, and the Health Belief
Model (HBM) have frequently been applied to research on HPV vaccination intentions or
behaviours, although often the theoretical origins of the concepts are not discussed, and
theoretical models are not tested. Buchanan (2008) has been one of the few researchers in
this area to specifically set out to test models of HPV vaccination decisions. In her
dissertation research, she found that an integrated model that incorporated three
components of the Health Belief Model (susceptibility, benefits, and self-efficacy) and
the subjective norms component of the Theory of Planned Behaviour was more predictive
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of university women’s intentions to obtain the HPV vaccine than either model alone.
More specifically, she found that the HBM alone accounted for 43% of variance in
intentions, the TPB accounted for 39% of variance, and the integrated model accounted
for 51% of the variance in intentions. In her studies, she examined the direct relationships
between the variables assessing each component of the models being tested, and the
outcome vaccination intentions. In light of her research findings, and after an
examination of both the HBM and the TPB, as well as past research in the area of HPV
vaccination, it was decided that all components of the Health Belief Model would be
measured in the current study, and that the concept of subjective norms from the Theory
of Planned Behaviour would also be assessed. Based on Buchanan’s findings, the
remaining components of the TPB were not assessed. The history of these theories is
briefly discussed next.
Background: Health behaviour theories. Health behaviour theories are ways to
examine the factors that influence whether people will perform certain health behaviours
(Conner & Norman, 1995). Ultimately, the practical application of using these theories is
to gain an understanding of how health behaviours can be modified so that negative
behaviours can be discouraged, and positive behaviours encouraged. Some of the most
popular health behaviour theories are the Health Belief Model (HBM) (Becker, Haefner
& Mainman 1977), the Theory of Planned Behaviour (TPB) (Ajzen, 1991), and the
Transtheoretical Model of Behaviour Change (Prochaska & DiClemente, 1983), which is
often called the “Stages of Change” model. Research into various types of health
behaviours has been conducted using these theories, with some theories being more
predictive of certain behaviours than others. The Health Belief Model, for instance, has
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historically been good at predicting vaccine intentions or acceptance (e.g., for the
influenza vaccine), but for other issues such as smoking cessation or weight loss, the
Transtheoretical model has gained popularity.
The Health Belief Model. The Health Belief Model (Becker, Haefner &
Mainman 1977) is one of the oldest health behaviour theories (Sheeran & Abraham,
1995). In the 1950s, health professionals recognized the need to develop a framework to
identify modifiable psychological variables that influence health behaviour (Sheeran &
Abraham, 1995). Kurt Lewin is credited as a primary influence on the group of
individuals who began the early research and theory building that would lead to the
Health Belief Model. Lewin’s idea that an individual’s behaviour is influenced by their
perception of situations or environments was embraced by these early researchers and is
reflected in the assumptions of the model (Rosenstock, 1974). Initial tenets of the model
stated that in order to propel an individual to participate in health behaviours, a person
needs to believe: (1) that they are susceptible to the disease or illness, (2) that the impact
of the disease would be at least moderately severe, (3) that taking a prescribed action
would be beneficial in that it would prevent the disease or that it would lessen its negative
impact on the individual, and (4) that engaging in the health behaviour would not mean
that an individual had to overcome strong psychological barriers (Rosenstock, 1974).
Thus, the initial four core components of the HBM are: perceived susceptibility,
perceived severity, perceived benefits, and perceived barriers. Additional research on the
development of the HBM eventually lead to the addition of the components of cues to
action, self-efficacy, and knowledge. A description of each of these components is
presented later in this document.
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The Theory of Planned Behaviour. The Theory of Planned Behaviour assumes
that individuals undertake a rational decision-making approach when considering health
behaviours (Edberg, 2007). It is assumed that people’s behaviours are influenced by their
(1) attitudes toward the behaviour, (2) what they believe other peoples’ perceptions of the
behaviour are (these perceptions are termed subjective norms in the TPB), and (3) their
level of perceived control for engaging in the behaviour (Edberg, 2007).
Definitions of the Model Components Measured in This Study
HBM: Perceived susceptibility. Perceived Susceptibility is an individual’s belief
in how susceptible one is to a disease, health problem, or condition. Rosenstock (1974)
described the various levels of perceived susceptibility that an individual may experience.
They range from an individual not believing they are at risk at all, to those who admit
there is a statistical probability of developing an illness but do not believe they are
personally at risk, to individuals who believe they are definitely at risk. In a meta-analysis
conducted by Janz and Becker (1984) perceived susceptibility was found to be a
significant predictor in 77% of examined studies, making it the third most predictive
component of the four core components of the HBM.
HBM: Perceived severity: Perceived severity is the component of the HBM that
assesses individuals’ perceptions of the severity of an illness, condition, or injury
(Maiman & Becker, 1974). When discussing the physical severity of an illness or injury,
effects can include things such as the impact of disease on the body, pain, health
complications, etc. (Edberg, 2007; Sheeran & Abraham, 1995). In addition to these
physical perceptions, perceived severity can also include perceptions of how severe an
impact an illness or injury can have on the practical, day to day aspects of one’s life (e.g.,
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not being able to drive a car as a result of breaking a leg) (Edberg, 2007; Rosenstock,
1974), as well as the severity of possible psychosocial effects and impacts on social roles
(e.g., feeling uncomfortable dating someone new as a result of having an STI) (Sheeran &
Abraham, 1995). Janz and Becker (1984) found that perceived severity was the least
predictive of the four core components, although it was still a significant predictor in 59%
of the studies they examined.
HBM: Perceived benefits. Perceived benefits are the benefits an individual
perceives will arise from engaging in a specific health promoting activity (Edberg, 2007;
Sheeran & Abraham, 1995). For example, in the context of HPV vaccination, an
individual might perceive that being vaccinated against HPV would result in the benefit
of immunity to the virus. In the meta-analysis conducted by Janz and Becker (1984),
perceived benefits were significant predictors in 81% of studies, making it the second
most predictive component of the four core components. Rosenstock (1974), in a
discussion of this component, proposed that individuals assess the benefits that multiple
courses of action have for themselves in relation to certain aspects of their health. An
individual’s health related behaviour will then be influenced not only by their opinion of
how beneficial one proposed course of action would be, but also in comparison to how
beneficial other courses of action would be as well. For instance, if an individual was
considering the HPV vaccine as a method to protect themselves from HPV infection, they
may also consider the benefits of condom use or abstinence in relation to the benefits of
the vaccine.
HBM: Perceived barriers. Perceived barriers are the obstacles an individual
believes stand between themselves and a desired health related activity (Sheeran &
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Abraham, 1995), or the negatives that may arise if any individual engages in certain
health behaviours (Edberg, 2007). Barriers can include practical barriers (e.g., time, cost)
as well as psychological barriers. These psychological barriers can include things such as
feelings and emotions (e.g., embarrassment, fear of stigma if asking for the HPV
vaccine), and psychologically related skills (e.g., lack of social skills, lack of selfefficacy) (Sheeran & Abraham, 1995). As Sheeran and Abraham point out, given this
broad definition, there is an abundance of possible barriers that can influence whether
individuals engage in health protective behaviours. In the study by Janz and Backer
(2008), perceived barriers was found to be the most predictive component of the model.
In 91% of the studies they examined, the barriers component of the HBM was a
significant predictor.
HBM: Cues to action. According to Edberg (2007), cues to action are external
events that motivate a person to act. Without these cues, health behaviour change might
not occur. Cues can be represented by a large range of things, such as mass media
campaigns, reading a story in a magazine, educational leaflets, conversations with
friends, and urgings of medical professionals, to name a few (Sheeran & Abraham, 1995).
In Maiman and Becker’s (1974) chapter on the HBM and its origins and correlates in
psychological theory, they discussed how cues to action make an individual aware of
their feelings on a certain topic, and allow them to make decisions about how they want
to act (e.g., should they engage in the behaviour or not?). To use cues to action
effectively in research with the HBM, Sheeran and Abraham (1995) argue that cues to
action should be operationalized by asking respondents if they received cues, and if so,
how much the cue influenced their decision to engage in the target behaviour. They also
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note that a crucial aspect of using Cues to Action in research is to ensure that the range of
relevant cues is assessed.
HBM: Self-efficacy. Self-efficacy is a construct originally derived from Social
Learning Theory (Bandura, 1977). It is a person’s belief in his or her ability to take an
action (Edberg, 2007; Leonard, Hotz, Hansen & Plotnikoff, 1999). When used in the
Health Belief Model, it measures a person’s self-efficacy in carrying out a health
behaviour (in the current study, getting the HPV vaccine). Self-efficacy has been found to
be predictive of health behaviours across many studies (Wallston, 2001).
HBM: Knowledge. The component of knowledge is rather self-explanatory; an
individual’s knowledge of a health issue is believed to have an impact on their desire to
engage in specific health protective behaviours. For instance, if an individual is not aware
of a particular health threat or protective behaviour, they cannot be expected to act on this
information. Thus, the amount of knowledge that an individual has about HPV or the
HPV vaccine may have an impact on their desire to receive the immunization.
TPB: Subjective norms. Broadly, subjective norms are “the customary codes of
behaviour in a group or culture, together with the beliefs about what those codes mean”
(Edberg, 2007, p. 39). The Theory of Planned Behaviour states that one of the
determinants of an individual’s intention to engage in a certain behaviour, is the
subjective norms that surround that behaviour. These norms are the beliefs that a person
has about significant others’ opinion of them engaging in the behaviour (Conner &
Sparks, 1995). Only the norms of individuals or groups (called “referents” in the TPB)
whom the person believes are significant are assumed to influence behaviour. In the
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current study, possible referents were parents, friends, and romantic partners, as well as
doctors or other health professionals, and media sources.
Interestingly, the impact that peers and social groups have on behaviour was noted
in early writings describing the HBM. For instance, Rosenstock (1974) states that beliefs
“are undoubtedly influenced by the norms and pressures of…social groups” (p.4). Thus,
by adding a social norms component to the planned adapted HBM, I am not only acting
in accordance with previous research findings in the area of HPV vaccination, but the
addition also falls in line with earlier conceptualizations of the HBM and related
concepts. A study that utilized the Theory of Planned Behaviour to assess mothers’
intentions to vaccinate their daughters for HPV also found that subjective norms were
associated with vaccine intentions (Askelson et al., 2010). Thus, the current study also
assessed participants’ subjective norms.
The Model Tested In The Current Study
When working with the Health Belief Model, one quickly realizes that there are
limitations to overcome when trying to develop a model to test the components described
in this theory. As Sheeran and Abraham (1995) discuss, no formal definitions of the
model components have been developed. Thus, definitions have been left open to the
interpretation of individual researchers. In addition, no clear paths between variables have
been established. For example, a formula was never developed to weigh perceived
benefits against perceived barriers, although the constructs are at times described as
mathematically related, with benefits needing to be subtracted from barriers (Sheeran &
Abraham, 1995). The result of the flexible operationalization of the constructs of the
HBM, and the lack of established hypotheses about how the components may impact one
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another, has meant that researchers develop their own measurements and models based
on their areas of research.
The goal of this study was to develop a comprehensive structural equation model
of vaccination decisions, which included an investigation into the interrelationships
between the model components. Because little model testing has been conducted in this
area, a model of vaccination decisions had to be developed from the ground up.
Hypotheses about the possible paths between components, and how the components and
variables may impact each other were developed after carefully considering the research
in this area. The initial model of HPV vaccine intentions that was developed and tested
for this study can be seen in Figure 1. Knowledge and Cues to Action are the first
variables to be considered in the model. It is proposed that the level of Knowledge an
individual has about HPV, and the Cues that they receive from others to obtain it, are the
primary variables that influence how the decision making process begins. Level of
Knowledge and Cues are then hypothesized to impact individuals’ perceptions of the
Severity of HPV, perceptions of Susceptibility to the virus, and views of the Subjective
Norms surrounding vaccination. Once these constructs have been processed by the
individuals, Benefits and Barriers associated with vaccinations are considered. Barriers
are also then influenced by perceptions of self-efficacy, as high or low levels of efficacy
may influence how able or unable an individual feels they are to overcoming barriers.
Finally, after an assessment of the Barriers and Benefits individuals believe surround
vaccination, vaccination intentions are formed.
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Figure 1
Proposed Model of HPV Vaccination Intentions
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Past HPV and HPV Vaccine Research Related to the Model Components Being
Tested
There have been multiple studies investigating factors that are associated with
anticipated or actual HPV vaccine acceptance. While the current study sought to
understand how some novel variables influence vaccination decisions, in order to develop
a comprehensive understanding of HPV vaccine decisions, various other factors that past
research had found to be predictive of immunizations were also investigated. Because this
study used a modified Health Belief Model as its theoretical framework, the results of
previous studies are organized and described below as they relate to applicable HBM and
TPB categories.
Susceptibility. The degree to which a woman or girl feels susceptible to HPV
infection has been found to influence vaccine acceptance. While a few studies have
specifically asked participants if they felt susceptible or at risk of acquiring HPV, more
studies have investigated factors that can presumably be thought to influence perceptions
of susceptibility (e.g., whether one is sexually active or not, whether one has ever had an
abnormal Pap test, whether one is married, etc.). One study that investigated perceived
susceptibility specifically was done by Kuitto, Pickel, Neumann, Jahn and Metelmann
(2010). They conducted a questionnaire study of 760 German women to investigate
factors associated with actual HPV vaccine receipt and found that high perceived risk of
HPV infection was indeed predictive of vaccination.
Current sexual activity and relationship status have been found to influence HPV
vaccination intentions or behaviours. For example, Marshall, Ryan, Roberton, and
Baghurst (2007) found that married individuals were unlikely to want the HPV vaccine in
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comparison to those who were unmarried. In addition, as individuals aged, they were less
likely to want to be vaccinated (one may assume because they felt less susceptible to
infection). In the same study, it was also found that those who were in a monogamous
relationship and those who were not currently sexually active reported that they would be
concerned about getting a vaccine that did not relate to their current life situation (i.e.,
they did not believe themselves to be at risk of infection). Caskey, Lindau and Alexander
(2009) found similar results in their study of 1011 females aged 13-26 years. When they
assessed barriers to HPV vaccine adoption, 13% of 13-17 year olds, and 23% of 18-26
years olds reported “other” reasons for not wanting the vaccine. These included being
married or already having HPV (and thus believing one is not susceptible). When sexual
activity was examined as a barrier, 47% of 13-17 years olds noted that not being sexually
active was an obstacle to receiving the vaccine, while 19% of 18-26 years olds reported
the same. Interestingly, the same study also found that 78-80% of participants reported
that they would want the vaccine if they had an abnormal Pap test in the past, indicating
again, that factors related to susceptibility influence desires to be vaccinated.
Having multiple sex partners or ever having had an STI has been found to be
predictive of vaccine acceptance in some studies. Jones and Cook (2008) conducted a
study examining intent to receive the HPV vaccine among 340 college students. Ever
having had an STI, or having a close friend or relative who had HPV was related to
greater intent to receive the HPV vaccine. Compared to individuals who had never had
sex, those who have had sex were more likely to intend to receive the vaccine. When
number of sexual partners was examined, individuals with more than 5 sexual partners
were more likely to want the HPV vaccine than were people with 1 to 5 partners.
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The influence of having an abnormal Pap test, and thus feeling more at-risk, and
its possible link to HPV vaccine acceptance were also found in other studies (Eaton et al.,
2008; Ferris, Waller, Owen & Smith, 2008; Short et al., 2010). A study of mid-adult
women who had experienced an abnormal Pap test found that these women were more
likely to report that they would want the HPV vaccine after receiving an educational
intervention, than women who had not had a history of abnormal tests (Ferris, Waller,
Owen & Smith, 2008). The authors of the same study also found that knowledge of the
link between HPV and cervical cancer, as well as beliefs about their own risk of acquiring
HPV, positively influenced women’s desires to be vaccinated. In a study that examined
perceived prevalence and risk of acquiring HPV in women who have sex with women (N
= 275), participants were also more likely to perceive that they were at risk for HPV
infection if they had ever had an abnormal Pap test (Eaton et al., 2008). Twenty-seven
percent of this population reported having had abnormal Pap tests in the past, and 5% had
been officially diagnosed with HPV.
In light of this past research, the current study investigated participants’
perceptions of susceptibility in various ways. General questions inquired specifically
about participants’ perceived susceptibility (e.g., do you feel susceptibility to HPV
infection?) and were used to create a scale measuring perceptions of susceptibility. In
addition, other questions about specific sexual, relationship, and gynecological
behaviours or experiences were also asked as these variables were proposed to influence
vaccination decisions.
Knowledge. A large amount of research investigating HPV knowledge was
conducted around the time of the HPV vaccine release. These early studies revealed that,
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in general, HPV knowledge was low to moderate (Brewer & Fazekas, 2007; Zimet,
2005). Lenehan et al. (2008) found that Canadian women had a moderate level of HPV
knowledge, although women knew little about the HPV vaccine. Research has also been
conducted to examine the influence that HPV knowledge has on intentions or actual
vaccination rates. The results of these studies have been mixed (see the review of HPV
vaccine predictors conducted by Brewer & Fazekas, 2007, for more information).
Some studies have found that higher levels of HPV knowledge are associated with
increased vaccination intentions or behaviours (Gerend, Weibley & Bland, 2009;
Woodhall et al., 2007). An interesting study that investigated the effectiveness of a
knowledge intervention on HPV vaccine acceptance, found that when comparing
individuals who had received an online knowledge intervention with individuals who did
not, that those who viewed the site felt increasingly susceptible to HPV infection, had
more knowledge about HPV and its risk factors, and had improved attitudes toward the
vaccine (Doherty & Low, 2008). Interestingly, while both men and women had more
positive attitudes toward vaccination after viewing the site, women’s scores were
significantly higher than men’s. It is important to note, however, that before viewing the
website intervention the researchers found that women knew more about HPV and its risk
factors than men, and that women felt more at risk for acquiring the virus. Another
intervention study found similar results where after receiving an intervention intended to
raise HPV related knowledge, participants’ acceptance of the HPV vaccine for their
daughters increased (Chan, Cheung, Lo & Chung, 2007).
In contrast to the research described above, some studies have not found a
relationship between HPV knowledge and vaccinations. For example, a study that
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compared two groups of participants, one who was given information about HPV and a
control group who was not, found that although knowledge differed between the two
groups at the end of the study, HPV vaccine acceptance was not significantly different
(Dempsey, Zimet, Davis & Koutsky, 2006). Buchanan (2008) also did not find that
knowledge predicted HPV vaccine intention in her college sample, although the internal
reliability of her measure was low, and might have accounted for the nonsignificant
results.
While the impact of knowledge on HPV vaccination appears to vary, the influence
of knowledge on other health behaviours seems likely. After all, knowing that a Pap test
is necessary and what it is for is likely to influence whether women get the test. It may be
that if knowledge does not have direct links to HPV vaccine acceptance, it has indirect
links. These indirect relationships may arise through the influence of knowledge on
factors such as perceptions of susceptibility, severity and social norms. This study
investigated whether knowledge has a direct impact on vaccination decisions, as well as
whether it had an impact indirectly, through variables such as perceived severity and
susceptibility. This was done through structural equation modeling.
Severity. How severe an individual believes HPV infection to be is theorized to
influence their HPV vaccination behaviours. While individuals generally perceive HPV
infection or its outcomes to be severe (Cates, Brewer, Fazekas, Mitchell & Smith, 2009),
the predictive ability of this construct as it relates to HPV vaccination is still debateable
(Brewer & Fazekas, 2007). Some studies have found a relationship between severity and
HPV vaccine behaviours. Zimet et al. (2005) found that parents who would accept the
HPV vaccine for their daughters were more likely to perceive an STI diagnosis as
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physically and emotionally severe. Other studies have not found such a relationship,
however. In her dissertation, Buchanan (2008) did not find that perceived severity was
predictive of HPV vaccine intentions, and neither did Jones and Cook (2008), who did not
find a relationship between perceived severity of HPV and intent to get the vaccine in
their study of male and female college students. Dempsey, Zimet, Davis and Koutsky
(2006), also did not find that severity was predictive of vaccine intentions.
In addition to investigating how severity is related to HPV vaccinations, research
has also reported on individuals’ perceptions of the severity of HPV or its outcomes. A
study that investigated racial differences in HPV knowledge and vaccine acceptability,
found that 71% of black women and 91% of white women believed that HPV would be a
serious threat to health (Cates, Brewer, Fazekas, Mitchell & Smith, 2009). Because of its
link to cancer, it is also important to understand if women associate HPV with cancer, and
whether they believe that this risk is severe. This study did this by investigating fear of
cervical cancer. Studies have shown that a fear of developing cancer is a common
reaction after a woman has an abnormal Pap test or is told she has HPV (Gath et al., 1995;
Juraskova et al., 2007; Karasz, McKee & Roybal, 2003; Maissi, Marteau, Hankins, Moss,
Legood & Gray, 2004). A Canadian study by Sauvageau, Duval, Cilca, Lavoie and
Ouakki (2007) found that 57% of their adult, female participants feared developing
cervical cancer, and that this anxiety about cervical cancer was consistent across all age
groups. The same study found that 93% of participants believed that cervical cancer is
serious. Similar findings were also found by Kahn, Rosenthal, Hamann and Bernstein
(2003), with 94% of their female sample reporting that they believed that cervical cancer
would be a moderate to severe health problem. Interestingly, a German study found that a
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fear of cancer predicted HPV immunizations (Kuitto, Pickel, Neumann, Jahn &
Metelmann, 2010).
While the research described above appears to indicate that perceived severity
does not influence HPV vaccine behaviour, a systematic review of HPV vaccination
predictors found mixed results about the impact that perceived severity has on vaccine
acceptance (Brewer and Kazekas, 2007). In light of this debate, and with the
understanding that individuals do believe that HPV is severe, the current study
investigated whether a relationship between these variables does exist. Indirect
relationships between the variables were also assessed during the testing of the proposed
model of HPV vaccination decisions.
Barriers. As discussed in the theory section of this document, the barriers that can
impede a person from engaging in a health behaviour can be both practical/physical as
well as psychological. Earlier in this paper some potential psychological barriers were
discussed, such as vaccine safety fears, medical distrust, and factors related to the STI
status of HPV. This study investigated whether these were indeed barriers to HPV
vaccination. Other barriers were also investigated. For instance, past research has
consistently found that cost is a major barrier to HPV vaccination, as is access to a health
care professional, and time. Types of barriers investigated by past research are discussed
now.
The cost of the HPV vaccine has been one of the most researched potential
barriers, and studies have found that cost does influences intentions to vaccinate. In their
study examining barriers to HPV vaccine adoption, Caskey, Lindau and Alexander (2009)
reported that 27% of women between 18 and 26 reported that the cost of the vaccine is
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too high. Kahn et al. (2008) also found that cost was a concern, where only 42% of girls
and women aged 13 to 26 from their study felt that they could afford to get vaccinated.
Not surprisingly then, a Canadian study found that 91% of male and female adults living
in Quebec would agree to the HPV vaccine if it was funded; however, this rate dropped to
72% if individuals had to pay $100 per dose (Sauvageau, Duval, Cilca, Lavoie & Ouakki,
2007). More worrisome, the proportion of individuals aged 18 to 25 (one of the most
important target groups for the vaccine) changed their perceptions of the vaccine once
cost was added as a factor, with the rate of people who would strongly agree that they
would get the vaccine falling from 56% to 28% if individuals had to pay. This change
was not as drastic for individuals aged 26 to 30. One can presume this is due to the
increased financial resources of this group. Rosenthal et al. (2008) found that 9% of their
parent sample thought that the HPV vaccine was too expensive, 47% were unsure, with
only 44% believing that the cost would not be prohibitive. In addition, the study by Kahn,
Rosenthal, Hamann and Bernstein (2003) also found that some participants reported cost
as a concern when contemplating HPV vaccination.
Cost is not the only practical barrier to vaccination, however. A fear of needles or
the pain of the injection has also been cited as a barrier in some studies (Burke, VailSmith, White, Baker & Mitchell, 2010; Kahn et al., 2003). Gottvall, Larsson, Hoglund
and Tyden (2009) found that 19% of their Swedish student sample reported that a fear of
needles would be a barrier. A qualitative research study by Short et al. (2010) found that
the vast majority of their adult sample (aged 27-55) believed that there were barriers to
HPV vaccine uptake and these included cost, a fear of side effects, and hassles. Burke,
Vail-Smith, White, Baker and Mitchell (2010), also found that a fear of side effects would
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act as a barrier. This was reported as a concern by 42.9% of their sample. Caskey, Lindau
and Alexander (2009) found that not having a regular healthcare provider is a barrier to
adoption as well, while the hassle of having to go to a doctor to get the vaccine was cited
as a barrier in another study (Burke et al., 2010).
As the above research demonstrates, a variety of psychological and practical
considerations can impact HPV vaccine intentions and actual uptake. The current study
investigated some of these practical and psychological barriers. These included fear of
stigma if asking a doctor for the vaccine, physician trust, pharmaceutical company trust,
STI stigma and shame, sexual permissiveness, and cost.
Benefits. In order for a person to be motivated to engage in a health promoting
behaviour, the HBM would propose that they recognize that the behaviour will be
beneficial. In her examination of the utility of the HBM for predicting HPV vaccination
intentions, Buchanan (2008) found that perceived benefits were predictive of intentions.
In Canada, Ogilvie et al. (2007) found that perceptions of the vaccine was the strongest
predictor of mother’s intentions to vaccinate their daughters against HPV. Items that
assessed these perceptions included items that inquired about HPV vaccine safety,
effectiveness, whether vaccine are beneficial in general, and whether the HPV vaccine is
beneficial for boys and girls, specifically.
Researchers have investigated whether participants believe that the HPV vaccine
will be/is effective. For instance, Rosenthal et al. (2008) found that 75% of their study’s
parent sample believed that the HPV vaccine would protect their children from cervical
cancer and genital warts, indicating that beliefs in the benefit of the vaccine vary (25% of
the sample did not believe it would be protective). Basu, Chapman and Galvani (2008)
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conducted a study that revealed that participants believed that being vaccinated against
HPV would significantly lower their risk of cervical cancer and genital warts. Of course,
belief in the effectiveness of the vaccine is a perceived benefit. If an individual believes
the vaccine will work to protect them from infection, then they will likely believe that the
vaccine is beneficial. Caskey, Lindau, and Alexander (2009) investigated the concept of
perceived effectiveness and vaccine uptake. They found that 16% of their female
participants, aged 13-26, reported that they were unsure if the HPV vaccine would work.
In their study, however, beliefs about the effectiveness of the vaccine were not predictive
of HPV vaccinations.
Dempsey, Zimet, Davis and Koutsky (2006) also investigated perceived benefits
of HPV vaccination. They found that parental beliefs about the benefit of the vaccine for
children or for society were significantly associated with vaccine acceptance. Relatedly,
an Icelandic study of willingness to participate in an HPV vaccine trial found that the
main reason individuals would want to participate in a trial was for their own or
community benefits (Gudmundsdottir et al, 2003). These studies revealed that not only
are individual benefits a motivating factor to encourage vaccinations, but that beliefs in
the benefit of vaccinations for society at large may also be predictive of vaccination
decisions (in the current study these beliefs are referred to as vaccine positive beliefs).
In light of the research summarized above, this study investigated the impact that
perceived benefits of HPV vaccination had on vaccination decisions. The variables that
assessed the construct of benefits in this study measured beliefs in the effectiveness of the
HPV vaccine, as well as beliefs that vaccines are beneficial for the self or society (vaccine
positive beliefs).
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Self-efficacy. Deciding to obtain a vaccine or to engage in any health promoting
activity will be influenced by how much self-efficacy a person has for engaging in the
behaviour. While self-efficacy beliefs for a variety of behaviours may be complex and
require concerted effort to develop (for example self-efficacy to quit smoking or to begin
a physical activity regime), the type of self-efficacy required to obtain a vaccine is likely
to be more focused on feeling efficacy to overcome barriers to adoption, for instance,
feeling efficacy in one’s ability to get to a doctor for three shots, or for saving the money
needed to purchase the shots. A link between self-efficacy and intentions to get the HPV
vaccine has been found in at least two studies (Buchanan, 2008; Kahn et al., 2008). Kahn
et al. (2008) found that intentions to get vaccinated were related to individuals’ beliefs in
their ability to get the vaccine, although the authors mention that this relationship was not
as strong as they had originally anticipated. Buchanan was also one of the first to examine
this construct and found it to be predictive of intentions as well. Due to its inclusion in
new versions of the HBM, and due to the promising results that other studies have found
when investigating this variable, this current study investigated how self-efficacy
influences HPV vaccination. After all, while individuals may recognize that there are
barriers to obtaining the HPV vaccine, they may have varying levels of self-efficacy for
overcoming such barriers.
Cues to action. Cues to action are the external events that occur that motivate a
person to act in a certain way. In terms of cues for HPV vaccination, these may be cues
from friends, family or media, although the most researched types of cue are those that
come from physicians or other health professionals. As discussed elsewhere in this
document, Caskey, Lindau and Alexander (2009) investigated factors that influence HPV
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vaccination in girls and women. They found that for both age groups investigated (those
13-17 and those 18-26) speaking with a healthcare provider was associated with
vaccination. For those aged 18-26, speaking with a family member was also predictive.
In their large study of parental attitudes toward the HPV vaccine, Dempsey, Zimet, Davis
and Koutsky (2006) found that physician recommendations were related to vaccine
acceptance. In a Canadian study, Lenehan et al. (2008) found that physician
recommendations would influence women’s willingness to obtain the vaccine. As these
results indicate, doctors who discuss the vaccine with their patients are likely to influence
uptake, indicating that cues to action are likely associated with HPV vaccinations. While
the majority of HPV vaccine research has investigated physicians’ cues to action, the
current study will also investigate cues from other sources as well.
Subjective norms. The final type of research that will be reviewed in this section
on past predictors of HPV vaccinations are studies that have investigated the impact of
subjective norms on HPV vaccination rates or intentions. Buchanan (2008) found that the
subjective norms component of the Theory of Planned Behaviour was the only
component from this model that was predictive of intentions to receive the vaccine in her
study comparing the HBM and the TPB. Limited other studies have also investigated
norms. Kahn et al. (2003) investigated 52 young women’s attitudes toward the HPV
vaccine, as well as their intentions to receive it. They found that various factors were
associated with intentions, one of which were women’s beliefs that others would approve
of the vaccine. These significant others included parents and romantic partners. Dempsey
et al. (2006) also investigated parental attitudes toward the HPV vaccine. Along with
other factors, including cues to action as noted above, they found that peers influenced
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decisions to obtain the vaccine. Finally, a Canadian study found that subjective norms
were predictive of mother’s intentions to vaccinate their daughters, with physician’s
recommendations being particularly influential (Ogilvie et al., 2007). In light of this
research, the current study examined participants’ beliefs about the subjective norms of
others.
The Current Study
This study was a theoretically guided investigation into factors that are related to
actual or intended HPV vaccinations in a sample of women who reside in Canada aged 18
to 30. A modified version of the Health Belief Model was used as the theoretical
framework for this study. All components of the HBM were utilized in the study model,
with the addition of the construct of subjective norms from the Theory of Planned
Behaviour. Direct relationships between the variables used to assesses the theory
components and the study outcomes were investigated. In addition, a proposed model of
HPV vaccination intentions was designed and tested.
While past studies have examined the impact of multiple variables on HPV
vaccinations, the current study investigated the impact of a number of novel variables.
The new variables that were assessed in this study were: distrust in physicians and
pharmaceutical companies, sexual attitudes, STI stigma and shame, and comfort asking a
physician for the vaccine due to fear of stigma. All of these variables were assessed under
the barriers component of the HBM. In addition to these novel variables, past research
has investigated various other factors and their relationship to HPV vaccination decisions.
These variables were organized using the theoretical framework from this study, and their
relationship with the study outcomes was also assessed. A brief discussion of the study
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variables that were assessed in this study follows. A summary of this description can also
be found in Table 1. For organizational purposes, each component of the model is listed
here along with the variables that will be used to assess it (1) To investigate the impact of
perceived susceptibility on HPV vaccination intentions or actual uptake, questions
inquiring about perceptions of susceptibility were asked and compiled into a scale. In
addition, questions inquiring about relationship history and sexual history were asked.
These questions may influence an individual’s perception of their susceptibility. Sexual
history questions included past and current condom use, number of sexual partners,
sexual experiences (e.g., ever having intercourse) and ever having been diagnosed with an
STI. (2) To investigate the perceived severity of HPV infection, questions assessing the
perceived severity of the virus on the body were asked, as were questions on the
perceived severity of treatment, fears of cervical cancer, and the social impact of
infection. (3) Perceived benefits of vaccination were assessed by asking participants
whether they believed that getting the HPV vaccine would be beneficial (i.e., it would
prevent HPV infection), and whether they valued vaccinations (vaccine positive beliefs).
(4) Two types of perceived barriers were investigated in this study: psychological
barriers and practical barriers. The psychological barriers included physician and
pharmaceutical company distrust, perceptions of STIs and related stigma and shame, fear
of stigma if asking a doctor for the vaccine, attitudes toward sex, and vaccine safety fears.
Practical barriers that were assessed included things such as cost and access to a doctor
one feels comfortable speaking with. (5) Knowledge of HPV was investigated through an
HPV knowledge questionnaire. Knowledge of the HPV vaccine was also assessed with
its own questionnaire. (6) Various cues to action were investigated by asking participants
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Table 1
Variables Used In the Current Study

Variable/Scale
Susceptibility scale questions
Relationship status info.
Sexual experience info.
Gynaecological health history
Severity of virus on body
Severity of treatment
Fears of cervical cancer
Severity of social impact
Vaccine efficacy
Vaccine positive beliefs
Pharmaceutical company trust
Physician trust
STI stigma and shame scale
Fear doctor stigma
Access to trusted medical care
Sexual attitudes (SAS)
General vaccine safety fears
HPV vaccine safety fears
Cost
HPV knowledge questions
HPV vaccine knowledge questions
Cues to action questions
Obtaining vaccine self-efficacy
Subjective norms

Perceived
Susceptibility

Perceived
Severity

Health Belief Model
Perceived
Perceived
Benefits
Barriers

Knowledge

Cues to
Action

Self
Efficacy

TPB
Subjective
Norms

X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
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if they have heard about the HPV vaccine from various sources (e.g., friends, the media,
romantic partners, parents). (7) Feelings of self-efficacy were investigated by asking
various questions about participants’ level of belief that they could obtain the vaccine in
order to create a scale score. Finally, (8) The influence of subjective norms on vaccination
intentions or actual uptake was also assessed. Participants’ beliefs of the opinions of
significant others on the topic of HPV vaccination were assessed (e.g., would this person
or group support you getting the vaccine?).
While many predictor variables have been described, it is also important to
understand how outcome variables were assessed in the current study. Actual vaccination
status was one of these outcomes. Whether female participants had received the HPV
vaccine or not was assessed, and participants were classified as either vaccinated or not
vaccinated. Thus, having obtained the HPV vaccine or not was one dichotomous outcome
variable used in this study. Individuals who had obtained the vaccine did not complete
any additional outcome items. The remaining outcome items assessed the intentions of
those who had not yet been vaccinated. Participants who had not received the vaccine
were asked about their intentions to receive it. More specifically, these individuals were
asked two questions (1) if they would like to get the vaccine, and (2) whether they think
they will actually get it, regardless of whether they want it or not. It was hypothesized that
the two outcome items, while similar, would assess two distinct aspects of vaccination
intentions. The first, desire to get vaccinated, assessed whether individuals want the
vaccine. The second item, thoughts about whether one would actually get it, assessed the
more complex idea that although individuals have a certain level of desire for the vaccine,
this level of desire may not correspond to whether an individual actually thinks they
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would ultimately engage in the behaviour. Much like a cigarette smoker may desire to
quit smoking, they may or may not think that they actually would quit. Social psychology
has shown that attitudes are often not predictive of behaviours (Myers & Spencer, 2001).
However, attitudes are more predictive when the measured attitude is specific to the
situation under investigation (Myers & Spencer, 2001). Thus, the current research aimed
to investigate both desires, and actual thoughts that one would engage in the behaviour.
In summary than, the current study had three main outcome variables that were
assessed: The relationship between the model variables and (1) whether individuals
obtained the vaccine or not (yes or no), (2) non-vaccinated women’s desire to get the
vaccine (one item rated on a 5 point scale), and (3) whether non-vaccinated women
thought they would actually get it (one item rated on a 5 point scale). Thus, the current
study investigated both actual uptake behaviours, as well as intentions. While all three
outcomes were used when testing the direct effects of the predictor variables on
outcomes, only HPV vaccine desires were used as the outcome when testing the proposed
model of HPV vaccination intentions.
Hypotheses
The overall research question this study attempted to answer was: “What factors
influence actual or anticipated HPV vaccinations in a sample of Canadian women aged
18-30?” The following set of hypotheses was developed to investigate the direct
relationships between the predictor variables used in this study, and the outcome
variables. All hypotheses, except for one, predicted positive relationships between the
components and the outcomes (e.g., higher perceived severity, more positive subjective
norms, or more cues to action would lead to more vaccinations or higher intentions to
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vaccinate). One hypothesis, which described perceived barriers, anticipated a negative
relationship, so that as perceived barriers increase, actual vaccinations or intentions to
vaccinate decrease. The study hypotheses were:
1. Perceived susceptibility to HPV infection will predict HPV vaccination, with
higher levels of susceptibility being positively associated with actual or intended
vaccinations.
2. Perceived severity of HPV infection will predict HPV vaccination, with higher
levels of perceived severity being positively associated with actual or intended
vaccinations.
3. Perceived benefits of receiving the vaccine will predict HPV vaccination, with
higher levels of benefits being positively associated with actual or intended
vaccinations.
4. Perceived barriers to receiving the vaccine will predict HPV vaccination, with
higher levels of perceived barriers being negatively associated with actual or
intended vaccinations.
5. Knowledge of HPV will predict HPV vaccination, with higher levels of
knowledge being positively associated with actual or intended vaccinations.
6. Self-efficacy for receiving the HPV vaccine will predict HPV vaccination, with
higher levels of efficacy being positively associated with actual or intended
vaccinations.
7. Cues to Action will predict HPV vaccination, with more cues being positively
associated with actual or intended vaccinations.
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8. Subjective norms will predict HPV vaccination, with positive norm beliefs
being positively associated with actual or intended vaccinations.

In addition to these hypotheses, it was also predicted that the proposed model of
HPV vaccination intentions developed for this study would be a valid model, in terms of
showing good fit with the study data. Please see Figure 1 to review the model that will be
tested. It was anticipated that knowledge and cues to action would influence perceived
severity, perceived susceptibility, and subjective norms, which in turn would influence
perceived barriers and benefits. Barriers were also anticipated to be impacted by selfefficacy. And finally, barriers and benefits were expected to impact vaccination decisions.
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Chapter II
Method
Participants
Participants were 374 women, aged 18 to 30, residing in Canada. Participant ages
ranged from 18 to 30 with an average age of 22.05 years (SD = 3.54). It should be noted
that due to their ages, all individuals who participated in this study were most likely not
involved in the grade eight school-based vaccination programs that began in 2006 or
2007. Thirty-six people who participated in this study were 18 years old at the time of
data collection, and thus may have been in grade 8 the first year the vaccine was offered
in schools. However, when asked why they obtained the vaccine, no participants reported
that it was offered to them at school for free. Three people did report that they were able
to obtain the vaccine at their school because they had medical insurance, but the type of
school and the age when the vaccine was offered were not reported. The majority of
participants, 90.4%, came from the province of Ontario, although women from five other
provinces also took part in this study. These provinces were Alberta, British Columbia,
Manitoba, New Brunswick, and Nova Scotia. The number of individuals from each of
these other provinces ranged from two to 16. The majority of participants, 95.4%, had
completed at least some university or college. When ethnic background was inquired
about, the majority of participants, 79.7% of the sample, reported that they were
White/Caucasian, 6.1% reported they were Middle Eastern/West Asian, 3.5% reported
they were Chinese/Japanese/South-East Asian, 3.2% reported they were Black/African
Canadian or American, 2.7% reported they were South Asian, 1.6% reported they were
Aboriginal, 0.8% reported they were Latin American/Mexican, 1.9% reported they were
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biracial, and 2.1% indicated they had an “other” background. Individuals could check
more than one option, and thus, percentages exceed 100.
Measures
Measures presented to vaccinated and unvaccinated participants were mostly
identical with the exception of some outcome measures. Where differences existed, they
have been noted below. Many of the measures described were adapted from previous
studies conducted by other researchers, or were created entirely by this author. Below,
credit is given to scale items created and used in previous research. If a source is not
mentioned, items were created by this author. Please see the Appendix to view
questionnaires developed for this study. Questionnaires developed by other researchers
are not included in this appendix. Before beginning this dissertation work, this author
conducted a study investigating male HPV vaccination intentions that utilized earlier
versions of some of the scales described below. While some of these adapted/created
scales were changed significantly before the current study was conducted (e.g., scales
assessing severity and susceptibility variables), some scales remained relatively
unchanged. These scales and their Cronbach’s alpha values are reported below where
applicable.
Demographic Variables
Demographic questions inquired about participant age, education level, ethnicity,
sexual orientation, household income, and province of residence.
Knowledge Variables
HPV knowledge. An HPV knowledge questionnaire, based largely on one
developed by Daley et al. (2008), was used to assess HPV knowledge. Daley’s scale

Factors that influence HPV vaccinations 67

contains 22 items and was found to have a Cronbach’s alpha of .81. Because recent
research and media stories have discussed the link between HPV and head and neck
cancers, two additional questions related to oral transmission were added to the scale for
this study. The Cronbach’s alpha for this scale in this study was found to be .84. In order
to determine if the items added to this scale improved the Cronbach’s alpha value, the
score for the original 22 items was calculated, and was found to be .81, indicating the
addition of the two items for this study improved the scale. Participants could respond to
each question by indicating true, false or unsure. Scores were computed by summing the
number of correct responses to each question.
HPV vaccine knowledge. To assess HPV vaccine knowledge, a seven item scale
was used. Six of the scale items were used by Caskey et al. (2009) in a study where the
questionnaire was administered to over 1000 female participants. Unfortunately, internal
reliability statistics for these six items were not reported, although the results of their
study did find that HPV vaccine knowledge varied. In addition to these six items, an
additional question was added by the present author to inquire about participants’
knowledge that the vaccine protects against genital warts. This was done to ensure that
the scale items inquired about both cervical cancer and genital wart protection. The
original six items made no mention of genital warts. Similar to General HPV knowledge,
response options were true, false or unsure, and scale scores were computed by summing
the number of correct responses. The Cronbach’s alpha for the seven item scale was
found to be .66. The alpha for the scale with just the original 6 items was .65, indicating
that the addition of the seventh item did not decrease the Cronbach’s alpha value.
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Perceived Susceptibility Variables
Sexual history questions. The study questionnaire contained 8 questions
inquiring about participants’ past sexual experiences. These questions investigated: sexual
orientation, if a participant ever engaged in sexual activity, how many sexual partners one
has had, sex of most recent sexual partner, how many individuals a participant has had
vaginal and anal intercourse with, age at first vaginal and anal intercourse, and how often
condoms were used with male sexual partners currently and in the past.
Relationship status. Three items assessed participants’ romantic relationship
status. The items inquired about current relationship status, relationship status over the
past two years (assessed with a five-point scale), and current relationship length.
Gynaecological health history. Information on participants’ gynaecological
history was gathered with five items which asked about Pap test history (if a test had ever
been done, if it was abnormal, and if abnormal, the medical follow-up that was done), and
STI and HPV infection experience.
Perceived susceptibility. To assess participants’ feelings of susceptibility to HPV
infection, four likert-scale questions were developed for this study. Questions asked
participants if they felt at risk of experiencing: HPV, cervical cancer, genital warts, and
having an abnormal Pap test. Response options ranged from 1 (very unlikely) to 5 (very
likely). The Cronbach’s alpha for the scale was found to be .88.
Perceived Severity Variables
Perceived severity of HPV infection. Perceived Severity of HPV Infection was
measured with five items that assessed participants’ emotional upset if they were to
become infected with HPV, or if they were to develop a symptom such as genital warts,

Factors that influence HPV vaccinations 69

or abnormal cervical cells. Upset at HPVs potential impact on the body and future fertility
was also assessed. Responses were recorded on a scale ranging from 1 (not at all) to 5
(very much). Then Cronbach’s alpha for this scale was .73.
Perceived severity of HPV treatment. Participants’ upset at the impact or pain
of treatment associated with HPV related illnesses such as genital warts or abnormal
cervical cells, was assessed with five likert-scale questions. Response options ranged
from 1 (not at all) to 5 (very much). The Cronbach’s alpha for this scale was .80.
Perceived severity of the social impact of HPV infection. Similar to the
previous two severity scales, perceived severity of the social impact of having HPV was
assessed with six likert-scale items. Questions inquired about participants’ upset if
various significant others (doctors, friends, romantic partners) found out the participant
had HPV, as well as the level of upset the participant would feel/did feel if they had to tell
future romantic or sexual partners that they were infected. Again, response options ranged
from 1 (not at all) to 5 (very much). The Cronbach’s alpha for this scale was .88.
Fear of cervical cancer. Past research has consistently found that women who are
told they have HPV or abnormal Pap tests, fear cancer. Because of this, the current study
investigated whether women’s fears of cervical cancer had an impact on vaccination
decisions. Fear of cervical cancer was assessed by adapting the items of the Fear of Breast
Cancer scale (Champion et al., 2004), to instead reflect fear of cervical cancer. The items
developed by Champion et al. were used, except where the word breast appeared, it was
replaced with the word cervical. Thus, the item that originally read “When I think about
breast cancer, I get nervous”, was changed to read “When I think about cervical cancer, I
get nervous”. Items were rated on a 5-point Likert scale ranging from 1 (strongly
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disagree) to 5 (strongly agree). The Cronbach’s alpha was .91 for the original Fear of
Breast Cancer Scale, and the construct validity of the original scale was supported by its
ability to predict mammography, as well as by relationships between the scale scores and
perceptions of threat and self-efficacy. The Cronbach’s alpha for the fear of cervical
cancer scale used in the present study was .94.
Perceived Benefit Variables
HPV vaccine effectiveness. Participants’ perception of the effectiveness of the
HPV vaccine was measured with eight likert-scale questions. Questions inquired about
participants’ beliefs about the protective benefits of the vaccine as they relate to HPV
infection, genital wart infection, abnormal cervical cells, future fertility, cancer, and
romantic and sexual relationships. Responses options ranged from 1 (not at all) to 5 (very
much). The Cronbach’s alpha for this scale was .94.
Vaccine positive beliefs. Past research has shown that some individuals support
HPV vaccination because it is beneficial to society. To tap into this construct, a 5-item
scale used by Marlow, Waller and Wardle (2007) to assess parents’ perceptions of the
importance of children’s vaccines was adapted for use in this study. Items were reworded
to assess participants’ beliefs in the positive impact of their own vaccinations, versus the
original scale that assessed parents’ perceptions of the importance of vaccinating their
children. Items asked participants about their level of belief that vaccinations protect
against outbreaks, and protect others. Items also assessed beliefs that vaccines contribute
to health, and that failing to get vaccinated puts others at risk. Responses were scored on a
5-point Likert scale that ranged from 1 (strongly disagree) to 5 (strongly agree). The
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Cronbach’s alpha for the scale used by Marlow and colleagues was .76. In the present
study the Cronbach’s alpha for the adapted scale was .90.
Perceived Barrier Variables
Vaccine safety fears. Vaccine safety fears were measured with six items that
inquired about participants’ concerns about vaccines in general, as well as about the HPV
vaccine specifically. These items were originally meant to assess two types of safety
concerns, those of vaccines in general, and those of the HPV vaccine. However, the items
were combined to create one scale due to a high correlation between the two scale scores.
Questions asked if participants thought vaccines were safe, and if they worried about side
effects. Participants could respond on a scale ranging from 1 (strongly disagree) to 5
(strongly agree). The Cronbach’s alpha for this scale was .91. A pilot study that was
conducted prior to this research utilized the two safety fear scales. The Cronbach’s alpha
values for these scales in the pilot study were .76 for the general vaccine safety concern
scale, and .81 for the HPV vaccine safety concern scale.
Fear of stigmatization if asking for the vaccine (Fear of Doctor Stigma). Due
to the sexually transmitted nature of the HPV virus, it was hypothesized that participants
may feel at risk of being stigmatized if they ask a health care provider for the HPV
vaccine. To assess these feelings, a ten item likert-type scale was used. Response options
ranged from 1 (strongly disagree) to 5 (strongly agree). Items asked participants if they
worry their doctor would think they sleep around, have poor morals, would cheat on their
romantic partner, are protecting themselves, etc., if they asked for the HPV vaccine. The
Cronbach’s alpha value for the scale was .92. An earlier version of this scale was used in
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the pilot study conducted by this author and yielded a Cronbach’s alpha value of .72 in
that study.
Brief Sexual Attitudes Scale (SAS). The Brief Sexual Attitudes Scale
(Hendrick, Hendrick and Reich, 2006) is a shortened (25 item) version of the original
SAS developed by Hendrick and Hendrick (1987). It was used to measure participants’
attitudes toward sex. The scale is comprised of four subscales assessing Permissiveness
(perceptions of casual sexuality), Birth Control (perceptions of responsible sexuality),
Communion (perceptions of idealistic sexuality), and Instrumentality (perceptions of
biological/utilitarian sexuality). Responses were recorded on a 5-point Likert scale that
ranged from 1 (strongly disagree) to 5 (strongly agree). When Hendrick et al. (2006)
assessed the internal reliability of the subscales, they found Cronbach’s alpha coefficients
for the permissiveness subscale to be .95, for birth control to be .87, for communion to be
.79, and for instrumentality to be .80. A total scale score is not computed. The main
subscale of interest in the current study was the Permissiveness subscale, where it was
found to have a Cronbach’s alpha of .92.
STI Stigma and Shame Scale. To measure the level of stigma and shame
participants associate with STIs, the STI Stigma and Shame Scales, developed by
Fortenberry et al. (2002) were used. These scales are made up of 6 items assessing
feelings of shame (original Cronbach’s alpha = .80) and five items assessing fears of
stigma (original Cronbach’s alpha = .77) in situations related to doctor visits for STI
related treatment and examination. In this study, responses were recorded on a 5-point
Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree). The items were
combined to create one scale score (confirmed as methodologically sound by principal
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component factor analysis). The Cronbach’s alpha value for the scale in the current study
was .92.
Physician Trust Scale. The Wake-Forrest Physician Trust Scale (Hall et al.,
2002) was used to measure participants’ trust in physicians. The scale is comprised of 10
items assessing various constructs related to physician trust, such as their competency,
thoughtfulness, and honesty. This scale has been shown to have comparable internal
consistency, reliability, and ranges as other similar measures (Hall et al., 2002). However,
the creators of this scale note that their measure also has the benefit of having a lower
mean score, a more normal distribution, and better discriminatory power (Hall et al.,
2002). Internal reliability was reported as .93 in the original study conducted by the scale
authors. Response options ranged from 1 (strongly disagree) to 5 (strongly agree). The
Cronbach’s alpha value for the scale in the current study was .94.
Pharmaceutical company trust. A 10 item measure to assess participants’ trust
in pharmaceutical companies was used in this study. It was previously developed for
another study conducted by this author. Questions inquired about issues such as trust,
employee honesty, profit motivation, and advertising claims. Items were scored on a 5point Likert scale that ranged from 1 (strongly disagree) to 5 (strongly agree). The
Cronbach’s alpha value for the scale in the current study was .85. In a pilot study
conducted by this author, this scale also had a Cronbach’s alpha value of .85.
Access to medical care. Six questions were used to assess participants’ access to
medical care, and to gather details about their health care provider. Participants were
asked if they have a regular family doctor, and if so, what the gender and age of their
doctor was. Participants were also asked how comfortable they feel speaking to their
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doctor about any health concern (measured on a 5-point Likert scale). If participants did
not have a regular doctor, they were asked if they have access to regular medical care, and
how comfortable they felt speaking to the doctor(s) that they do come into contact with.
Cost. Four questions to assess how the cost of the HPV vaccine might influence
participants’ desire to get the vaccine were asked. Response options ranged from 1 (not at
all) to 5 (very much). These four items were used to create a scale score, which was found
to have a Cronbach’s alpha of .80.
Insurance. Participants were asked two questions to determine if they had
insurance coverage that would have paid for the HPV vaccine. They were asked if they
have an insurance plan, and if so, if they knew if it covered the vaccine at the time they
considered and made their decision to get vaccinated or not.
Self-Efficacy Variable
Self-efficacy for obtaining the HPV vaccine. A four item scale was used to
assess unvaccinated participants’ level of self-efficacy for obtaining the HPV vaccine.
Three of the scale items were taken from a study conducted by Kahn et al. (2008). These
items inquired about participants’ belief that they could get all three vaccines, that they
would have time to get the vaccine, and that they would be able to afford it. Kahn et al.
found a Cronbach’s alpha of .82 for the scale comprised of these three items. An
additional fourth item was added to this scale for this study, in order to strengthen its
ability to assess self-efficacy for overcoming barriers to HPV vaccination. The item asked
participants if they felt they could “overcome barriers to getting the HPV vaccines”.
Responses to all items were measured on a 5-point Likert scale ranging from 1 (very
unlikely) to 5 (very likely). The Cronbach’s alpha value for the scale was .81. If the item
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that was added for this study was removed from the scale, the Cronbach’s alpha of the
original three items was .72, indicating the addition of this item strengthened the scale.
Cues to Action Variable
Cues to action. Inspired by other HPV vaccine studies, a 10 item scale was
created and used to assess cues that are believed to prompt participants to obtain, or want
to obtain, the HPV vaccine. The 10 items each began with a yes/no statement asking if
participants had experienced a prompt from the subject of the item (e.g., a friend,
romantic partner, school, commercial, news story). If participants indicated that they had,
they were then asked to rate, on a 5-point scale ranging from 1 (made me definitely not
want to get the vaccine) to 5 (made me definitely want the vaccine), how much influence
this prompt had on their desire to want the HPV vaccine. For this study, scores were
computed by assessing how many positive cues to action (cues that encouraged the
individual to get the vaccine) an individual had received. If a cue encouraged an
individual to maybe want the vaccine, one point was awarded. If a cue encouraged an
individual to definitely want the vaccine, two points were awarded. Thus, scale scores
could range from 0 (no positive cues) to 20 (all 10 cues made the individual definitely
want the vaccine).
Subjective Norm Variables
Subjective norms about HPV vaccination. An eight item measure was used to
assess participants’ beliefs in the social norms surrounding HPV vaccination. The
measure was inspired by one developed and used by Buchanan (2008). It was comprised
of eight items listing eight different significant others or groups, and asked participants to
indicate whether they believed the significant other or group would endorse HPV
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vaccination or not. Responses were recorded on a five-point likert scale ranging from 1 (I
definitely should not get the HPV vaccine) to 5 (I definitely should get the HPV vaccine).
The Cronbach’s alpha value for the scale was .89.
Open-Ended Question
An open ended question was placed at the end of the study questionnaire in order
to provide participants with an opportunity to provide additional information about
reasons why they have or have not gotten the HPV vaccine. Participants were asked to:
“Please describe all of the reasons why you have or have not gotten the HPV vaccine.”
Outcome Measures
Actual vaccine obtainment. To determine if participants had received the HPV
vaccine or not, they were asked if they had obtained any of the HPV vaccine shots.
Individuals could indicate if they had or not, and if so, they were asked to indicate how
many of the shots they had received. Individuals were considered to have been vaccinated
if they received at least one shot.
Desire to get the HPV vaccine. Non-vaccinated participants were asked to
indicate on a five-point scale ranging from 1 (definitely not like to) to 5 (definitely would
like to), how much they would like to get the HPV vaccine, regardless of whether they
think they actually will.
Actually think will get the vaccine. Non-vaccinated participants were also asked
how likely they are to actually get the HPV vaccine. Responses were recorded on a fivepoint likert scale ranging from 1 (very unlikely) to 5 (very likely).
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Procedure
This study was approved by the Research Ethics Board at the University of
Windsor. Data were collected in the Fall of 2011. Participants were recruited for this webbased study in three ways: (1) The University of Windsor psychology participant pool
website, (2) Email snowball sampling, and (3) The social networking site Facebook.
Individuals who were recruited through the psychology participant pool were able to view
a description of the study online through the participant pool system, and were able to
choose to sign up to participate. If individuals signed up for this study, they were given
access to the study website where they could complete the study at any time within a one
week time frame. Individuals who were recruited through email snowball sampling
received an email which contained a description of the study and a link to the study
website. The author sent out the original email message to family and friends with the
request that the email be forwarded on. The third method used to recruit participants was
through Facebook. A Facebook “page”, describing the study and providing potential
participants with the web link to the study, was developed. Facebook users could have
found this page through a variety of methods. For instance, individuals conducting key
word searches could have located the page and viewed it (e.g., HPV Vaccine, HPV
Canada), but probably the most effective method of Facebook recruitment was through
requests to participate in the study that were sent out by this author, to Facebook Friends,
which included a request to forward the study page information on to eligible women.
Incentives for participation varied depending upon how participants learned of the
study. Women who were registered in the psychology participant pool received one bonus
point in an eligible psychology class in exchange for their participation. Women who
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learned of the study through any of the other methods were offered the chance to enter a
random draw for two $250 Amazon.ca gift cards. The gift cards were sent electronically
to the winners’ email addresses.
This study was hosted on-line through the web survey provider FluidSurveys.
FluidSurveys stores collected data within Canada, ensuring that data is stored securely
and can be accessed only by survey creators. The first web page participants encountered
when they clicked on the study web link was the “Letter of Information to Participate in
Research” page. Participants were required to indicate that they had read the letter before
they could continue to the next study page, complete screening questions, and if eligible
to participate, begin the questionnaire.
Once participants had completed the study questionnaire they were asked if they
would like to provide their information to receive the type of compensation advertised
to them in the study recruitment materials (bonus point or draw entry). If participants
chose to provide their personal information, they were routed to a new FluidSurvey
that collected their information and stored it in a new, separate database from their
questionnaire data. This was done to ensure that survey data could not be linked to
participants’ names or email addresses.
Data Analysis
The data analytic strategy for this study included logistic regression and multiple
regression analyses, as well as testing the proposed modified Health Belief Model
presented earlier in this paper through Structural Equation Modeling (SEM). To begin,
logistic regression analyses were conducted to investigate the relationships between the
variables assessing each of the study’s model components (e.g., Perceived Severity,
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Perceived Benefits), and a dichotomous outcome variable: vaccination status (have
received the HPV vaccine or have not received the HPV vaccine). Following these
logistic regressions, the rest of the analyses conducted used only the data from women
who had never been vaccinated.
Two sets of multiple regression analyses were conducted next. The intent was to
examine factors that predict intentions to receive the HPV vaccine. The first group of
multiple regressions investigated the relationships between the variables assessing the
model components, and an outcome variable that asked participants if they would like to
get the HPV vaccine, with possible responses ranging from one to five. The second group
of multiple regressions investigated the relationships between the component variables
and an outcome that asked participants if they actually thought they would get the
vaccine, regardless of whether they wanted it or not. This outcome variable was also
measured on a five-point scale.
Following the examination of direct relationships between the proposed predictor
variables and the various outcomes, structural equation modeling was used to test the
modified Health Belief model of HPV vaccination intentions that was proposed in this
study. See Figure 1 to review this model.
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Chapter III
Results
Data Screening
In order to participate in this study, individuals had to meet specific criteria. A
participant had to be a woman, living in Canada, aged 18 to 30. The first page of the
study website, which described the purpose of the study and the participation criteria, was
visited by 458 individuals. Of these visitors, 394 people met the participation criteria and
began the survey. Not all individuals who began the survey completed it. In total, 374
women, or 94.9% of those who began it, completed the survey.
Data was screened for outliers by examining boxplots and comparing means of the
total sample to means of a 5% trimmed sample (removing individuals with the top 2.5%
and the bottom 2.5% of values). Boxplots revealed that while a few individuals (e.g., 2-10
people) had outlying scores on some variables, that no one individual was responsible for
many outlying scores. When total sample means and 5% trimmed means were examined,
it was found that mean scores either did not change, or changed very little. Thus, it was
decided that no participants would be removed due to outlying responses. Missing data
was also not a problem for the 374 women who completed the survey. While some
questions could only be answered by a portion of the sample based on their answers to
previous survey questions (e.g., questions about Pap testing could only be answered by
individuals who had ever had a Pap test), for questions in which all individuals could
provide responses, very little missing data was detected. Thus, again, no individuals had
to be removed from the final dataset. Graham (2009) states that if 5% or less of data is
missing, that listwise deletion is an acceptable approach to dealing with missing data. As
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this was the case with this dataset, listwise deletion was used when conducting descriptive
and regression analyses in SPSS. Because SEM modeling requires complete data, for any
missing cases (which were minimal) mean substitutions were used.
Tests of scale score normality (kurtosis) were also conducted. Byrne (2010) states
that for the purposes of SEM that a kurtosis score greater than 5.0 should be considered
non-normal. Based on this this rule, no scales were found to have non-normal
distributions.
Factor Analysis and Reliability of Study Measures
Due to the lack of validated scales to measure the various constructs under
investigation, many of the measures used in this study had to be adapted from previous
research or were designed specifically for this project. Because of this, it was important to
ensure that these created scales were factor analysed. All created scales were analysed
using principal components factor analysis without rotation, and it was found that with
the exception of the scales assessing (1) participant concern about experiencing stigma if
asking a doctor for the HPV vaccine (Fear of Doctor Stigma), and (2) subjective norms
assessing how much others influence the participants’ behaviours (HPV Subjective
Norms), that all of the scales proved to be unidimensional measures of the constructs they
were intended to assess. Specifically, all scales had items that loaded on Factor 1 with
values of at least .35 and no strong loadings on another factor. After examining the factor
structure of the Fear of Doctor Stigma scale, it was decided that the two items that did not
load onto the primary factor be removed, reducing the scale from 12 items to 10. The Fear
of Doctor Stigma Scale asks participants “If I asked my doctor for the HPV vaccine, the
doctor would think…”. The two items that were removed were “nothing of it” and “that I
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want to protect my sexual partners”. The HPV Subjective Norm scale was also
strengthened by removing the one item that did not load adequately, reducing this scale
from eight to seven items. The item that was removed inquired about the opinions of
religious organization members in the participants’ life. After these changes were made,
the scale items for each of the two measures were factor analysed again. The results
revealed that for each measure, all items now loaded well onto one factor.
Cronbach’s alpha reliability coefficients were computed for all scales. Please see
Table 2 to view Cronbach’s alpha values for each scale, the scale possible range and
actual range, and the scale mean and standard deviation. All values were acceptable
(Cronbach’s alpha > .70), except for the value for the HPV vaccine knowledge scale,
which had a Cronbach’s alpha value of .66. Due to its lower value, and because research
has found mixed results when investigating the relationship between knowledge variables
and HPV outcomes variables, the decision was made to exclude this scale from analysis.
Because there were two knowledge scales used in this study, HPV knowledge and HPV
vaccine knowledge, one scale was still available to represent the knowledge component
of the theoretical model, and thus the exclusion of the vaccine knowledge scale did not
hinder the ability to test the proposed theoretical model.
In order to ensure that scale intercorrelations were not too high, leading to
multicollinearity, correlations were computed between all continuous variables (see Table
3). Only two scales were found to be highly correlated. These scales were the scale
assessing general vaccine safety fears and the scale assessing HPV vaccine safety fears (r
= .69). As mentioned in the Measures section, due to this high correlation, and because of
the conceptual similarity between the two scales, the items that comprised them
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Table 2
Cronbach’s Alpha Values, Scale Ranges, and Scale Means and Standard Deviations for
Scales used in Analyses
Cronbach
Alpha

Possible
range

Actual
range

Mean

Standard
deviation

.84

0-24

0-24

14.47

4.49

.66

0-7

0-7

5.01

1.47

.88

1-5

1-5

1.89

0.88

.73

1-5

2.8-5

4.48

0.56

.80

1-5

1.2-5

4.28

0.66

.88

1-5

1-5

4.05

0.94

.94

1-5

1-5

3.36

1.04

.90

1-5

1-5

3.71

0.88

.94

1-5

1.25-5

3.51

0.94

.91

1-5

1-5

3.37

0.90

.92

1-5

1-4.3

1.82

0.66

.92

1-5

1-4.4

2.02

0.81

.92

1-5

1-4.91

2.41

0.82

.94

1-5

1-5

3.55

0.85

Pharmaceutical Company
Trust

.85

1-5

1-4.6

2.85

0.58

HPV Vaccine Cost

.80

1-5

1-5

2.12

1.21

Measure

HPV Knowledge
HPV Vaccine Knowledge
Susceptibility
General Severity
Treatment Severity
Social Severity
HPV Vaccine Effectiveness
Vaccines Positive Beliefs
Fear Cervical Cancer
Safety Concerns
Asking Dr. Stigma
SAS Permissiveness Subscale
STI Sigma and Shame
Physician Trust
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Cronbach
Alpha

Possible
Range

Actual
Range

Mean

Standard
Deviation

Vaccination Self Efficacy

.81

1-5

1-5

3.54

0.90

HPV Vaccine Subjective
Norms

.89

1-5

1-5

3.26

0.65

-

0-20

0-14

2.34

2.78

Measure

Positive Cues to Action
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Table 3
Correlations Between Continuous Study Variables
1 Desire Vac
2 Actually Think Vac
3 HPV Knowledge
4 Susceptibility Scale
5 General Severity
6 Treatment Severity
7 Social Severity
8 Fear Cerv Cancer
9 Vac Effectiveness
10 Vac Pos Beliefs
11 Safety Concerns
12 SAS Perm
13 Stigma And Shame
14 Physician Trust
15 Pharm Trust
16 Vac Cost
17 Fear Dr. Stigma
18 Pos Cues Action
19 Self-Efficacy
20 Subjective Norms
Note. *p < .05, ** p < .01.

1
1
.78**
-.08
.16*
.01
-.05
-.02
-.08
.67**
.54**
-.42**
.13
-.05
.15*
.34**
.17*
-.15*
.63**
.39**
.54**

2

3

4

5

6

7

8

9

10

11

12

13

1
-.10
.03
.11
-.01
.05
.02
.61**
.42**
-.25**
.03
.02
.25**
.23**
.02
-.14*
.58**
.39**
.52**

1
.29**
-.20**
-.19**
-.18**
-.10
-.13*
-.12
-.09
.33**
-.36**
-.08
-.15*
-.10
-.11
-.03
.05
.02

1
-.14*
-.07
-.10
.10
.06
.05
-.05
.31**
-.17*
-.15*
-.12
.10
-.02
.15*
.03
.10

1
.58**
.47**
.32**
.14*
.12
.22**
-.30**
.22**
.12
.11
-.01
.07
.07
-.03
.00

1
.52**
.31**
.12
.09
.27*
-.20**
.28**
.03
.04
.00
.05
-.01
-.05
-.05

1
.26**
.12
.08
.20**
-.27**
.44**
.13
.08
.08
.12
.05
-.05
.05

1
.05
.06
.31**
-.20**
.27**
-.04
-.03
.02
.09
.06
-.17**
-.05

1
.50**
-.24**
.06
-.02
.22**
.29**
.21**
-.18**
.50**
.39**
.45**

1
-.43**
.02
.13
.18**
.32**
.14*
.00
.37**
.26**
.29**

1
-.18**
.14*
-.11
-.34**
-.07
.05
-.20**
-.24**
-.29**

1
-.30**
-.15*
-.09
.07
-.04
.06
.18**
.09

1
-.04
.00
.01
.36**
-.04
-.11
-.08
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14
1 Desire Vac
2 Actually Think Vac
3 HPV Knowledge
4 Susceptibility Scale
5 General Severity
6 Treatment Severity
7 Social Severity
8 Fear Cerv Cancer
9 Vac Effectiveness
10 Vac Pos Beliefs
11 Safety Concerns
12 SAS Perm
13 Stigma And Shame
14 Physician Trust
15 Pharm Trust
16 Vac Cost
17 Fear Dr. Stigma
18 Pos Cues Action
19 Self-Efficacy
20 Subjective Norms
Note. *p < .05, ** p < .01.

1
.28**
-.03
-.16
.22**
.10
.16*

15

1
.06
-.07
.26**
.27**
.27**

16

17

1
.10
.05
-.26**
.11

1
-.18**
-.17*
-.26**

18

1
.34**
.47**

19

1
.40

20

1
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were combined in order to create one scale score to assess vaccine safety fears (this
combined scale score represents the variable called Vaccine Safety Concern within this
document). No correlations between any of the other scale predictor variables were found
to be high.
Sample Characteristics
Recruitment source. Participants were asked how they found out about this
study. Of those who answered this question, 298 found out about it through the university
psychology participant pool (79.7% of the sample), and 73 found out about it online
through Facebook or email (19.5% of the sample). Three people did not answer this
question.
Romantic relationships and sexual history. The majority of participants, 94.4%
of the sample, reported that they were heterosexual, 3.7% were bisexual, 0.3% were
lesbian, and 1.1% reported their sexual orientation as “other”. For those individuals who
reported that they were bisexual, 12 out of the 14 women had had a male sexual partner as
their most recent partner. The majority of study participants were either single and not
dating (27.5%), or in a committed dating relationship but not living together (38.8%). A
fairly equal proportion of the remaining participants were either single and dating
(14.4%), cohabitating with a partner but not married (8.8%), or married (10.4%). The
average reported relationship length was 3.59 years (SD = 2.87). When asked if they had
ever engaged in any type of sexual activity (touching, intercourse, other activities), 84%
of participants indicated that they had. The number of reported sexual partners an
individual had ever had any type of sexual contact with ranged from 1 to 45, with a mean
of 5.12 (SD = 5.66). When vaginal intercourse was inquired about specifically, 72.7% of
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individuals reported that they had had vaginal intercourse. The average age at which
vaginal intercourse first took place was 17.38 (SD = 2.10), and the mean number of
partners a woman had had was 4.23 (SD = 5.05). Participants were also asked about their
experiences with anal intercourse, and 19.5% of the women reported that they had
engaged in this type of sexual activity. The average age of first anal intercourse was 19.48
(SD = 2.56), and the mean number of partners was 1.39 (SD = 0.72). Condom use with
past and present sexual partners was also investigated. With past partners, 4.4% of
women who had had vaginal intercourse reported that they never used condoms, 10.7%
reported they did not use them often, 9.2% reported they used them half of the time,
22.1% reported they used them most of the time, and 26.5% of participants always used
them. With current partners, 30.5% of participants did not use condoms, 10.7% did not
often use them, 6.6% of participants reported they used them half the time, 14% reported
they used them most of the time, and 26.5% reported they always used them.
Sexual health. Participants were asked if they had ever had a Pap Smear test.
Surprisingly, only 59.6% of the sample had ever had a Pap test (39.3% of individuals had
never had one, and 0.2% of the women were unsure). To investigate this further, the
proportion of women who had had vaginal intercourse and who had ever had a Pap test
was analysed. Results revealed that 78.7% of women who had had vaginal intercouse had
had a Pap test. When participants were asked if they had ever had an abnormal Pap test,
47 women (12.6% of all participants) reported that they had. Women who had had an
abnormal Pap test were asked to indicate the highest level of intervention that they had
received as a result of their abnormal test. Twenty women reported that they had a followup Pap test, 12 women had a colposcopy, and nine women had abnormal cells removed.
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Five women reported other outcomes such as: requiring yearly biopsies, nothing being
done, and currently awaiting follow-up appointments.
Whether individuals had ever had an STI was also investigated. Only 4.5% of
participants (17 women) reported that they had ever had an STI (0.8% reported they were
unsure if they had ever had one). When asked about HPV or genital wart infection
specifically, 3.7% of participants (14 women) reported that they had been diagnosed with
this STI.
HPV Vaccine Obtainment
Participant vaccination rates. One of the main objectives of this study was to
investigate factors that predict HPV vaccine obtainment. For the purposes of the
following analyses, obtainment was defined as a participant having obtained at least one
HPV shot. The majority of study participants had not received an HPV vaccine shot.
More specifically, 269 people had not received the vaccine (71.9% of the sample), while
101 women had (27.0% of the sample). Of those who had received the vaccine, 75
women (74.26% of those who received at least one shot) reported getting all three shots,
12 reported getting two (11.88%), and 11 (10.89%) reported getting one. The majority of
women who reported that they had received only one shot reported that they would not be
going back for any more, while the majority of women who reported that they had
received two shots reported that they would be finishing the series. A summary of these
vaccination rates, as well as a summary of the reasons given for not wanting to continue
to be vaccinated, is presented in Table 4.
Table 5 presents a summary of key demographic and relationship and sexual
history variables based upon HPV vaccination status. Chi square analyses and t-tests were
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Table 4
Summary of Participant Vaccination Rates
N (% of sample)

Vaccine Obtained
No
Yes

269 (71.9)
101 (27.0)

Number of Shots Obtained
One
Two
Three

11 (2.9)
12 (3.2)
75 (20.1)

Reasons For Not Completing
HPV Vaccine Series
No time

9

Decided not important

4

Cost

3

No consistent health care
provider

3

Read a story about the
vaccine online

2

Negative side effect

1

Afraid of needles

1

Friend or family did not
want me to continue

1

Note. An individual was classified as having obtained the vaccine if they reported
receiving any number of shots.
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used to test for possible group differences based on the key demographic variables. Please
see Table 5 to review the results of these tests.
HPV vaccine obtainment: Logistic regression analyses. In order to examine
the impact that the study variables have on actual vaccination behaviours, logistic
regression analyses investigating the predictive ability of the variables representing each
model component except for self-efficacy which was not assessed in participants who had
received the vaccine, were conducted. Thus, seven logistic regressions, one for each
model component (Knowledge, Susceptibility, Severity, Benefits, Barriers, Cues to
Action, and Subjective Norms) were conducted, with actual vaccination status (whether
one obtained at least one shot of the vaccine or not) as the dichotomous outcome variable.
Knowledge. A logistic regression was run to examine whether HPV knowledge
predicted HPV vaccination behaviour. The logistic regression revealed that HPV
knowledge scores did not predict whether women received the HPV vaccine or not,
model χ2 (1, N = 370) = 1.50, p >.05.
Perceived Susceptibility. It was predicted that a number of relationship variables
(relationship status and relationship length), a gynecological variable (ever having had an
abnormal Pap test), and sexual history experiences (ever having engaged in vaginal or
anal intercourse, number of vaginal or anal sexual partners), as well as scores on the HPV
Susceptibility Scale would be related to HPV vaccine obtainment. Because some
relationship, sexual, and gynecological health history questions were not applicable to all
individuals (e.g., those who had never had sex were unable to indicate a number of
individuals that they had intercourse with), multiple logistic regressions were conducted
to test this model component, rather than just one. This was done in order to ensure a
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Table 5
Demographic, Relationship, and Sexual History Information by HPV Vaccination Status

N (% of sample)

Vaccine Not
Obtained
N = 269
N (% of sample)

Vaccine Obtained
N = 101

χ2
1.27

Relationship status
Single
Dating
Committed
Relationship

24 (23.8)
17 (16.8)

78 (29.0)
37 (13.8)

60 (59.4)

154 (57.2)

Yes, have engaged in
sexual activity

89 (88.1)

222 (82.5)

1.23

Yes, have had a Pap
Test

72 (71.3)

149 (55.4)

6.93*

Have had an abnormal
Pap

18 (17.8)

28 (10.4)

1.26

4 (4.0)

9 (3.3)

n/a

Mean (SD)

Mean (SD)

t

Age

21.2 (2.84)

22.37 (3.71)

3.23*

Relationship length in
years

2.72 (2.12)

3.92 (3.07)

Age first vaginal
intercourse

16.84 (1.57)

17.59 (2.22)

3.15*

Number of vaginal
intercourse partners

4.42 (4.19)

3.72 (5.30)

1.09

Told have HPV

3.06*

Note. An individual was classified as having obtained the vaccine if they reported
receiving any number of shots. * p < .01.
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large enough sample size for the analyses. Only two susceptibility variables were found
to individually predict HPV vaccine obtainment: relationship length, and whether an
individual had ever had vaginal intercourse. These two variables were then entered into a
logistic regression together in order to determine whether both still predicted vaccine
obtainment. The tested model was significant. Model χ2 (2, N = 222) = 9.84, p < .01,
Hosmer & Lemeshow R2 = 8.74, p > .05, .04 (Cox & Snell), .06 (Nagelkerke).
Relationship length negatively predicted HPV vaccination behaviours (B = -0.01, p <
.05), and vaginal intercourse status positively predicted HPV vaccination status (B = 1.12,
p = .05). Individuals who had had vaginal intercourse were three times more likely to
receive the HPV vaccine than those who had never had vaginal intercourse, odds ratio =
3.08, 95% CI [0.99, 61.42]. Meanwhile, as relationship length increased, the odds of
having the HPV vaccine diminished slightly, odds ratio = 0.99, 95% CI [0.98, 1.00].
Predictive success of the model was 72.1%.
Perceived Severity. A logistic regression was run to determine if scales assessing
participants’ perceptions of the severity of HPV in general, HPV treatment, and HPV’s
social impact, as well as fears of cervical cancer, were predictive of vaccine obtainment.
The model investigating these severity measures was not significant, χ2 (4, N = 367) =
6.78, p >.05. An examination of the predictive ability of each of the individual measures
was conducted and it was found that perceptions of the severity of HPV vaccine treatment
did significantly impact HPV vaccination decisions (B = 0.51, p < .05). For every point
increase in perceptions of the severity of HPV treatment, the likelihood that an individual
would get vaccinated increased approximately one and half times, odds ratio = 1.68, 95%
CI [1.05, 2.67].
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Perceived Benefits. The impact that beliefs about the effectiveness of the HPV
vaccine (Vaccine Effectiveness), and beliefs about the benefits of vaccination (Vaccine
Positive Beliefs), have on actual HPV vaccination behaviours was investigated next. It
was found that the model that included both of these variables significantly predicted
HPV vaccination behaviours, Model χ2 (2, N = 368) = 77.41, p < .01, Hosmer &
Lemeshow R2 = 12.44, p > .05, .19 (Cox & Snell), .27 (Nagelkerke). Predictive success of
the model was 75.0%. Both scales assessing benefits were found to be positively
predictive. As participants’ beliefs that the HPV vaccine would effectively reduce HPV
infection increased (B = 0.92, p < .01), and as beliefs that vaccinations are beneficial to
society increased (B = 0.45, p < .05), the likelihood that an individual would get
vaccinated increased. For each scale point that beliefs about the effectiveness of the HPV
vaccine increased, the likelihood that an individual would get the HPV vaccine increased
2.52 times, 95% CI [1.78, 3.56]. For each scale point that beliefs that vaccines are
beneficial for society increased, the likelihood that an individual would get the vaccine
increased 1.57 times, 95% CI [1.07, 2.30].
Perceived Barriers. There were many barriers to HPV vaccination that were
predicted to influence inoculation behaviours. The following variables were entered into a
logistic regression model as possible predictors: Pharmaceutical Company Trust,
Physician Trust, STI Stigma and Shame, Fear of Doctor Stigma, access to a health care
professional, the Permissiveness subscale of the Sexual Attitudes Scale, HPV Vaccine
Safety Fears, Vaccine Cost, and having insurance that would pay for the vaccine. It was
found that the model was predictive of HPV vaccination behaviours, Model χ2 (9, N =
336) = 159.25, p < .01, Hosmer & Lemeshow R2 = 11.00, p > .05, .38 (Cox & Snell), .54
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(Nagelkerke). An examination of the possible predictors revealed that three of the
variables significantly predicted vaccination uptake: HPV Vaccine Safety Fears (B = 1.49, p < .01), Fear of Doctor Stigma (B = -1.07, p < .01), and whether the vaccine was
covered by insurance (B = -2.55, p < .01). In addition, one variable approached
significance: STI Stigma and Shame (B = 0.40, p = .58). Prediction success of the model
was 84.8%. When the influence that HPV Vaccine Safety Fear has on HPV vaccination
behaviours was examined, it was found that as concern about the safety of vaccines
increased, the likelihood that an individual would get vaccinated decreased, odds ratio =
0.23, 95% CI [0.15, 0.35]. Relatedly, as concern that physicians would have negative
opinions about the participant if they asked for the HPV vaccine increased (Fear of
Doctor Stigma), the likelihood that an individual would get the HPV vaccine decreased,
odds ratio = 0.34, 95% CI [0.19, 0.62]. Individuals who did not have insurance that
covered the vaccine were less likely to get vaccinated, odds ratio = 0.08, 95% CI [0.04,
0.16]. Finally, the impact of participant’s beliefs about the stigma and shame associated
with STIs and its impact on HPV vaccine behaviour approached significance. As
perceptions of stigma and shame increased (become more negative), the likelihood of
getting vaccinated decreased, odds ratio = 1.50, 95% CI [0.99, 2.27].
Cues to Action. A logistic regression was conducted to investigate whether
Positive Cues to Action would predict HPV vaccination behaviour. Results indicated that
cues to action did predict vaccination behaviours, Model χ2 (1, N = 346)= 68.11, p < .01,
Hosmer & Lemeshow R2 = 11.97, p < .05, .18 (Cox & Snell), .26 (Nagelkerke).
Predictive success of the model was 76.3%. Positive Cues to Action positively influenced
vaccination behaviour (B = 0.38, p < .01). As the number of positive cues increased, there
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was a greater likelihood that an individual would receive the HPV vaccine, odds ratio =
1.46, 95% CI [1.32, 1.62].
Subjective Norms. Finally, it was predicted that Subjective Norm scores would
predict actual HPV vaccination outcomes. The model testing this prediction was
significant, Model χ2 (1, N = 368) = 72.38, p < .01, Hosmer & Lemeshow R2 = 30.18, p <
.01, .18 (Cox & Snell), .26 (Nagelkerke). Predictive success of the model was 77.4%. As
Subjective Norm scores increased (indicating more positive norms), individuals were
more likely to get the HPV vaccine, odds ratio = 6.03, 95% CI [3.74, 9.74].
Final logistic regression model of all significant predictors. With the number of
possible predictor variables within each component narrowed down, it was then possible
to conduct a logistic regression on all variables that had been found to significantly
predict vaccine behaviours. The only variable that was excluded from this analysis was
relationship length, because its inclusion resulted in too small of a sample size to
adequately test for effects. The following variables were entered as possible predictors of
HPV vaccine obtainment: whether an individual had had vaginal intercourse, perceptions
of the severity of HPV treatment (Treatment Severity), Vaccine Effectiveness, Vaccine
Positive Beliefs, HPV Vaccine Safety Fears, Fear Doctor Stigma, whether the vaccine is
covered by insurance, STI Stigma and Shame, Positive Cues to Action, and Subjective
Norms. The results of the analysis revealed that the model was predictive, Model χ2 (10,
N = 340) = 197.71, p < .01. Predictive success of the model was 87.9%. The variables
that maintained their predictive power were: Treatment Severity, HPV Vaccine Safety
Fears, Fear of Doctor Stigma, and whether the vaccine was covered by insurance. Positive
Cues to Action also approached significance as a predictor. As perceptions of the severity
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of HPV treatment and positive cues to action increased, individuals were more likely to
get the vaccine. As fear of doctor stigma and vaccine safety concerns increased, the
likelihood that an individual would get vaccinated decreased. And finally, individuals
who had insurance were more likely to get the vaccine. Please see Table 6 for a summary
of the model statistics.
Predictors of Intentions to Receive the HPV Vaccine for Those Who are Not
Vaccinated
Participants who had not received any HPV vaccine shots (N = 269) were asked
two related questions to assess their intentions to obtain the HPV vaccine: (1) how much
would you like to get the HPV vaccine (regardless of whether you think you actually
will), and (2) How likely are you to actually get the vaccine? Participants could respond
on a five-point likert scale that ranged from one (definitely not like to/very unlikely) to
five (definitely would like to/very likely). The mean responses to both questions, in
general, revealed a lack of interest in obtaining the vaccine. Individuals were more likely
to want to get the vaccine (M = 2.88, SD = 1.19), than they were to actually think they
would get it (M = 2.48, SD = .08). In order to verify that these two outcome measures
were indeed measuring separate constructs, a Pearson correlation analysis and t-test was
conducted. The two items were found to have a high correlation, r = .79, p < .001. The
students t-test was also significant, t(265) = 8.55, p < .001, indicating that although the
items are related, they do assess unique aspects of intentions to vaccinate.
Desire to Get the Vaccine.
Due to the large number of possible predictor variables proposed in this study, the
first step in investigating predictors of participants’ desire to get the HPV vaccine was to
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Table 6
Logistic Regression Results: Predictors of Actual HPV Vaccination Behaviour (N = 340)

B (SE)

Lower

95% CI for Odds Ratio
Odds Ratio
Upper

Constant

0.30 (2.02)

Vaginal intercourse

-0.33 (0.47)

0.29

0.72

1.80

Severity of HPV treatment

0.99 (0.36)**

1.33

2.68

5.42

HPV vaccine effectiveness

0.39 (0.25)

0.91

1.48

2.39

Vaccine benefits

-0.10 (0.26)

0.54

0.91

1.52

Vaccine safety

-1.46 (0.27)**

0.14

0.23

0.39

Fear stigma from doctor

-1.20 (0.36)**

0.15

0.30

0.61

Insurance covered

-2.37 (0.39)**

0.04

0.09

0.20

STI stigma and shame

0.38 (0.23)

0.93

1.46

2.31

Cues to action

0.15 (0.08)*

1.00

1.17

1.37

Subjective norms

0.07 (0.34)

0.55

1.08

2.10

Note. Model χ2 = 197.71, p < .01, Hosmer & Lemeshow R2 = 7.56, p > .05, .44 (Cox &
Snell), .64 (Nagelkerke). * p = .057. ** p < .01.
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conduct various multiple regressions in an effort to narrow down the number of predictor
variables before a final regression model combining the various theoretical components
was tested. These initial regressions were organized to test the variable(s) assessing each
theoretical component. For most of the model components, one multiple regression
analysis containing all of the possible predictor variables in that component was run.
However, for the Susceptibility component, because the variables had varying sample
sizes, various regressions had to be run for each of these possible predictor variables.
In order to investigate the predictive ability of the Knowledge component of the
theoretical model being tested, a regression was run with HPV Knowledge scores as the
predictor, and Desire to Get the HPV Vaccine (on a scale of 1 to 5) as the outcome. The
regression was not significant, F(1,265) = 0.52, p > .05.
To investigate the Susceptibility component of the theory, various linear
regression analyses were conducted. Because variables assessing this component include
a lot of dichotomous predictors that represent life experiences (e.g., ever having had
vaginal intercourse, ever having had an abnormal pap, relationship status), in order to
ensure an adequate sample size for the analyses, separate regressions were run for each
predictor. A regression was run with each of the following variables as a predictor, and
desire to get the HPV vaccine as the outcome: Relationship status (single or in a
relationship), Pap test status (ever have an abnormal test or not), vaginal intercourse
status (have had or have not had), anal intercourse status (have had or not had), number of
vaginal sexual partners, number of anal sexual partners, Susceptibility Scale scores, and
relationship length. Two susceptibility variables were found to be predictive of a
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desire to get the HPV vaccine: Susceptibility Scale scores, F(1,265) = 8.05, p < .01,
adjusted R square = .03, and relationship length F(1,265) = 4.74, p < .05, adjusted R
square = .01. As susceptibility scores increase, desire to get the vaccine also increases (β
= .17, p < .01), and as relationship length increases desire to get the vaccine decreases (β
= -.13, p < .05).
Next, the impact of the variables assessing the Severity component of the theory
was tested with one multiple regression, with Desire to Get the Vaccine as the outcome
variable and the following variables as predictors: Score on the General Severity scale,
score on the Treatment Severity scale, score on the Social Severity scale, and score on the
Fear of Cervical Cancer scale. None of the variables in this model were found to be
predictive of participants’ desire to get the vaccine, F(4,259) = 0.38, p > .05.
To test the variables assessing the Benefits component of the theory used in this
study, a multiple regression was conducted with scores on the Vaccine Positive Beliefs
scale, and the Vaccine Effectiveness scale as predictors. The model testing both of these
predictors was significant, F(2,262) = 115.49, p < .001, adjusted R square = .46. An
examination of standardized beta values revealed that perceptions of the effectiveness of
the HPV vaccine (β = .51, p < .001), and vaccine positive beliefs (β = .26, p < .001),
predicted desires to get the HPV vaccine. As beliefs about the effectiveness of the vaccine
and vaccine positive beliefs increase, desires to get the vaccine also increase.
The Barrier component of the theory was tested by running one multiple
regression analysis using the following predictor variables: Pharmaceutical Company
Trust, Physician Trust, STI Stigma and Shame, Fear of Doctor Stigma, Permissiveness
subscale of the Sexual Attitudes Scale, regular healthcare provider status (have one or
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don’t have one), availability of insurance to cover costs, and perceptions about the cost of
the HPV vaccine (Vaccine Costs). The model was significant, F(9,229) = 8.97, p < .001,
adjusted R square = .23. An examination of standardized beta weights revealed that the
following were significant predictors: HPV Vaccine Safety Fears (β = -.30, p < .001),
Pharmaceutical Company Trust (β = .22, p < .01), Vaccine Costs (β = .13, p < .05), and
Fear of Doctor Stigma (β = -.12, p < .05). As Concerns about the safety of the vaccine
and fear of doctor stigma increase, desires to get the vaccine decrease. As trust for
pharmaceutical companies increase, desires to get the vaccine also increase, revealing that
low levels of trust will lead to less desire to get vaccinated. And finally, as concerns about
the cost of the vaccine increases, desire to get the vaccine also increases.
The remaining three components of the theoretical model being tested in this
study, Cues to Action, Self-Efficacy, and Subjective Norms, were each tested with their
own multiple regression analysis, each with one predictor variable: Positive Cues to
Action for the Cues to Action regression, feeling of efficacy for the Self-Efficacy
regression, and Subjective (Social) Norms surrounding HPV vaccination for the
Subjective Norms regression. Each of the three regressions were significant: Cues to
Action F(1,246) = 166.22, p < .001, adjusted R square = .40, Self-Efficacy F(1,261) =
49.20, p < .001, adjusted R square = .16, and Subjective Norms F(1,265) = 107.99, p <
.001, adjusted R square = .29. As cues to action (β = .64, p < .001), self-efficacy (β = .40,
p < .001), and subjective norms (β = .54, p < .001) increased, desire to get the vaccine
increased.
Multiple regression of all significant predictors. The significant predictors from
each theoretical component that were identified in the regressions above, were then
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entered into a final multiple regression model in order to investigate which variables
would still significantly predict Desire to Receive the HPV Vaccine, when all possible
contributing variables were taken into account. Using the Enter method, a significant
model emerged F(11,212) = 37.15, p < .001, adjusted R square = .64. Variables that were
found to still significantly predict participants’ desire for the HPV vaccine were: beliefs
about vaccine effectiveness, thoughts about HPV vaccine safety, Positive Cues to Action,
Vaccine Positive Beliefs, and Subjective Norms. Results revealed that as beliefs about the
effectiveness of the HPV vaccine (β = .31, p < .001), Positive Cues to Action (β = .29, p
< .001), social norms encouraging the vaccine (β = .14, p < .01), and Vaccine Positive
Beliefs (that vaccines in general are useful) (β = .13, p < .05) increased, so too did a
desire to get the HPV vaccine. Meanwhile, as worry about the safety of the HPV vaccine
increased (β = -.18, p < .001), desire to get the vaccine decreased. See Table 7 for a
summary of these findings.
Actually Think they Would get the Vaccine
An analysis of predictors of whether participants believe they will actually get the
vaccine was conducted next. The analysis was conducted in the same fashion as the
analysis of the question assessing desire to get the vaccine, with various initial regressions
being run to test predictors for each model component, and then conducting a final
multiple regression with all significant predictors.
To begin, a regression testing whether HPV Knowledge is predictive of
participants’ belief they would actually get the vaccine was conducted. This regression
was not significant, F(1,265) = 1.23, p > .05, indicating that HPV knowledge was not
predictive of these vaccination intentions.
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Table 7
Multiple Regression Results: Predictors of a Desire to Obtain the HPV Vaccine (N =
224)

Constant

HPV vaccine effectiveness
Vaccine safety
Cues to action
Susceptibility scale
Vaccine positive benefits
Pharmaceutical trust
Fear stigma from doctor
Vaccine cost
Vaccination efficacy
Subjective social norms
Relationship length
Note. R2=.66. *p<.05. ** p < .01.

β

sr2

0.07

.31**

.05

-0.26

0.07

-.18**

.02

0.16

0.03

.29**

.05

0.09

0.06

.07

.00

0.18

0.07

.13*

.01

0.06

0.10

.03

.00

0.01

0.08

.01

.00

0.04

0.04

.04

.00

0.06

0.07

.04

.00

0.29

0.10

.14**

.01

-0.00

0.00

-.05

.00

B

SE B

0.28

0.63

0.37

Factors that influence HPV vaccinations 104

To investigate whether certain life experiences and perceptions of susceptibility
predict beliefs about whether one would actually get the vaccine or not, separate
regressions were run with each of the following variables as the predictor, and beliefs that
one would actually get the HPV vaccine as the outcome: relationship status (single or in a
relationship), Pap test status (ever had an abnormal test or not), vaginal intercourse status
(have had or have not had), anal intercourse status (have had or not had), number of
vaginal sexual partners, number of anal sexual partners, Susceptibility Scale Score, and
relationship length. Three susceptibility variables were found to be predictive of
participants’ beliefs that they would actually get the vaccine: abnormal pap test status
F(1,145) = 4.51, p < .05, adjusted R square = .02, relationship length F(1,265) = 9.59, p
< .01, adjusted R square = .03, and having ever had anal intercourse F(1,265) = 5.15, p <
.05, adjusted R square = .02. Those who had had an abnormal pap test (β = -.17, p <
.05), and those who had ever had anal intercourse (β = -.14, p < .05) were less likely to
think they would actually get the vaccine. Similar to other analyses, longer relationship
length was associated with lower belief that one would actually get the vaccine (β = -.19,
p < .01).
The Severity component variables were tested next. Participant scores on the
General Severity Scale, the Treatment Severity Scale, the Social Severity Scale, and the
Fear of Cervical Cancer scale were entered into the regression as possible predictors, with
participants’ belief that they would actually get the vaccine as the outcome variable. Only
one of these variables, general perceptions of the severity of HPV, was found to be
predictive F(1,265) = 5.15, p < .05, adjusted R square = .02. As perceptions of the
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severity of HPV increased, thoughts that one would actually get the vaccine also
increased (β = .15, p < .05).
The predictive ability of the Benefit component variables were tested in one
regression. Scores on the Vaccine Positive Beliefs scale and the Vaccine Effectiveness
scale were entered as predictors of participants’ beliefs they would actually get the
vaccine. Both variables were found to be predictive F(2,262) = 85.87, p < .001, adjusted
R square = .39. As beliefs about the effectiveness of the HPV vaccine (β = .55, p < .01)
and vaccine positive beliefs (β = .14, p < .05) increased, thoughts that one would actually
get the vaccine also increased.
To investigate which Barrier component variables were predictive of actual beliefs
that one would get the vaccine, one regression analysis was conducted using the
following predictor variables: Pharmaceutical Company Trust, Physician Trust, STI
Stigma and Shame, Fear of Doctor Stigma, Permissiveness subscale of the Sexual
Attitudes Scale, regular healthcare provider status, perceptions of the cost of the HPV
vaccine (HPV Vaccine Costs), and availability of insurance to cover costs. The model
was significant, F(9,229) = 5.21, p < .001, adjusted R square = .14. An examination of
standardized beta weights revealed that the following were significant predictors: HPV
Vaccine Safety Fears (β = -.18, p < .01), Pharmaceutical Company Trust (β = .16, p <
.05), and Physician Trust (β = .19, p < .01). Worry about stigma if asking a doctor for the
vaccine approached significance (β = -.12, p = .064), as did whether the vaccine was
covered by participants’ insurance (β = .12, p = .055). As vaccine safety concerns and
fears about doctor stigma increase, thoughts that one would actually get the vaccine
decrease. As trust in pharmaceutical companies and physicians increase, thinking that one
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would actually get the vaccine increases. And finally, having insurance increases thoughts
that one would actually get the vaccine.
The remaining three components of the theoretical model being tested in this
study, Cues to Action, Self-Efficacy, and Subjective Norms were, again, each tested with
their own multiple regression analysis, each with one predictor variable: Positive Cues to
Action for the Cues to Action regression, feelings of efficacy for the Self-Efficacy
regression, and subjective social norms surrounding HPV vaccination for the Subjective
Norms regression. The three regression analyses were significant: Cues to Action
F(1,246) = 142.50, p < .001, adjusted R square = .36, Self-Efficacy F(1,261) = 46.65, p <
.001, adjusted R square = .15, and Subjective Norms F(1,265) = 97.75, p < .001, adjusted
R square = .27. As cues to obtain the vaccine (β = .61, p < .001), feelings of self-efficacy
(β = .39, p < .001), and subjective norms (β = .52, p < .001) increase (become more
positive), so do thoughts that one would actually get the vaccine.
Multiple regression of all significant predictors. All of the variables that were
found to be significant predictors in these initial regressions, except for pap test normality
status and number of anal intercourse partners, were then placed together into a final
multiple regression model in order to determine which variables would still emerge as
predictive of beliefs that one would actually get the HPV vaccine. Pap test normality
status and number of anal intercourse partners could not be placed into the regression
analysis because the number of individuals who never received an HPV vaccine shot and
who had reported their pap test status or anal intercourse status was too small to be
reliably used in the regression analysis. The final multiple regression model that was run,
using the Enter method, was found to be predictive of participants’ beliefs that they
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would actually get the vaccine F(10, 233) = 27.79, p < .001, adjusted R square = .52.
Variables that were found to still significantly predict participants’ desire for the HPV
vaccine were: Vaccine Effectiveness, Positive Cues to Action, Self-Efficacy, and
Subjective Social Norms. Results revealed that as beliefs about the effectiveness of the
HPV vaccine (β = .31, p < .001), positive cues to action (β = .29, p < .001), self-efficacy
(β = .10, p < .05), and social norms encouraging the vaccine (β = .17, p < .01) increased,
so too did beliefs that one would actually get the HPV vaccine. See Table 8 for a
summary of these findings. To see a summary of the final significant predictors of all
three outcome measures please see Table 9.
Testing a Model of HPV Vaccination Intentions
While it is important to identify variables that have a direct effect on HPV
vaccination decisions, it is likely that more complex relationships exist between the
variables assessed in this study. In order to examine more complex relationships between
the study variables and HPV vaccination intentions, a model was tested through structural
equation modeling (SEM). The proposed model is displayed in Figure 1. Readers are
reminded that in SEM, squares indicate observed variables (a variable that has been
measured directly), while ovals represent latent variables (a construct that is inferred
based on multiple measured variables). As Figure 1 demonstrates, it is proposed that
vaccination intention decisions begin with an individual having a certain level of
knowledge about HPV, and with an individual receiving positive cues to action
(prompting to receive the vaccine). Knowledge and Cues to Action then affect
perceptions of HPV Severity, HPV Susceptibility, and HPV vaccine Subjective Norms.
Perceptions of Severity, Susceptibility, and Subjective Norms then impact

Factors that influence HPV vaccinations 108

Table 8
Multiple Regression Results: Predictors of Beliefs Participants Would Actually get the
HPV Vaccine (N = 244)
β

sr2

0.09

.04

.00

0.33

0.07

.31**

.05

Vaccine safety

-0.07

0.08

-.05

.00

Cues to action

0.15

0.03

.29**

.05

Vaccine Positive benefits

0.07

0.07

.05

.00

Pharmaceutical Trust

-0.10

0.10

-.05

.00

Physician Trust

0.07

0.06

.06

.00

Vaccination Efficacy

0.13

0.06

0.10*

.01

Subjective social norms

0.34

0.10

.17**

.02

Relationship Length

-0.00

0.00

-.07

.00

B

SE B

-.49

.65

Severity General

0.07

HPV vaccine effectiveness

Constant

Note. R2=.54. *p<.05. ** p < .01.
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Table 9
Significant Regression Predictors for each of the Three Outcomes

Actual Vaccinations
Severity of Treatment
Vaccine Safety Concerns
Fear of Doctor Stigma
Insurance Coverage
Cues to Action

Desire to Obtain the Vaccine
Vaccine Effectiveness
Vaccine Positive Beliefs
Vaccine Safety Concerns
Cues to Action
Subjective Norms

Actually Think Will Get the Vaccine
Vaccine Effectiveness
Cues to Action
Self-Efficacy
Subjective Norms
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individuals’ assessments of HPV vaccination Benefits and Barriers. Because the SelfEfficacy measure used in this study measures participants’ ability to overcome barriers to
be vaccinated, it was predicted that Self-Efficacy would also impact assessment of
Barriers. Finally, it was predicted that perceived Benefits and Barriers would impact
desire to receive the vaccine.
Assessing the fit of a model tested by SEM is done through the use of fit indices.
These indices provide information about the fit of the overall model, and because no one
index is able to assess the accuracy of the model, various indices need to be examined. In
order to assess fit in the current study the following fit indices were used: CFI, RMSEA,
IFI, and SRMR. In order to demonstrate good model fit, CFI and IFI values should be
over .90 (although the CFI value must also remain under 1.0). RMSEA values are said to
represent good fit when the value is .05 or less. If the value is above .05 but below .10 the
model is said to have adequate fit, and if the value is over .10 the model has bad fit. And
finally, values of the SRMR index below .08 are considered to indicate good fit.
CFA Measurement Model
As recommended by Kline (2005), before a test of the proposed model could
begin, it was necessary to perform a CFA analysis of the measurement model. This step
was necessary because of the unvalidated nature of some of the measures used in this
study, and the lack of prior research into the relationship between these measured
variables and the latent variables they are anticipated to represent. The purpose of the
CFA is to determine if the variables assessed in this study are indeed associated with the
latent variables they are predicted to measure. Per Kline, in order to assess a CFA model,
all latent variables are assumed to covary with each other, and thus their associations are
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left unanalysed. Observed variables that did not serve to measure a latent variable but
instead directly represent a component of the model (e.g., knowledge, self-efficacy) were
also added into the CFA model and were allowed to covary with one another, and with
the latent variables. Thus, all of the model components were free to covary. Per Kline, the
variance of all of the latent variables was fixed to one for this analysis (Kline, 2005).
Please see Figure 2 for a diagram of the original measurement model tested with CFA.
As the diagram illustrates, four variables were believed to assess perceptions of
Susceptibility: The HPV Susceptibility Scale score, relationship length in years, number
of vaginal sex partners, and a composite score developed from summing various life
experiences that would impact participants’ assessment that they were susceptible to HPV
infection (e.g., ever having an abnormal pap, ever having an STI). Eight variables were
believed to assess the latent Barriers variable: Comfort Talking with a Doctor, HPV
Vaccine Safety Fears, the SAS Permissiveness subscale, the STI Stigma and Shame
Scale, Trust in Pharmaceutical Companies Scale, Trust in Physicians Scale, Vaccine
Costs, and Fear of Doctor Stigma (if asking for the vaccine). It was believed that two
variables would assess perceived Benefits of the HPV vaccine: Vaccine Effectiveness and
Vaccine Positive Beliefs. And finally, perceptions of General Severity, Treatment
Severity, and Social Severity were thought to assess the Severity component of the
model. In addition, four observed variables, each measuring a model component
(Knowledge, Self Efficacy, Social Norms, Positive Cues to Action), were also included in
the CFA model. Finally, participants’ rating of their intention to receive the HPV vaccine
was included as the final outcome variable in the model.
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Figure 2:
Original CFA Measurement Model

Figure 2. SLE = Susceptibility Score Based on Life Experiences. SusSc = Susceptibility
Based on Life Experiences. RLYear = Relationship Length Years. SexPV = Number Sex
Partners Vaginal Intercourse. VEff = Vaccine Effectiveness. VPB = Vaccine Positive
Beliefs. SevG = Severity General. SevT = Severity Treatment. SevS = Severity Social.
VSaf = Vaccine Safety Concern. SASp = Sexual Permissiveness. STISS = STI Stigma
and Shame. CTDr = Comfort Talking to Dr. PhT = Pharmaceutical Company Trust.
AskSt = Fear Doctor Stigma. DrT = Physician Trust. VCost = Vaccine Cost.
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The results of the CFA indicated that the measurement model had reasonable-topoor fit, χ2(178, N = 269) = 553.36, p < .001; Goodness of fit indices: CFI = .735,
RMSEA = .089 (CI = .080-.097), IFI = .745, SRMR = .099. In an effort to increase model
fit, possible modifications were sought out. The first step was to examine variable
normality. It was found that the variable Number of Vaginal Sex Partners departed from
normality (kurtosis = 25.54), and so the decision was made to remove this variable from
the model. Because the main focus of this analysis is to test the basic structure of the
theoretical model being investigated, and because there are numerous other susceptibility
variables that can be used in this analysis, the decision was made to drop this variable
rather than to transform it. The next step was to examine model regression estimates. Four
variables were found to be non-significant measures of the latent variables they were
presumed to assess. These variables were: Relationship Length in Years, Vaccine Cost,
Pharmaceutical Company Trust, and Physician Trust. It was decided that these four
variables would also be removed from the model.
The second version of the CFA model was run and it had improved fit, χ2(71, N =
269) = 214.32, p < .001.; Goodness of fit indices: CFI = .886, RMSEA = .073 (CI = .061.086), IFI = .891, SRMR = .068. All CFA model regression weights were significant.
Modification index recommendations were examined to determine if any changes to the
model would improve model fit. No significant change recommendations were made.
According to Kline (2005), a model can be said to have good fit if the RMSEA value is
.05 or less. Any RMSEA value over .10 indicates a model with bad fit. Values in between
these cut-offs are said to have reasonable fit. Kline also recommends that the lower and
upper RMSEA confidence intervals be examined. Ideally, the lower CI value should fall
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below .05 and the upper value should fall below .10. Because of the range of values
included in the confidence intervals of this CFA model, it was decided that this
measurement model had reasonable fit and would be used in the SEM analysis.
Structural Equation Model: HPV Vaccination Intentions
The next step to test the proposed model of HPV vaccination intentions was to
take the measurement model that was assessed with the CFA analysis, and to add the
paths indicating the proposed relationship directions between the model variables. Please
see Figure 3 to view the full version of the model that was tested. When the model was
tested, it was found to have reasonable-to-bad fit, χ2(109, N = 269) = 394.46, p < .001.;
Goodness of fit indices: CFI = .743, RMSEA = .099 (CI = .088-.109), IFI = .750, SRMR
= .108. In order to improve model fit, regression weights were examined to determine if
any of the proposed model paths were non-significant. Three paths were found to be nonsignificant. The path leading from Cues to Action to Severity, the path leading from HPV
Knowledge to Social Norms, and the path leading from Susceptibility to Benefits. These
three paths were removed from the model. Regression modification indices also
recommended the addition of a path from Positive Cues to Action to Benefits. Because it
makes sense that receiving positive cues to get vaccinated would encourage women to
think about the benefits of vaccination, the decision was made to add this path. This new
version of the model was then tested.
The second version of the SEM model had improved, reasonable, fit, χ2(111, N =
269) = 329.72, p < .001.; Goodness of fit indices: CFI = .803, IFI = .808, RMSEA = .086
(CI = .075-.097), SRMR = .010. An examination of the model regression weights
revealed that the path between perceptions of Severity and Benefits was no longer
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Figure 3
Original SEM Model Tested
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significant. Thus, the decision to remove this path from the model was made. An
examination of modification indices for regression weights did not find any
recommendations that would significantly improve the fit of the model. A rerunning of
the model (model version 3) with the deletion of the path between Severity and Benefits
found little change in the fit of the model. The model still had reasonable fit, χ2(112, N =
269) = 332.79, p < .001.; Goodness of fit indices: CFI = .802, IFI = .806, RMSEA = .086
(CI = .075-.096), SRMR = .101. An examination of the regression weights revealed that
all paths were significant. A review of changes suggested by the modification indices
showed that allowing the error terms of the Benefits latent variable and the Vaccine
Safety Concern variable to covary would improve model fit. In SEM, error terms may
need to be correlated for various reasons. These include the two variables assessing
similar constructs, a variable missing from the model that if included would have effects
on both variables, and finally, because of method bias such as socially desirable
responding on both variables (Garson, 2012). Because it makes sense that these benefit
and vaccine safety beliefs could have a mutual influence in common, these two error
terms were allowed to covary. No other modification indices provided useful information
for improving the model.
The fourth version of the model was run, and it was found that model fit did
improve, χ2(111, N = 269) = 296.87, p < .001.; Goodness of fit indices: CFI = .833, IFI =
.837, RMSEA = .079 (CI = .068-.090), SRMR = .094. An examination of the model
regression weights revealed that all paths were significant. Modification indices revealed
three rational modifications that would improve model fit. Modification indices
recommended that the Self Efficacy variable be allowed to covary with the error term of
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three variables: Positive Cues to Action, Benefits, and Social Norms. Because it seems
possible that these four variables may have a common influence that is not assessed in
this model (e.g., Optimism, Trust), but which may impact all of these variables, the
decision was made to allow these error terms to covary. These changes were made and
the model was run again.
The fifth version of the model was found to have improved fit, χ2(108, N = 269) =
232.38, p < .001.; Goodness of fit indices: CFI = .888, IFI = .891, RMSEA = .066 (CI =
.054-.077), SRMR = .069. All model regression weights were significant and no
modification indices had suggestions for significant model improvement. In light of this,
the decision was made to cease modifying the model, and to determine that this is the
final version. Please see Figure 4 and Figure 5 for the final version of the model. Figure 5
contains only the model component variables so that standardized regression weights can
be viewed.
Supplemental Analyses
Scale score mean differences between HPV vaccinators and non-vaccinators.
To aid in the interpretation of the study results, mean outcome scale differences between
those who received the vaccine and those who did not were investigated with t-tests (see
Table 10). Results revealed that these two groups had significantly different average
scores on the following variables: Treatment Severity, with those who obtained the
vaccine believing that treatment would be more severe than those who did not get it;
Vaccine Effectiveness, with those who obtained the vaccine believing the vaccine is more
effective; Vaccine Positive Beliefs, with those who obtained the vaccine believing it is
more positive than those who did not get it; Vaccine Safety Concerns, with those who
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Figure 4
Final SEM Model
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Figure 5
Final SEM Model Components with Standardized Regression Weights
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Note. Model covariances and error terms are not shown in this depiction. All regressions are significant at at least .05.
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Table 10
T-tests Comparing Outcome Scale Scores of Vaccinated and Unvaccinated Participants

Vaccinated

Measure

Unvaccinated

M

SD

M

SD

t

p

Susceptibility Scale

1.91

.84

1.87

.89

-.30

>.05

Severity General

4.47

.54

4.47

.57

.077

>.05

Severity Treatment

4.40

0.55

4.23

0.70

-2.37*

< .01

Severity Social

4.13

.88

4.03

.97

-.90

>.05

Fear of Cervical Cancer

3.59

.89

3.49

.95

-.85

>.05

Vaccine Effectiveness

4.07

0.76

3.10

1.01

9.91*

< .001

Vaccine Positive Beliefs

4.20

0.76

3.53

0.86

-6.82*

< .001

Vaccine Safety Concerns

2.70

0.85

3.63

0.78

9.98*

< .001

SAS Permissiveness

2.13

.76

1.98

.83

-1.55

>.05

STI Stigma and Shame

2.39

.80

2.43

.83

.43

>.05

Physician Trust

3.72

0.72

3.48

0.88

2.44*

< .05

Pharma. Company Trust

3.00

0.55

2.79

0.58

-3.22*

< .001

Cost Concern Scale

1.91

.98

2.19

1.27

2.13*

<.05

Fear Doctor Stigma

1.52

0.55

1.92

0.66

5.38*

< .001

Self-Efficacy

3.85

.91

3.52

.90

-1.69*

<.05

Social Norms

3.72

0.64

3.10

0.58

-8.50*

< .001

Positive Cues to Action

4.36

3.047

1.57

2.22

-8.14*

< .001

Note. *p < .05
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obtained the vaccine believing it is more safe; Fear of Doctor Stigma, with those who
obtained the vaccine fearing stigma less than those who did not obtain the vaccine; Dr.
Trust, with those who obtained the vaccine having more trust in their physician;
Pharmaceutical Company Trust, with those who obtained the vaccine having more trust in
pharmaceutical companies; Cost, with those who obtained the vaccine having less
concern about cost than those who did not get the vaccine; Subjective Norms, with those
who obtained the vaccine reporting more positive norms for the vaccine than those who
did not get it; And Positive Cues to Action, with those who obtained the vaccine having
received more positive cues to action.
Physician sex and patient comfort. Research on doctor-patient communication
has found that the gender of a doctor and patient can impact their communication. In light
of this, a linear regression was conducted in order to determine if the sex of participants’
doctors influenced their fear of experiencing stigma if asking for the vaccine. The
regression investigating this relationship was not significant, F(1,329) = 0.81, p < .001,
adjusted R square = -.001, indicating that fears of stigma were not related to the gender
of the doctor. This lack of significance also held true when this possible relationship was
examined for just women who received the vaccine, and just those who had not received
the vaccine. An additional analysis was then conducted to determine whether health care
provider gender influenced participants’ level of comfort in talking with their health care
provider in general. The regression investigating this relationship was significant,
F(1,329) = 22.61, p < .001, adjusted R square = .062. With individuals feeling more
comfortable with female doctors (M = 3.88, SD = .93) than male doctors (M = 3.35, SD =
1.06).
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Recommending the HPV vaccine to male and female friends and family
members. In addition to the main outcome items used in this study, participants were also
asked some additional outcome items that were not a main focus of the current
investigation. Two of these items examined whether participants would recommend the
HPV vaccine to their male or female friends and family members. Responses to each
question were recorded on a 5-point scale that ranged from 1 (definitely would not) to 5
(definitely would). A t-test to investigate whether participants would make different
recommendations for male and female friends was significant, t(370) = 8.47, p < .001.
Participants were more likely to recommend that their female friends and relatives get the
vaccine (M = 3.24, SD = 1.39) than they were to recommend their male friends and
relatives to get it (M = 2.79, SD = 1.35). Additional analyses also revealed that
participants’ vaccination status was related to whether they would recommend the
vaccine to female friends or family members, F (3,367) = 28.80, p < .001, and to male
friends or family members, F (3,364) = 15.89, p < .001. Post hoc tests revealed that
participants who had received two or three of the vaccine shots were more likely to
recommend vaccination to their female friends and family members than were individuals
who had not had any vaccinations. For males, those who had had three shots were more
likely to recommend the vaccine than those who had no shots.

Factors that influence HPV vaccinations 123

Chapter IV
Discussion
When girls and women obtain the HPV vaccine they are protecting themselves
against a virus that can lead to cancerous cells and genital warts, and all of the negative
psychological and social implications that these illnesses can have for them. A vaccine for
HPV was first released in 2006, and while many studies that had investigated anticipated
obtainment of the vaccine reported that it would most likely be obtained by the majority
of the targeted population, actual vaccination rates have not reached anticipated levels,
especially for girls and women who are not eligible for the school-based vaccination
program. There are many possible factors that could explain why girls and women choose
to obtain the vaccine or not. This study used a modified version of the Health Belief
Model to examine the relationship between psychosocial variables and HPV vaccination
in a sample of women residing in Canada. Direct relationships between the study
variables and actual and anticipated HPV vaccinations were investigated through logistic
and multiple regression. While past research has examined the direct relationships
between many of the components/variables used in this study and HPV vaccinations,
many of the model’s components have not been sufficiently researched to date. Some
variables have received little attention in the research literature or have not been
measured adequately (e.g, perceived susceptibility, self-efficacy, cues to action), while
the effects of others have been found to be inconsistent (e.g., knowledge, perceived
severity). Another model component, perceived barriers, has repeatedly been found to be
predictive of vaccine related outcomes, but due to the large number of factors that can be
classified as potential barriers, additional novel barriers to HPV vaccination had yet to be
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investigated (e.g., medical establishment variables, sexuality variables). This study
attempted to remedy some of these shortcomings.
In addition to analyses investigating direct effects, in order to investigate more
complex relationships, a modified Health Belief model of HPV vaccination intentions
was tested using Structural Equation Modeling. Few studies in this area have tested
complex models of health behaviour. In addition, those that have explored the match
between health behaviour change theories and HPV vaccinations have not used structural
equation modeling to test possible models. Instead, these studies have used regression
analysis, which limits the types of relationships between the model variables that can be
explored. This study is novel in that the complex interrelationships between the model
components were tested with SEM, providing a clear and complex picture of the decision
making process as it related to HPV vaccination intentions.
This discussion describes the major findings of this study, beginning with an
examination of vaccination and health behaviour rates. Next, support or lack of support
for the study hypotheses are described, so that a clear picture of the usefulness of each
model component can be determined. After this, a discussion of the results organized by
type of outcome (actual vaccinations, desire to get vaccinated, and actual thoughts on
whether one would obtain the vaccine) can be found. Finally, as the last step in describing
the results of this study, a discussion of the model that was tested was undertaken.
Following the various descriptions of the study results, a discussion of practical
implications, limitations, and recommendations for future research is presented.
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Vaccination and Health Behaviour Rates
Not surprisingly, this study found that the majority of participants had not
received the HPV vaccine, with 72% of participants reporting they never received it, and
27% of the sample reporting they had received at least one shot. While studies conducted
prior to the release of the vaccine reported that high proportions of young women
believed they would obtain it, uptake rates after its release were lower than anticipated,
especially in non-school-based settings. The results found in the current study are in line
with rates found in other studies that were conducted after the release of the vaccine. For
example, Caskey, Lindau and Alexander (2009) found that 30% of 13 to 17 year olds, and
9% of 18 to 26 year olds had received the HPV vaccine. As these rates demonstrate,
vaccination rates after the release of the vaccine were lower than anticipated, and have
stayed low over time.
In order to assess participants’ sexual risk taking and sexual health behaviours, the
women in this study were asked to provide information such as their age of first
intercourse, the number of sexual partners they had, their STI status, and whether they
had ever had a pap test. When asked about their sexual experiences, 84% of study
participants reported that they had engaged in some form of sexual activity. When vaginal
intercourse was investigated specifically, it was found that 73% of the women in this
study had had vaginal intercourse, that the average number of sexual partners the women
had had was four, and that the average age of first intercourse was 17 years old. When
anal intercourse was investigated, it was found that almost 20% of the women had
engaged in it, with the average age of first experience being higher than for vaginal
intercourse, at 19 and a half years. Individuals also reported having fewer anal intercourse
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partners, with the average being 1.39. These values correspond roughly to Canadian
sexual experience statistics, although the women in this study appear to engage in sexual
intercourse a year later than the national average. Nationally, the average age of first
vaginal intercourse is 16.5 years (Rotermann, 2005), and 86% of youth have had sex by
the age of 24 (Rotterman, 2012). The difference in age of first intercourse may be related
to the educated sample used in this study, or may be due to regional differences, as a large
proportion of this sample came from Ontario. Ontario youth seem to be slightly less
sexually experienced compared to national averages, with fewer Ontario youth engaging
in sex than the Canadian average (Rotermann, 2005).
To date, Pap testing has been the most effective preventative action that a woman
can take to avoid cervical cancer. This study found that 60% of the women who
participated had ever received a Pap test. While this number at first seems low, further
examination found that almost 80% of women who had had sexual intercourse had
received a Pap test. Because physicians may not recommend Pap tests to women who
have not yet engaged in sexual intercourse, these statistics are not surprising. For
example, in a national health survey it was found that 77% of heterosexual Canadian
women report having had a Pap test within the last three years (Tjepkema, 2008). As
these results indicate, then, the women involved in this study were proactive about
protecting their gynecological health through the traditional method of Pap testing.
Participants were asked to indicate if they had ever had an abnormal Pap test, and almost
13% of the sample had had an abnormal test. This rate is slightly higher than national
abnormality rates, as 8% of Pap tests done in Canada require follow-up due to
abnormality (The Canadian Women’s Health Network, 2007). This difference may be a
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reflection of the age range of the study participants (younger women are more likely to
have abnormal Pap tests), or it may be due to self-selection bias, as young women who
have experienced an abnormal Pap may have been more interested in participating in this
study.
The women in this study were also asked if they had ever had an STI. Results
indicated that 4.5% of the sample had had an STI, and 3.7% of the sample had been told
they have HPV. This is similar to rates of common STI diagnoses in the general Canadian
population. For example, 4.3% of 15-29 year olds have had Chlamydia. Because HPV is a
non-reportable STI, exact national rates are not available. However, given its prevalence,
it is likely that symptomatic HPV rates in the Canadian population are similar or higher
than those for Chlamydia. This suggests that the current study does not have an
overrepresentation of women diagnosed with HPV.
Overall, the HPV vaccination rates and sexual experiences reported in this study
closely reflect those of women in the Canadian population. Because of this, the results of
this study are likely to reflect the experiences of Canadian women from an educated
background.
Discussion of Regression Results Organized By Hypotheses
Hypothesis 1: Perceived susceptibility to HPV infection will predict HPV
vaccination. It was predicted that feeling susceptible to HPV would predict HPV
vaccinations. When actual vaccine obtainment was investigated, two susceptibility
variables were initially found to be predictive: relationship length in years, and whether
an individual had ever had vaginal intercourse. As relationship length increased,
participants were less likely to get the vaccine, and women who had never had sexual
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intercourse were less likely to be vaccinated. These results coincide with results found in
previous research, which found that individuals in monogamous relationships, and
individuals who had never had sexual intercourse, were less likely to want the HPV
vaccine (Buchanan, 2008; Caskey, Lindau & Alexander, 2009; Marshall, Ryan, Roberton,
& Baghurst, 2007). From the perspective of women, the finding that those who have not
had intercourse are less likely to obtain the HPV vaccine makes sense. These individuals
likely believe they are not at risk of acquiring an STI, and thus they do not believe they
need to be vaccinated. Unfortunately, this is the group of women for whom the vaccine is
most protective. While the initial regression investigating the susceptibility variables and
actual vaccine obtainment found a significant relationship, when the susceptibility
variables were entered into the regression investigating all significant predictors of actual
obtainment, they were found to no longer be predictive. Thus, while a relationship exists,
it appears to be small, with other variables accounting for actual obtainment decisions.
For women who had never been vaccinated, belief in susceptibility to HPV
infection influenced desires to get vaccinated. Susceptibility scale scores and relationship
length predicted desires. Women who felt more susceptible to infection were more likely
to desire the vaccine, while the longer a woman was in a relationship, the less likely she
was to desire it. As noted in the literature review section of this document, few studies
have used a measure to assess actual feelings of susceptibility to HPV infection. The
finding here, that a desire to get the vaccine is related to feelings of susceptibility, is one
of the only studies (see Kuitto, Pickel, Neumann, Jahn & Metelmann, 2010, for another
example) that shows that actual feelings of susceptibility (as assessed with a measure and
not inferred based on demographic data such as relationship status) can be related to a
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desire to be vaccinated. When the significant susceptibility variables discussed here were
placed into the regression with other significant predictors of a desire to get the vaccine, it
was found that they were no longer significant. Thus, while a small relationship might
exist, again, other variables such as perceptions of vaccine effectiveness, positive cues to
action and subjective norms have been found to be more predictive of desire to be
vaccinated.
Finally, when women who had never been vaccinated were asked if they actually
thought they would get the vaccine, regardless of whether they wanted it or not, it was
found that abnormal pap test status, relationship length, and ever having anal intercourse
were predictive of beliefs that one would actually get the vaccine. Similar to the other
regression findings, the longer a woman was in a relationship, the less likely she was to
think she would actually get the vaccine. Surprisingly however, women who had had an
abnormal pap test in the past, or who had ever had anal intercourse, were less likely to
think they would actually get the vaccine. These findings were surprising because
previous research has found that women who have engaged in more sexual risk taking,
such as having multiple sex partners (more than 5 partners versus 1-5), or having ever had
an STI, were more likely to want to be vaccinated (Jones & Cook, 2008). Previous
research has also found that women who had had an abnormal pap test in the past were
more likely to want the HPV vaccine after an educational intervention than were women
who had not had an abnormal Pap test (Ferris, Waller, Owen & Smith, 2008). Seemingly
incongruous findings as they relate to risk and health behaviours are not completely
unheard of in the health care field, however. For instance, research has shown that some
women who are at risk for breast cancer are less likely to be screened for it, and that this
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lack of screening behaviour is related to anxiety about finding a problem (Rimer,
McBride & Crump, 2001).
The reason for the surprising findings in this study may relate to how this
particular question was worded. In the current study, number of anal intercourse partners
and abnormal Pap test status were not found to be predictive of desire to get the vaccine.
It is this type of intention (desire) that past research has investigated. Asking women if
they actually think they would get the vaccine (regardless of whether they want it or not)
may activate a more complex thought process. While a woman may recognize that she
wants the vaccine, certain factors, such as knowledge of her Pap history and sexual risktaking/experience, may influence her perception of her HPV infection likelihood and thus
her thoughts on vaccination. For example, women who have had an abnormal pap test
may believe that they already have HPV, and thus they may decide that given the
likelihood that they have HPV (high) they are less inclined to overcome barriers (e.g.,
time, cost) to actually get the vaccine, even though they may want it. It could also be that
women who think they have already been exposed to HPV believe they are immune to it,
or may not be aware that they can contract other strains of the virus. Thus, they do not
realize that they would benefit from the vaccine. Similar to the previous two outcomes,
however, when these susceptibility variables were entered into the regression with other
significant predictors, they were no longer predictive, again indicating a weak
relationship between susceptibility and the outcome.
In conclusion, while it initially appears that susceptibility variables do influence
actual and anticipated vaccinations, in interesting ways, it becomes clear with further
analyses that susceptibility variables, when considered in the context of other predictors,
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are not strong predictors of any of the HPV vaccine outcomes. Other factors play a much
greater role in directly predicting vaccination behaviour.
Hypothesis 2: Perceived severity of HPV infection will predict HPV
vaccination. Hypothesis two stated that participants’ perceptions of the severity of HPV
would influence vaccinations, with the likelihood of wanting or obtaining the vaccine
increasing as perceptions of severity increased. Various types of severity were assessed in
this study: perceptions of the severity of treatment, of the social impact of having HPV, of
HPV in general, and of fears of cervical cancer. Only perceptions of the severity of
treatment were found to influence whether a woman got the vaccine or not. Women who
were more concerned about treatment were more likely to want to get the vaccine.
Concern about treatment severity proved to be a strong predictor of women’s actual
vaccination decisions, as it maintained its predictive ability when all significant predictors
of vaccine obtainment were placed into the final regression equation.
For those who had not yet received the vaccine, severity was not found to be
predictive of a desire to get the vaccine, although concerns about general severity were
found to be related to actually thinking one would want the vaccine. This relationship was
small, however, and when other factors that influence women’s vaccination decisions
were taken into account, concerns about severity no longer had an impact on whether
women would think they would get the vaccine or not.
The results of this analysis parallel what has been found in previous research:
mixed support for the influence that severity has on HPV vaccination decisions.
Interestingly, previous research that has investigated whether severity is predictive of
intentions to vaccinate also did not find a relationship (Buchanan, 2008; Dempsey, Zimet,
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Davis & Koutsky, 2006; Jones & Cook, 2008). Thus, the lack of strong significant
findings of a relationship between perceptions of severity and intentions in this study is
not necessarily surprising. The interesting finding here, however, is that treatment
severity was found to be predictive of actual vaccination behaviours.
Hypothesis 3: Perceived benefits will predict HPV vaccination. It was
hypothesized that the more benefits an individual believed the HPV vaccine would
provide, the more likely they would be to get vaccinated or to intend to get vaccinated. It
was found that both beliefs about vaccine effectiveness and vaccine positive beliefs
predicted actual vaccine obtainment when they were placed in the regression alone with
vaccination status as the outcome. However, when they were entered into the regression
model with other significant predictors, they were no longer predictive.
The benefit variables proved to be more predictive of intentions to vaccinate.
When desire to obtain the vaccine and beliefs that one would actually get the vaccine
were assessed, both benefit variables were found to be predictive of each of these
intentions. When placed into regressions with other significant predictors, the benefit
variables were still predictive. Both vaccine effectiveness and vaccine positive beliefs
continued to be predictive of a desire to get the vaccine, while beliefs about vaccine
effectiveness continued to predict beliefs that one would actually get the vaccine. These
results are similar to those of previous research, which found that perceived benefits
predicted intentions (Buchanan, 2008). These previous studies also had found that
women’s beliefs that the vaccine would help themselves or their children (similar to
vaccine effectiveness in this study), or their community or society (similar to vaccine
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positive beliefs in this study) were predictive of intentions (Dempsey et al., 2006;
Gudmundsdottir et al, 2003).
In summary then, it appears that beliefs about the benefits of vaccination are
strong predictors of intentions to vaccinate, and yet are not the strongest predictors of
actual vaccination behaviours. While little previous research in the area of HPV
vaccinations has investigated these two benefit variables, this study suggests that these
are important variables to consider when trying to understand what factors may influence
women to think about obtaining the vaccine.
Hypothesis 4: Perceived barriers will predict HPV vaccinations. It was
predicted that more perceived barriers would negatively impact HPV vaccination
behaviours. A large number of barrier variables were used in this study, and thus it was
not surprising that for each outcome assessed, some barrier variables were predictive
while some were not.
When actual vaccine uptake was investigated, it was found that concerns about the
safety of the HPV vaccine, women’s fears of experiencing stigma from their health care
provider, and insurance coverage significantly impacted actual uptake. These variables
maintained their significance when entered into regressions with other variables,
indicating that various barriers do play an important role in predicting actual vaccine
uptake.
When a desire to get the HPV vaccine was investigated, concerns about vaccine
safety, trust in pharmaceutical companies, cost, and fear of experiencing stigma from a
doctor were associated with women’s desires to get vaccinated in initial analyses.
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However, when other significant predictors were also taken into account, only vaccine
safety concerns had a large enough influence on desire to maintain its significance.
A similar lack of significance in the final regression model for barrier variables
was also found when participants’ thoughts that they would actually get the vaccine were
assessed. In the final regression investigating what barriers would influence whether
women thought they would actually get the vaccine, no barrier variables proved to be
predictive.
In summary, then, women’s concerns about the safety of vaccines, their fears of
experiencing stigma from their doctor, and whether they had insurance, were the barriers
that maintained their predictive ability for at least one of the outcomes. Interestingly,
fears of experiencing stigma if asking a physician for the vaccine was one of the novel
variables that was investigated in this study. This finding indicates that the STI status of
the vaccine may influence women’s decisions to vaccinate. Scale means revealed that
while both vaccinated and unvaccinated women on average do not believe that their
physicians would make negative judgements about them, women who got the vaccine
disagreed more strongly that their doctor would judge them negatively. While the idea
that patients do not want their doctors to view them negatively is not a new one in
medical research, with medical research showing that patients give socially desirable
information to their doctors because of concern with creating a desirable impression,
fearing a loss of control, or even to avoid a lecture (Bilney & D’ Ardenne, 2001; Dew et
al., 2007; Lewis, Matheson & Brimacombe, 2011), the fact that vaccination uptake is
impacted by a fear of stigma from doctors is a unique finding in the area of HPV
vaccination research. Even though the strength of the relationship between the fear of
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stigma and vaccine uptake in this study was small, it will still be interesting to investigate
this construct further in future research. It may be that fears of stigma are not as salient in
questionnaire research, and that more complex experiments to investigate its effects in
actual social interaction settings is needed. In summary, the finding that concerns about
stigma may impact vaccination decisions is an important one to consider when experts
look at ways to increase vaccinations, as some women may have concerns that they will
be viewed negatively by others for asking for or obtaining this vaccine. Fear of stigma
will also be an important variable to investigate in future STI vaccine studies, as other
STI vaccines are currently in development.
When the discussion turns to the other two barriers that were strong predictors of
uptake, cost and concern about safety, their impact on vaccine obtainment was less
surprising. Many media sources have documented (and fueled) public concern about the
safety of the HPV vaccine, and about vaccines in general. In addition, past research into
vaccination decisions, both about vaccines in general and the HPV vaccine specifically,
have found that concerns about safety were related to uptake (Kahn et al., 2008; Prislin,
Dyer, Blakely & Johnson, 1998). In this study, safety concern was one of the variables
that had the largest difference in average scores when t-tests investigated differences
between those who obtained the vaccine and those who didn’t. Those who obtained the
vaccine had an average score of 2.7 out of 5 on the concern scale, while those who did not
get vaccinated had an average score of 3.63 out of 5, revealing that those who did not
obtain the vaccine actually reported that they did worry about the safety of the vaccine,
while those who did get it reported a more neutral position.
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Past research has consistently found that cost is a factor that individuals consider
when thinking about the HPV vaccine (Caskey, Lindau & Alexander, 2009; Kahn et al.,
2008; Sauvageau, Duval, Cilca, Lavoie & Ouakki, 2007). Because of this it is not
surprising that the insurance variable was found to be predictive of actual vaccination
behaviours. It may be that those who have to pay for the vaccine simply could not afford
it, or they may not have felt that they needed the vaccine enough to pay for it when it is
rather expensive. Interestingly, the cost scale itself was not predictive of vaccination
decisions in the final regression analyses This finding may be a true one, although the
scale used in this study was not validated in other research, and so this finding could also
be related to measurement error. The results from this study however, found that on
average, participants reported that they were a little concerned about cost when they
completed the cost scale; however, other variables such as benefits, cues to action and
subjective norms proved to be more predictive of actual or intended vaccination
decisions.
Hypothesis 5: Knowledge will predict HPV vaccinations. HPV Knowledge was
hypothesized to predict HPV vaccine obtainment and intentions. Surprisingly, knowledge
was not directly related to any of the outcomes, neither actual nor intended vaccinations,
assessed through the regressions conducted in this study. Previous research found mixed
results when investigating the predictive ability of this variable, and thus while
unexpected, the lack of support for this hypothesis is not entirely out of line with the
findings from previous studies (Buchanan, 2008; Dempsey et al., 2006). While this study
did not find that knowledge directly impacted vaccination related outcomes, knowledge
did act upon other model variables, so that while it did not directly predict HPV vaccine
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decisions and intentions, it was still indirectly related to these outcomes. Further
elaboration of this result appears in the discussion of the structural equation model tested
for this study that appears later in this section. In terms of the original hypothesis though,
no support for the hypothesis was found.
Hypothesis 6: Self-efficacy will predict HPV vaccination. It was theorized that
feelings of self-efficacy for obtaining the vaccine would be related to intentions to
vaccinate. Participants who had already received the vaccine were not asked to complete
the items assessing self-efficacy, and so relationships between efficacy and actual
vaccination decisions were not investigated. It was found that women with higher feelings
of self-efficacy to obtain the vaccine were more likely to believe that they would actually
get the HPV vaccine. This relationship between feelings of efficacy and thoughts that one
would get the vaccine was significant, both in the individual regression investigating the
relationship, and when it was placed in the final regression with other significant
predictors. Feelings of self-efficacy were also initially predictive of desires to get the
vaccine, although this relationship become nonsignificant when other, more predictive
variables, were added into the analysis. Buchanan (2008) and Kahn et al. (2008) also
found that self-efficacy predicted intentions to vaccinate.
Hypothesis 7: Cues to Action will predict HPV vaccinations. It was anticipated
that Cues to Action would be related to HPV vaccination behaviours. The results of this
study revealed that Positive Cues to Action were indeed a strong predictor of actual
vaccine obtainment, desire to get the vaccine, and thoughts that one would actually get
the vaccine. Urgings to get the vaccine were predictive of each of these outcomes when
assessed in initial regressions, and also when placed into regression equations with all
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significant predictors, thus, revealing strong support for this hypothesis. While past
research has found that cues from physicians and families do predict vaccinations
(Caskey, Lindau and Alexander, 2009; Dempsey et al., 2006), the present study shows
that cues from other sources also have a positive influence on vaccination behaviours. In
this study, the number of cues an individual received, and their type, served as the cues
variable. Cues could come from sources such as family, doctors, friends, advertisements,
and romantic partners. Findings indicated that the more people or sources who talk to or
educate women about the HPV vaccine, the more likely one is to be vaccinated, or to
want the vaccine.
Hypothesis 8: Subjective Norms will predict HPV vaccinations. Subjective
norms were hypothesized to predict HPV vaccination behaviours and intentions.
Women’s perceptions of the social norms surrounding the vaccine were found to predict
actual vaccine obtainment when assessed apart from other significant predictors (although
not when assessed with others), and to strongly predict both desire to get the vaccine, and
thoughts that one would actually get it. This significance held true for both outcomes
when norm scores were entered into the regressions that included other significant
predictors, indicating that what others think about the vaccine does influence women’s
decisions. This supports findings by Buchanan (2008), who found that the subjective
norms component of the Theory of Planned Behaviour was the only component from this
model that was found to be predictive of intentions in her study. This idea, that the social
discourse and norms surrounding certain vaccines influences uptake is not a new one, and
has been discussed in research for other types of vaccines as well. For an interesting and
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timely discussion of how public perceptions influence vaccination decisions (and in
particular vaccine confidence), see Larson, Cooper, Eskola, Katz & Ratzan (2011).
Because subjective norms were so predictive of desire and thoughts that one
would actually want the vaccine, reasons for why norms were not predictive of actual
vaccination behaviours were investigated further. Questionnaire items used to measure
this construct were examined, and it appeared that these items may not have been worded
adequately to assess this construct for individuals who had already received the vaccine.
More specifically, the response options were not worded appropriately. An example item
was “My romantic partner thinks…” and example response options were: “I definitely
should not get the HPV vaccine”, and “Maybe I should get the HPV vaccine”. Because
the wording of the items implies that a vaccination decision has not yet been made,
individuals who had already been vaccinated may have been confused by this wording. If
the items had been worded differently, the findings for this variable as they relate to
actual vaccination behaviours may be more reliable. Future research in this area should
aim to measure this variable more appropriately.
Regression hypotheses overview. While many of the study variables were
significant in initial regressions that only looked at the relationship between outcomes and
each component, and the variable(s) that measured it, when all significant predictor
variables from the various components were placed together into final regressions to
assess each outcome, some variables lost their significance. Two of the modified Health
Belief model components were not found to be directly predictive of any outcomes after
the final regressions were conducted. These two components were perceived
susceptibility and knowledge. Only one model component, cues to action, was predictive
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of all three outcomes. The remaining model components were predictive of one or two
outcomes. In summary, then, the majority of the hypotheses that predicted relationships
between the model components and study outcomes were supported. However, specific
hypothesis support varied across different outcome variables. In order to better
understand the variables and model components that were predictive of different
outcomes, a summary and discussion of the direct predictors of each outcome is presented
next.
Predictors of Actual Vaccinations
Because this research is one of the few studies that has investigated factors that
are related to actual vaccinations, the findings in this section may be particularly useful to
health professionals. The model components that significantly predicted actual vaccine
obtainment were: Severity (the severity of treatment variable), Barriers (vaccine safety
concerns, fear of doctor stigma, insurance), and Cues to Action (positive cues to action).
Fear of the severity of HPV treatment and cues to vaccinate are likely the factors that
encourage women to get vaccinated, while the barrier variables discourage uptake.
What do these significant findings mean? While many barrier variables were
hypothesized to predict actual vaccine uptake, only three were found to do so. Given past
research findings that have reported concerns about the safety of the HPV vaccine, and
given some individuals’ concern about vaccine safety in general, the fact that concerns
about safety was one of the significant predictors of obtainment was not surprising. In
addition, many past studies have found that cost is associated with HPV vaccination
uptake, and so the significance of the insurance variable was also highly anticipated.
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Perhaps the most interesting finding in terms of significant barrier variables, is the
finding that women’s fears of experiencing stigma from a doctor was predictive of
uptake. This is a novel variable in HPV vaccine research, and to this authors knowledge,
is investigated here for the first time. Even though the statistical analyses from this study
revealed that this variable had only a small impact on the outcomes, this finding is still
important because it provides new information about a barrier to HPV vaccinations that
health professionals need to recognize and research further. With this new knowledge,
healthcare professionals can know to act to reassure their patients that obtaining the
vaccine is a smart and healthy choice, and that they will not be negatively judged for
doing so. Interestingly, given the relationship between Fear of Doctor Stigma and vaccine
uptake in the current study, it is rather surprising that STI Stigma and Shame scores were
not predictive of actual vaccination behaviours. This may be an interesting avenue for
future research.
While the hypothesis that perceived severity would predict uptake was supported,
it is interesting that only one type of severity, treatment severity, was significantly related
to behaviours. Treatment severity items asked participants how upset they would be if
they had to receive treatment for certain medical issues associated with HPV. This is in
contrast to other severity items, which intuitively may seem more likely to be predictive
of behaviours (for example, items asking participants if they would be upset if they were
told they have HPV, or genital warts, or abnormal cervical cells). It may be that
pondering the actuality of treatment for an illness, which includes physical discomfort,
time commitments, and social interactions, versus an illness in the abstract, is more
powerful than pondering the severity of illness in general.
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Finally, a surprising finding when looking at predictors of vaccine uptake, was the
lack of a significant relationship between any of the benefit variables and vaccine
obtainment. It appears that positive thoughts about the vaccine do little to directly impact
actual vaccinations. While individuals’ own positive beliefs about the vaccine may not be
a strong enough motivator to push them to get the vaccine, encouragement from others to
get the vaccine (cues) was. This study shows that a mix of social (positive cues to action)
and negative (perceptions of treatment severity) factors most strongly influence
vaccination decisions.
Predictors of Desire to Get Vaccinated, and Thoughts That One Will Actually Get It
While predictors of actual vaccine obtainment may be regarded as the most
important variables to identify when it comes to investigating HPV vaccinations, it is also
important to understand factors that predict intentions to vaccinate in those who have
previously decided to forgo the vaccine. Interventions can and should target these
individuals, especially considering the large number of women who fit into this category.
Thus, understanding factors that will make these women consider getting vaccinated is
important.
For participants who had never been vaccinated, the variables that were found to
be predictive of the two types of intentions were generally similar, although there were
some differences. The model components that were predictive of a desire to get the
vaccine were: Benefits (Vaccine effectiveness, Vaccine Positive Beliefs), Barriers
(Vaccine Safety Concerns), Cues to Action, and Subjective Norms. Model components
that were predictive of thoughts that one would actually get vaccinated were: Benefits
(Vaccine effectiveness), Cues to Action, Self-Efficacy, and Subjective Norms.
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One of the most surprising findings here, is that barriers were not strongly related
to either outcome. Only one barrier, concern about the safety of the vaccine, was
predictive of desires, and no barriers were predictive of thoughts that one would actually
get the vaccine. In contrast, three barriers were found to predict actual vaccine
obtainment.
Subjective norms were found to influence both desires to get the vaccine, and
thoughts that one would actually get it, indicating that women’s thoughts about the
vaccine were influenced by what they perceived to be the social norms surrounding this
issue. In light of this, it will be important that intervention efforts in this area focus on
increasing societal acceptance of the HPV vaccine. This could be accomplished by means
such as encouraging dating partners to both get vaccinated, or encouraging friends, or
parents and children, to talk about the vaccine together. The more sources that women
receive encouragement from, the more likely they will be to get vaccinated.
The perceived benefits associated with vaccination were also found to be
predictive of both intention outcomes. This is not surprising, and was predicted. It is
logical that individuals who perceive benefits to vaccination will want to be vaccinated,
and are more likely to think they actually will do so. It is interesting to note that benefit
variables were initially found to be predictive of actual vaccination decisions, but that
their predictive influence was not as large as the influence of other variables. For
individuals who have not been vaccinated, however, perceived benefits are still a strong
motivating factor to wanting the vaccine.
Feelings of self-efficacy related to getting the HPV vaccine were found to predict
beliefs that one would actually get vaccinated, but not desires to get it. Self-efficacy items
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asked participants if they were confident that they could get the vaccine in light of things
like cost, time, and potential barriers. This finding demonstrates that individuals who
report that they are not likely to actually get the vaccine are aware that they lack the
ability to overcome some of the barriers to obtainment that were listed in the efficacy
questionnaire. This finding also highlights that researchers need to carefully word their
outcome items when doing research, to ensure that items really ask what it is that
researchers want to know. While desires to get the vaccine and thoughts that one actually
will do so are closely related constructs, and do share many of the same predictors, there
are some interesting differences between the two variables.
Why Predictors May Vary for Actual and Intended Outcomes
One of the interesting questions that the results of this study raises, is why the
variables that influence actual vaccination behaviours and intentions to vaccinate differ.
These differences are likely related to barriers. While forming an intention to do
something does not require one to become keenly aware of, and overcome barriers, acting
or not acting requires one to acknowledge, think about, and then overcome obstacles (or
not). This idea is clearly demonstrated by the current study finding that more barrier
variables were predictive of actual vaccination behaviours then they were of intentions.
Discussion of the Model of HPV Vaccination Intentions
The proposed model explaining the process through which HPV vaccination
desires are formed, was found to have good fit to the data after a small number of
modifications. In the original model, the decision process is depicted as beginning with
the components HPV Knowledge and Cues to Action. It was hypothesized that the
decision process begins with knowledge about the topic, and also when one is prompted
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to think about the topic at hand (in this case HPV vaccinations). These two components
were both hypothesized to influence perceptions of Severity, Susceptibility, and
Subjective Norms. These hypothesized relationships were supported for the most part,
although some relationships were not present. Knowledge was not found to influence
Subjective Norms, and Positive Cues to Action were not found to influence perceptions of
Severity. In addition, an unanticipated relationship between Cues to Action and the
Benefits variable was discovered. A discussion of each component and the relationships
between them follows.
For the Knowledge component, the results of the SEM confirmed that knowledge
does influence how susceptible one feels to HPV and how severe one believes HPV is.
Knowledge does not influence social norms, however. It was anticipated that HPV
knowledge may impact social norms, because increased knowledge would allow one to
be more aware and critical of the perceptions of others. This hypothesis was not
supported, however.
Examination of the relationships that were found, or not found, between positive
cues to action and the three components believed to be influenced by them, revealed that
cues to obtain the vaccine were related to women’s perceptions of their susceptibility to
HPV. Prompts to obtain the vaccine were also found to be related to subjective norms, but
were not found to be related to perceptions of severity. The lack of a relationship between
Cues and Severity could be explained by the idea that receiving Cues does not necessarily
mean that one understands HPV and the impact it can have on health. Receiving prompts
to obtain the vaccine did appear to influence individuals’ feelings of susceptibility
though, and they also made participants aware of the social norms surrounding the
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vaccine. Positive Cues to Action was also, unexpectedly, found to be related to perceived
benefits. This unanticipated relationship does make sense however, as the more positive
cues one receives for the vaccine, the more likely they would be to perceive the benefits
of vaccination.
When looking at the original model that was proposed, the next set of anticipated
relationships involved the components of Susceptibility, Severity, and Subjective Norms.
These components were each hypothesized to be related to perceived benefits and
barriers. Results revealed that the social norms surrounding the vaccine are related to
women’s perceptions of both the benefits and the barriers of vaccination. Women’s
perceptions of HPV severity and their susceptibility to HPV infection were both found to
be related to perceived barriers to vaccination, but they were not found to be related to
perceived benefits. The lack of a relationship between feelings of susceptibility and
severity, and the perceived benefits of vaccination was surprising. It was anticipated that
women with more worry (higher perceived severity and susceptibility), would believe
there were more benefits to obtaining the vaccine because vaccination would lessen their
worries. Instead, it appears that the potentially negative feelings of severity and
susceptibility are related only to women’s perceptions of HPV vaccination barriers. It
may be that once women’s thoughts about the unpleasant topics of HPV severity and
susceptibility are activated, that they begin to worry about other negative things such as
fears of vaccine safety, fear of stigma, and costs.
Returning to the proposed model tested for this study, a relationship between
feelings of self-efficacy and women’s perceptions of the barriers surrounding vaccination
was predicted. This relationship was supported by the results of this study, an important

Factors that influence HPV vaccinations 147

finding because it shows that participants may have the potential to overcome barriers
that they believe stand in their way to vaccination. Due to the way that self-efficacy was
assessed in this study, with items measuring women’s feelings that they could overcome
various real-world obstacles (time, money) to getting vaccinated, it was not anticipated
that feelings of self-efficacy would impact any other theoretical component.
The final set of predictions made in the original model were that Benefits and
Barriers would be related to desires to obtain the HPV vaccine. These predictions were
supported in this study. Both components were found to be significantly related to the
outcome. Interestingly, perceived benefits had a much stronger relationship with vaccine
desires than did perceived barriers. This finding falls in line with the results of the
regression analyses conducted earlier. While both types of benefits predicted desires to
obtain the vaccine in the regressions, only one of many barriers proved to be predictive.
While the model tested in this study had good fit with the data, the women that
make up the study sample represent a privileged group of women, with the majority of
women having at least some university education and being Caucasian. It may be that if
this model was tested on a less privileged group of women, minority, poor or uneducated
women for example, that some of the component relationships would change.
Underprivileged women face life challenges and develop perspectives about the world
that privileged women do not necessarily develop. For example, underprivileged women
often have lower levels of educational obtainment, which may impact how the knowledge
component of the model would influence the study variables. In addition, these women
would likely face more or stronger barriers to vaccination uptake. Cost may prove to be a
much more important predictor of decisions for this group of women, as may fears of
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stigma, or distrust of physicians or the healthcare system. Disadvantaged groups typically
have experienced more stigma, and have less faith in healthcare and the altruism of
healthcare professionals, and thus these factors may have an impact on what a model of
HPV vaccine intentions looks like for these women. Of course, other model components
and variables may also be impacted as well. Infection and treatment may be deemed more
severe due to a lack of resources to deal with it, or women may feel more susceptible for
example. The complex interactions between the variables may change in interesting ways
when the model is tested on other groups of women. Thus, future research should seek to
test the current model of HPV vaccine intentions, as well as alternate models, with other
groups of women.
In summary, the model of desires to obtain the HPV vaccine that was proposed in
this study was supported with a few modifications. These modifications were all logical,
and provide a deeper, and perhaps more interesting, understanding of the relationships
between the model components. In addition, while the results of the regression analyses
presented earlier seemed to suggest that certain model components are not related to HPV
vaccine outcomes, the SEM model reveals that all components are important to the
decision making process. Not all components are directly related to the outcomes, but
they do impact other components. Because no previously published research in the area of
HPV vaccinations has tested a SEM model of decision making, this study provides an
important starting place from which to research the decision making process related to
actual and intended HPV vaccination decisions.
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Limitations
As is true for all research, there were limitations to the current study that warrant
discussion. While a substantial number of women participated in this study, a larger
sample size would have allowed for a better analysis of the impact of some of the study
variables on outcomes. More specifically, demographic or personal history variables that
were only reported by a small number of participants (e.g., HPV status, HPV treatment),
could not be analysed for their impact on the outcome variables. A larger sample size
might have allowed for this. In addition, the sample for this study was predominantly
white and college educated, and a more diverse sample would have been more
representative of women in general. The final issue related to sample is the age of the
women recruited for this study. While it is important to investigate predictors of
vaccinations in women 18 to 30, it would also be very beneficial to conduct a study with
younger girls and their parents.
Another limitation of the current study concerns some of the study measures.
Because this investigation was based on a theoretical model that had not been extensively
tested in this area, various study measures had to be created or modified. As a result,
obtaining or creating alternative measures for some of the variables in this study may
result in additional significant findings. An example of a measure in need of modification
is the Subjective Norm measure. The items were not worded well for women who had
already received the vaccine. Thus, analyses using this measure for this population may
be less reliable in the current study. Research in the area of HPV vaccinations should
continue to modify and evaluate the appropriateness of measures in order to confirm the
findings found in this study.
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A related idea that also needs to be considered when contemplating the findings
from this research, is the retrospective nature of the study, in that predictors of actual
vaccinations were assessed after vaccination were or were not obtained. It may be that
individuals who obtained the vaccine have different views and perceptions, as a result of
having obtained the vaccine, than they did before they obtained it. Future research should
address this limitation by assessing attitudes before an individual has obtained the
vaccine, and then comparing the views of those who were vaccinated and not vaccinated.
Another aspect of the present study that some may consider to be a limitation, is
the method used to recruit participants. Participants were recruited from two sources and
completed the study online. The majority of the sample came from the Psychology
Department participant pool. The participant pool is comprised of Introductory
Psychology students, as well as individuals in various other psychology courses at the
university. A large proportion of University of Windsor students take Introductory
Psychology; thus, the students within the participant pool come from a variety of
backgrounds and likely represent a diversified group of women within the university
setting. In light of this, while using a participant pool may be a limitation, the diversity of
the group makes it less of a concern then it may be otherwise. The second group of
women who participated in this study were recruited through email and the social
networking site Facebook. Because the email and Facebook recruitment advertisements
originated with the author, the women who participated in this study and who heard about
it through this method may be limited, in that they might constitute a more homogeneous
group of women with some degree of connection to the researcher or her acquaintances.
While the types of recruitment used in this study is a limitation, the examination of the
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sample characteristics and the comparison made to an average Canadian sample revealed
that in many respects this sample is similar to the average Canadian woman.
Another possible limitation with this study is the fact that data was collected
online. However, in this age of high computer usage, 79% of Canadian households have
the internet (Statistics Canada, 2010), and especially among the age demographic
recruited for this study, it is not anticipated that having to use a computer to complete the
study would lead to problems with the integrity of the data collected. Thus, collecting
data online likely had minimal impact on the external validity of the study.
Implications
The results of this study have several important practical implications. This study
clearly highlights the fact that previous research findings based on only the analysis of
direct relationships between variables and HPV outcomes do not provide an accurate
picture of all of the factors that influence vaccination decisions. Thus, it is important for
health professionals and researchers who are designing interventions and educational
programs related to HPV vaccinations to understand the complex range of variables that
may have both direct and indirect relationships with HPV vaccination decisions. For
instance, the regression results from this study might seem to suggest that HPV
knowledge is not related to vaccine outcomes, and thus may lead to the erroneous
conclusion that increasing knowledge will not have an effect on HPV vaccine outcomes.
However, the results of the model testing in this study clearly show that knowledge does
have an impact on outcomes indirectly, through its relationship to perceptions of severity
and susceptibility, and thus educational efforts in this area would still be important.
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Another interesting implication that arises from the current study is related to the
finding that concern about experiencing stigma from a health care provider if asking for
the vaccine can impact vaccination decisions. This is an important finding, and should be
taken into account by health professionals when they are offering women the vaccine.
Professionals should plan an approach to offering the vaccine that indicates to women
that they will not be judged negatively for accepting it. An intervention in this area would
be an interesting next step. For example, a study investigating whether an intervention
designed to decrease women’s fears of stigma increases vaccine acceptance could be
conducted. Information could be provided through various methods in order to assess
which is most effective. For example, a face to face discussion with a health care
provider, an online program recommended by a reliable source, or printed educational
materials provided by the healthcare provider or their support staff to patients. It should
be noted that research into the usefulness of a Canada-based sexual health related website
found that using the internet as a sexual health promotion tool is very effective, in that
websites can have far reach, be cost-effective, and can be tailored so that they are
interactive and engaging (Barak & Fisher, 2003). In addition to interventions targeted at
the public, training could also be offered to health care providers so that they learn how to
interact with patients in a way that makes women feel safe and free from stigma.
This study also revealed that concerns about vaccine safety do play a role in HPV
vaccination decisions. Efforts to reduce vaccine concerns at both the individual level
(e.g., when women are visiting with their health care providers), and at the societal level
(e.g., through government and public health campaigns) are needed.
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Finally, another important implication of the current study was the finding that
positive cues to action do influence vaccinations. Thus, the more types of positive cues
that a woman receives, the more likely it is that she will be vaccinated. Positive public
service messages, commercials, encouragement from doctors, and efforts to have women
encourage each other, should be developed and investigated in order to encourage vaccine
uptake.
Suggestions for Future Research
One of the most important tasks for future research in this area is to focus on
developing and validating scales to assess the model components and variables that were
investigated in this study. While some variables were assessed with previously validated
scales, others were not, and this inability to use well researched measures may have
impacted the results of the current study. Thus, researchers looking at HPV vaccinations
should focus on identifying variables that may have an impact on vaccine decisions, and
how to measure them most effectively.
One of the more novel findings from this study is that women’s fear of stigma
when asking for the vaccine can impact their vaccination decisions. Future research into
possible interventions related to this would be valuable. Training health professionals to
be aware of this barrier and how to overcome it in their discussions and education with
women, and evaluating the impact of such training efforts, would be an interesting avenue
of research.
Finally, future research in this area should also move away from the analysis of
only direct relationships among variables and outcomes, and should begin to focus more
on complex modeling. Because there were no previous SEM studies investigating HPV
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vaccination decisions to my knowledge, the model tested in this study was exploratory.
Additional research involving complex modeling is needed in this area, so that alternative
models can be tested and compared. This will be the only way that a full understanding of
the factors that influence vaccinations will be available. Continuing research in this area
has the potential to positively impact women’s lives by increasing vaccinations. This
might lead to fewer HPV infections, less distress from symptoms, and saved lives.
Conclusion
This study investigated factors that predict actual and anticipated HPV
vaccinations. Results revealed that the predictors of actual vaccine obtainment were
women’s perception of the severity of HPV treatment, concerns about vaccine safety,
whether one had insurance coverage for the vaccine or not, level of fear of experiencing
stigma from their doctor, and positive cues to action. Factors that have an impact on
intentions to receive the HPV vaccine were participants’ belief that vaccines are
beneficial, beliefs that the HPV vaccine would be effective, concerns about vaccine
safety, positive cues to action, self-efficacy, and social norms surrounding the vaccine.
This study was beneficial to the area of HPV vaccine research, not just because it
identified direct predictors of vaccination decisions, but also because it revealed that these
predictors are different for actual versus intended vaccination decisions, and that even
predictors of certain types of intentions vary somewhat, as desires to get the vaccine had
some different predictors than did actually thinking one will get the vaccine. Finally, this
study was also beneficial because it tested and found support for a complex model of
HPV vaccination intentions and is the first study to use theory to successfully build and
find support for a model of HPV vaccination intentions using SEM.
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Appendix
Questionnaires Developed for This Study
Perceived HPV Susceptibility
Rated on a five-point scale: 1 (very unlikely) 2 (somewhat unlikely) 3 (50/50 chance) 4
(somewhat likely) 5 (very likely)
1. Do you feel at risk of being infected with HPV?
2. Do you feel at risk of getting cervical cancer?
3. Do you feel at risk of getting genital warts?
4. Do you feel at risk of having an abnormal Pap test?

Perceived Severity of HPV Infection
Rated on a five-point scale: 1 (not at all) 2 (a little) 3 (somewhat) 4 (quite a bit) 5 (very
much)
General Severity Questions
1. How upset would you be if / were you when you were told that you have the HPV
virus?
2. How upset would you be if / were you when you were told that your Pap test was
abnormal?
3. How upset would you be if / where you when you were told that you have genital
warts?
4. Would you / did you worry about the impact of an HPV infection on your body?
5. Would you / did you worry about your future fertility if you had HPV?
Treatment Severity Questions
1. How upset would you be / were you if you had to have treatment to remove genital
warts?
2. How upset would you be / were you if you had to have treatment to remove abnormal
cervical cells?
3. How upset would you be / were you when thinking about the impact of HPV on your
body?
4. Do you believe treatment for genital warts is/ was painful?
5. Do you believe treatment for abnormal cervical cells is/was painful?
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Social Severity Questions
1. How upset would you be / were you if your doctor knew you had HPV?
2. How upset would you be / were you if your sexual partner knew you had HPV?
3. How upset would you be / were you if your friends knew you had HPV?
4. How upset would you be / were you if you had to tell future sexual partners that you
had HPV?
5. If you were single and dating would you worry / did you worry about telling future
sexual partners that you had HPV?

HPV Vaccine Effectiveness
Rated on a five-point scale: 1 (not at all) 2 (a little) 3 (somewhat) 4 (quite a bit) 5 (very
much)
1. In general, how effective do you think the HPV vaccine is?
2. In general, I believe the HPV vaccine would benefit me.
3. I believe the HPV vaccine would benefit me because it would reduce my risk of HPV
infection.
4. I believe the HPV vaccine would benefit me because it would reduce my risk of
Genital Warts
5. I believe the HPV vaccine would benefit me because it would reduce my risk of
developing cancer.
6. I believe the HPV vaccine would benefit me because it would protect my future
fertility
7. I believe the HPV vaccine would benefit my current or future romantic relationship(s)
8. I believe the HPV vaccine would benefit my current or future sexual relationship(s)

HPV Vaccine Safety Fears
Rated on a five-point scale: 1(strongly disagree) 2 (disagree) 3 (neutral) 4 (agree) 5
(strongly agree)
1. I worry about the safety of the HPV vaccine
2. I worry the HPV vaccine has not been out long enough to properly judge its safety.
3. I worry about side effects from the HPV vaccine
4. I worry about the safety of vaccines in general
5. I worry about side effects from any type of vaccine
6. I believe vaccines are safe.
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Fear of Dr. Stigma
Rated on a five-point scale: 1(strongly disagree) 2 (disagree) 3 (neither agree nor
disagree) 4 (agree) 5 (strongly agree)
If I asked my doctor for the HPV vaccine, the doctor would think…:
1. That I sleep around
2. That I am responsible
3. That I will cheat on my romantic partner
4. That I have poor morals
5. That I don’t trust my romantic partner
6. That I am protecting myself
7. That my relationship is on the rocks
8. That I am loose
9. Nothing of it (*removed before analysis)
10. That I want to protect my sexual partner(s) (*removed before analysis)
11. That I am smart
12. That I am a bad person

Pharmaceutical Company Trust
Rated on a five-point scale: 1(strongly disagree) 2 (disagree) 3 (neutral) 4 (agree) 5
(strongly agree)
1. I trust pharmaceutical companies
2. The only thing pharmaceutical companies care about are profits
3. I feel like I have to do my own research about whether certain drugs or vaccines are safe.
4. Pharmaceutical companies properly test their drugs before they are made available to the
general public.
5. The people who work for pharmaceutical companies are honest people.
6. I worry that pharmaceutical companies do not tell the truth about all of the side effects and
reactions that people have to their products.
7. Pharmaceutical companies charge significantly more for their products than they need to make
a reasonable profit.
8. Pharmaceutical companies bribe doctors to recommend their products.
9. Developing and testing new drugs and vaccines is a long and complex process and
pharmaceutical companies do the best they can to make the process safe and fair.
10. Pharmaceutical companies make false claims in their advertising

Cost
Rated on a five-point scale: 1(not at all) 2 (a little) 3 (somewhat) 4 (quite a bit) 5 (very
much)
1. Is/was cost a concern when you think about/thought about getting the HPV vaccine?
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2. Is the HPV vaccine a fair price?
3. Does/did the cost of the HPV vaccine influence your decision to get the vaccine?
4. Can you/could you afford to get the HPV vaccine?
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